ENDOCRINOLOGY RESEARCH AND CLINICAL DEVELOPMENTS
MELATONIN, SLEEP AND INSOMNIA No part of this digital document may be reproduced, stored in a retrieval system or transmitted in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services.
ENDOCRINOLOGY RESEARCH AND CLINICAL DEVELOPMENTS Thyroid Hormones: Functions, Related Diseases and Uses Francis S. Kuehn and Mauris P. Lozada (Editors) 2009. ISBN: 978-1-60741-080-5 2009. ISBN: 978-1-60876-647-5 (E-book)
Nervous, Immune, Endocrine Regulatory Systems and Diseases Associated with Nerve Growth Factor Co-Secretion Ildikó Molnár 2010. ISBN: 978-1-60876-780-9
Estrogens: Production, Functions and Applications James R. Bartos (Editor) 2009. ISBN: 978-1-60741-086-7 2009. ISBN: 978-1-60876-220-0 (E-book)
Handbook of Hyperthyroidism: Etiology, Diagnosis and Treatment Lionel Mertens and Jeremy Bogaert (Editors) 2010. ISBN: 978-1-60876-441-9
Handbook of Oxytocin Research: Synthesis, Storage and Release, Actions and Drug Forms Hugo Jastrow and Daniela Feuerbach (Editors) 2009. ISBN: 978-1-60876-023-7 Foot Ulcers: Causes, Diagnosis, and Treatments Petr E. Overhaussen (Editor) 2009. ISBN: 978-1-60741-799-6 Neuroendocrinology Research Developments Nejc S. Penkava and Logan R. Haight (Editors) 2010. ISBN: 978-1-60876-983-4
The Pineal Gland and Melatonin: Recent Advances in Development, Imaging, Disease and Treatment Mehmet Turgut, Raj Kumar and Paul Steinbok (Editors) 2010. ISBN: 978-1-60876-717-5 Differential Diagnosis of Hyperthyroidism Mehtap Cakir 2010. ISBN: 978-1-61668-242-2 Melatonin, Sleep and Insomnia Yolanda E. Soriento (Editor) 2010. ISBN: 978-1-60741-859-7
ENDOCRINOLOGY RESEARCH AND CLINICAL DEVELOPMENTS
MELATONIN, SLEEP AND INSOMNIA
YOLANDA E. SORIENTO EDITOR
Nova Biomedical Books New York
Copyright © 2010 by Nova Science Publishers, Inc. All rights reserved. No part of this book may be reproduced, stored in a retrieval system or transmitted in any form or by any means: electronic, electrostatic, magnetic, tape, mechanical photocopying, recording or otherwise without the written permission of the Publisher. For permission to use material from this book please contact us: Telephone 631-231-7269; Fax 631-231-8175 Web Site: http://www.novapublishers.com NOTICE TO THE READER The Publisher has taken reasonable care in the preparation of this book, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained in this book. The Publisher shall not be liable for any special, consequential, or exemplary damages resulting, in whole or in part, from the readers‘ use of, or reliance upon, this material. Any parts of this book based on government reports are so indicated and copyright is claimed for those parts to the extent applicable to compilations of such works. Independent verification should be sought for any data, advice or recommendations contained in this book. In addition, no responsibility is assumed by the publisher for any injury and/or damage to persons or property arising from any methods, products, instructions, ideas or otherwise contained in this publication. This publication is designed to provide accurate and authoritative information with regard to the subject matter covered herein. It is sold with the clear understanding that the Publisher is not engaged in rendering legal or any other professional services. If legal or any other expert assistance is required, the services of a competent person should be sought. FROM A DECLARATION OF PARTICIPANTS JOINTLY ADOPTED BY A COMMITTEE OF THE AMERICAN BAR ASSOCIATION AND A COMMITTEE OF PUBLISHERS. Library of Congress Cataloging-in-Publication Data Melatonin, sleep and insomnia / editor, Yolanda E. Soriento. p. ; cm. Includes bibliographical references and index. ISBN 978-1-61122-834-2 (eBook)
Published by Nova Science Publishers, Inc. New York
Contents Preface
vii
Chapter I
Conditioned Arousal in Insomnia Patients: Physiological, Cognitive, Cortical—An and/or Question? Aisha Cortoos, Elke De Valck and Raymond Cluydts
Chapter II
Neuropathology of Insomnia in the Adult: Still an Enigma! Jean-Jacques Hauw and Chantal Hausser-Hauw
Chapter III
Non-Pharmacological Alternatives for the Treatment of Insomnia – Instrumental EEG Conditioning, a New Alternative? Kerstin Hoedlmoser, Thien Thanh Dang-Vu, Martin Desseilles and Manuel Schabus
Chapter IV
A Novel Disease Condition Presenting with Insomnia and Hypersomnia Asynchronization Jun Kohyama
Chapter V
Aggression in Older Adult Populations Sarah E. Parsons, Luis F. Ramirez, Philipp Dines, Scott Magnuson and Martha Sajatovic
Chapter VI
The Impact of Cultural Changes on the Relationship between Senior Sleep Disturbance and Body Mass Index among Older Adults in Two Asian Societies Bingh Tang and Lyn Tiu
Chapter VII
Chapter VIII
A Novel Model Using Generalized Regression Neural Network (GRNN) for Estimating Sleep Apnea Index in the Elderly Suffering from Sleep Disturbance Bingh Tang and Weizhong Yan Hormones and Insomnia Axel Steiger and Mayumi Kimura
1 35
69
103 135
161
191 205
vi Chapter IX
Contents Insomnia Among Suicidal Adolescents and Young Adults: A Modifiable Risk Factor of Suicidal Behaviour and A Warning Sign of Suicide? Latha Nrugham and Vandana Varma Prakash
Chapter X
Melatonin and Nocturia Kimio Sugaya, Saori Nishijima, Katsumi Kadekawa and Minoru Miyazato
Chapter XI
Melatonin and Other Sleep-Promoting Melatoninergic Drugs Under the Aspects of Binding Properties and Metabolism Rüdiger Hardeland
Chapter XII
Melatonin for Medical Treatment of Childhood Insomnias Jan Froelich and Gerd Lehmkuhl
Chapter XIII
Melatonin: Its Significance with Special Reference to Sedation and Anesthesia Argyro Fassoulaki, Anteia Paraskeva and Sophia Markantonis
Chapter XIV
Sleep Disturbance in Obsessive-Compulsive Disorder Enrico Pessina, Sylvia Rigardetto, Umberto Albert, Filippo Bogetto and Giuseppe Maina
Chapter XV
Effects of Sunbathing on Insomnia, Behavioural Disturbance and Serum Melatonin Level Keiko Ikemoto
Chapter XVI
Neuroimaging Insights into Insomnia Martin Desseille, Thien Thanh Dang-Vu, Manuel Schabus, Kerstin Hoedlmoser, Camille Piguet, Maxime Bonjean, Sophie Schwartz and Pierre Maquet
227 249
273 291
303 315
329 337
Chapter XVII Neuroimaging Insights into the Dreaming Brain Martin Desseilles, Thien Thanh Dang-Vu, Manuel Schabus, Virginie Sterpenich, Laura Mascetti, Ariane Foret, Luca Matarazzo, Pierre Maquet and Sophie Schwartz
357
Index
375
Preface Melatonin is a naturally occurring hormone that is released into the body when the eyes register that it's getting dark. When the eyes send the message to the brain that darkness is falling, a gland in the brain (the pineal gland) releases melatonin, which then signals the body to "wind down" and prepare for sleep. Melatonin regulates our waking and sleeping cycles in addition to performing other jobs. Consequently, insomnia is a symptom of a sleeping disorder characterized by persistent difficulty falling asleep or staying asleep despite the opportunity. Insomnia is a symptom, not a stand-alone diagnosis or a disease. By definition, insomnia is "difficulty initiating or maintaining sleep, or both" and it may be due to inadequate quality or quantity of sleep. It is typically followed by functional impairment while awake. This new and important book gathers the latest research from around the world in the study of melatonin and insomnia with a focus on such topics as: the neuropathology of insomnia in adults, hormones and insomnia, insomnia among suicidal adolescents, melatonin and nocturia, melatonin and its significance with anesthesia and sedation, and others. Chapter I - Insomnia has become fully recognized as one of the most prevalent sleep disorders in society with a profound impact on multiple aspects of daytime functioning and quality of life. Major advances in the non-pharmacological approach to insomnia include the work of Morin and colleagues on the behavioral and cognitive treatment of insomnia and the introduction of the behavioral model published by Spielman and Glovinsky (1991). Other researchers quickly followed resulting in an increasing amount of studies validating this perspective with its separate components. In the last 15 years, the nature of the conditioned arousal as one of the components in this model has been a major topic of interest. In this context, the neurocognitive model, published by Perlis and colleagues in 1997, argues for the extension of the arousal concept with a third component: cortical arousal. The latter is reflected by high frequency EEG activity during sleep, which is thought to mirror the lack of cognitive deactivation, resulting in a disruption of the normal sleep onset and maintenance processes. Some studies have shown the presence of high frequency EEG activity during the sleep onset period, NREM and REM sleep. Furthermore, beta and gamma EEG activity seem to be related to the subjective misperception of sleep, so often seen in insomnia patients. However, other studies revealed no significant differences in the sleep EEG between insomnia patients and controls. In addition to the theoretical overview, this chapter includes a
viii
Yolanda E. Soriento
study exploring the different arousal components in a group of selected insomnia patients with objective findings. Seventeen insomnia patients diagnosed according to DSM-IV criteria and 12 healthy controls were included in our study. Next to a general assessment of hyperarousal through the use of cortisol assay and questionnaires, a wake EEG and polysomnography were performed to evaluate the presence of cortical hyperarousal both during wakefulness and sleep. In comparison to a control group, insomnia patients experienced more cognitive and emotional arousal, but no increase in physiological arousal, both subjectively as well as objectively. Indications of cortical arousal were only present during the sleep onset period, reflected by a stable alpha EEG level and slower increase of delta power, related to longer sleep onset latencies. Furthermore, the cortical arousal variables were correlated significantly with objective sleep disruption, not with sleep perception. Together with previous studies, these results point to a large variability in insomnia patients as to the expression of hyperarousal and its different components. Chapter II – Insomnia Insomniais a very frequent symptom, usually due to non organic brain diseases. In some organic brain disorders, however, sleep impairment occurs through a series of mechanisms: structures responsible for need for sleep are lesionned ; the biological clock doesn‘t give the start for sleep; sleep networks responsible for inhibition of waking structures are not efficient; mechanisms carrying on sleep or responsible for waking stages are damaged. In each case, examples of those brain disorders leading to insomnia (tumors, strokes, traumas, neurodegenerative disorders) are reviewed, focusing on the neuropathological description of structures involved in sleep network. When possible, clinicopathological correlates are suggested. Chapter III - There is already profound knowledge about the evidence that cognitive behavioral therapy (CBT) is effective for the treatment of insomnia (Benca, 2005; Morin et al., 1999; Morin, 2004; Morin et al., 2006). However, the characterization of nonpharmacological treatment effects like CBT on specific sleep parameters (e.g., sleep spindles, sleep architecture, electroencephalographic (EEG) power densities during sleep after CBT) are scarce (Cervena et al., 2004). In our approach we investigated if instrumental conditioning of 12-15Hz EEG oscillations would enhance sleep quality as well as declarative memory performance in healthy subjects. Additionally preliminary data indicating instrumental conditioning of 12-15Hz EEG oscillations as a promising treatment of insomnia will be presented. EEG recordings over the sensorimotor cortex show a very distinctive oscillatory pattern in a frequency range between 12-15Hz termed sensorimotor rhythm (SMR). SMR appears to be dominant during quiet but alert wakefulness, desynchronizes by the execution of movements and synchronizes by the inhibition of motor behavior. This frequency range is also known to be high during light non-rapid eye movement (NREM) sleep, and represents the sleep spindle peak frequency. In the early 70ies Sterman, Howe, and MacDonald (1970) could demonstrate in cats that instrumental conditioning of SMR during wakefulness can influence subsequent sleep. Hauri (1981) was then the first to apply effectively a combination of biofeedback and neurofeedback to humans suffering from psychophysiologic insomnia. Results revealed that the patients benefited from the instrumental conditioning protocols. As research surprisingly stopped at that point, we
Preface
ix
intended to clarify the effects of instrumental SMR conditioning (ISC) on sleep quality as well as on declarative memory performance with today‘s technologies and by using a well controlled design which included a control group receiving the same amount of attention and training. Our results confirmed that within 10 sessions of ISC it is possible to increase 1215Hz activity significantly. Interestingly, the increased SMR activity (i) was also expressed during subsequent sleep by eliciting positive changes in various sleep parameters like sleep spindle number or sleep onset latency and (ii) was associated with the enhancement of declarative learning. In addition to these fascinating results, preliminary data from our laboratory point to the possibility that people suffering from primary insomnia could likewise benefit from this conditioning protocol as indicated by improved measures of subjective and objective sleep quality. Chapter IV - More than half of the preschoolers/students in Japan have recently complained of daytime sleepiness, while approximately one quarter of junior and senior high school students reportedly suffer from insomnia. These children might suffer from behavioral-induced insufficient sleep syndrome due to inadequate sleep hygiene, and conventional therapeutic approaches often fail. The present study addressed whether asynchronization, a novel clinical notion, could be responsible for the pathophysiology of these sleep disturbances and could provide a better understanding for successful interventions. This clinical concept was designed with special reference to the basic concept of singularity. The essence of asynchronization comprises disturbances in various aspects (e.g., cycle, amplitude, phase, and interrelationship) of biological rhythms that normally exhibit circadian oscillation. These disturbances presumably involve decreased activity of melatonergic and serotonergic systems. The major triggers for asynchronization are hypothesized to be a combination of light exposure during the night, which decreases melatonin secretion, as well as lack of light exposure in the morning, which decreases activity in the serotonergic system. Prevention of asynchronization must include acquisition of morning light and avoidance of nocturnal light. Possible potential therapeutic approaches for asynchronization involve conventional and alternative therapies. We should know more about the property of the biological clock. Chapter V - In 2005, a report from the United Nations Populations Division noted that the number of individuals aged 60 years and older is expected to nearly triple, increasing from 672 million in 2005 to almost 1.9 billion by 2050. Currently the elderly population in developed countries has surpassed the number of individuals under the age of 14 years, and by the year 2050 it is anticipated that there will be two elderly persons for every child. Population aging is thus anticipated to precipitate a situation in the United States where health care needs for older-adult populations may exceed care access and availability. This may be particularly pressing in the case of mental health conditions accompanied by behavior that put individuals at physical risk. It has been reported that 27% of all workplace violence occurs in nursing homes. Aggressive behavior by older individuals with mental disorders incurs substantial humanitarian and financial burden on patients, families and society at large. This review will address aggression in elderly populations with general medical conditions that include delirium, toxic states and drug-drug interactions as well as in populations with dementing illness, mood and anxiety disorders and psychotic disorders. A pragmatic approach
x
Yolanda E. Soriento
optimizing safety and quality of life for individuals, families and caregivers is stressed. Lastly, recommendations for future research in late-life aggressive behavior are provided. Chapter VI – Population aging has materialized as an innovative demographic inclination with imperative insinuation for government programs, public health and education, and family restructuring. Among such changes, insomnia, snoring and sleep apnea, in conjunction with sleep hygiene have been usually ignored. Changes in sleep are part of the ageing process. Nocturnal total sleep time can become more fragmented with age, with an increase in awaking early in the morning and nighttime awakenings. Body mass Index (BMI) and body weight have important health and educational implications across the lifespan. Most recent attention has been focused on the issue of obesity, an epidemic that occurs in most parts of the world. Yet the older Filipinos have prevalence of underweight, approximately thirty per cent of the population, while that of overweight close to ten percent. By comparison, in Taiwan, the prevalence of underweight is less than ten percent, while approximately thirty percent of Taiwanese elderly are overweight. The main purpose of this chapter is to signify the economic and cultural impacts on healthy weight and BMI maintenance in potentially decreasing the prevalence of sleep disturbance and improving quality of the elderly life in two Asian societies. With advancing age, age-related changes have been described for sleep–wakefulness and additional behavioral cycles. Trends in the relationship between elderly sleep disturbance and BMI in the observed two societies merit our serious attention. Further study is necessary to investigate whether the differences between two societies are caused the limitation of hospital-based study or by differences in ethnicity. Chapter VII – Objective: The main objective of this chatper is to present a novel model for classifying senior patients into different apnea/hypopnea index (AHI) categories based on their clinical variables. Methods and materials: The proposed model is a generalized regression neural network (GRNN). Three important variables were first selected from the original 30 clinical variables. The GRNN was trained using 75 patients that were randomly selected from the 117 patients. The remaining 42 patients were used for testing GRNN model. The design parameter of the network, i.e., the spread of the radial basis function, was empirically optimized. To alleviate the model complexity, the original AHI values were dichotomized into two different groups, i.e., AHI>13 and AHI<=13. The use of GRNN for this application appear fairly novel, notwithstanding that there is a host of literature on predicting obstructive sleep apnea (OSA) syndrome from demographic or other easy means to assess clinical variables. Results: The proposed model has sensitivity and specificity of 95.7% and 50.0%, respectively, for the training cases, while 88.0% and 52.9%, respectively, for the testing cases. Conclusions: The proposed neural network model has outperformed existing classification approaches in terms of classification accuracy and generalization, thus it can be potentially used in clinical applications, which would lead to a reduction of the necessity of in-laboratory nocturnal sleep studies. Chapter VIII - Human sleep is characterised by an electrophysiological component, which is recorded by the sleep EEG, and by distinct patterns of the secretion of various
Preface
xi
hormones. A bidirectional interaction exists between these two components of sleep. During disturbed sleep, changes of sleep EEG and of hormone secretion occur. For example during an episode of depression and during normal ageing, slow wave sleep and growth hormone (GH) secretion decrease whereas wakefulness increases and the activity of the hypothalamopituitary-adrenocortical (HPA) system is changed. During depression and during primary insomnia, elevated HPA activity is mirrored by increased cortisol levels. There is much evidence from preclinical and clinical studies that various neuropeptides and steroids participate in sleep regulation, and that changes in their activity contribute to disturbed sleep. The reciprocal interaction of the peptides growth hormone-releasing hormone (GHRH) and corticotropin-releasing hormone (CRH) plays a keyrole in sleep regulation. In young normal male subjects, GHRH promotes slow wave sleep and GH secretion, whereas CRH exerts opposite effects. Changes in the GHRH/CRH ratio in favour of CRH are thought to result in disturbed sleep, particularly in insomnia-related depression (CRH overactivity) and in normal ageing (reduced GHRH activity). Treatment with a CRH-1 receptor antagonist was shown to improve sleep in patients with depression. The menopause is a major turnpoint of sleep quality in women. In postmenopausal women the levels of circulating estrogens and progesterone are low. Replacement therapy with these steroids improved sleep in postmenopausal women. Chapter IX – This chapter examines existing research literature on sleep difficulties, primarily insomnia and the various dimensions of suicidality among adolescents and young adults as compared to adults. Studies have been grouped into epidemiological studies, clinical studies and reviews. Findings on gender have been given special importance. The literature overview has been complemented by case vignettes from a major corporate hospital in New Delhi (India). The chapter concludes by stating that a relationship appears to exist between insomnia and suicidality, especially with completed suicide, regardless of age. However, far too little is known about the relationship for clinicians to be able to use it as research evidence, as almost all the findings on suicidal behaviour came from cross-sectional studies, whether epidemiological or clinical. Therefore, the conclusion calls for research studies with a prospective design. Chapter X - Nocturnal frequency of urination (nocturia) is common in the elderly, and it is one of the most troublesome urologic symptoms. Urinary frequency interferes with daily activities, while nocturia may also result in sleep disturbance that can cause daytime fatigue as well as worsening the quality of life (QOL). Multiple factors may contribute to the occurrence of nocturia, including pathological conditions such as cardiovascular disease, diabetes mellitus, lower urinary tract obstruction, anxiety disorders or primary sleep disorders, and various other behavioral and environmental factors. Recently published guidelines have attributed the occurrence of nocturia to nocturnal polyuria and/or diminished nocturnal bladder capacity. However, since these factors may express the states of nocturia rather than the causes, it remains difficult to develop effective treatments for nocturia if the underlying etiology is not determined. Accordingly, in order to investigate which factors are strongly related to occurrence of nocturia, we performed a suite of examinations in elderly persons who had nocturia without any other diseases (elderly nocturia group) and two (young adult and elderly) control groups. As the results, sleep disturbance (a decrease of the nighttime plasma melatonin level),
xii
Yolanda E. Soriento
hypertension (an increase of nighttime plasma catecholamine levels), and excessive fluid intake (an increase of total urine volume) were major factors contributing to nocturia in the elderly. On the other hand, some elderly persons do not consider nocturnal urination to be bothersome even if they have a number of episodes. So, as a next step, the factors related to nocturnal urination that was not considered bothersome by comparing biochemistry tests were investigated between subjects who felt nocturnal urination ( twice per night) as bothersome and those who did not. As the results, the plasma melatonin level was lower in the bothersome group than in the non-bothersome group. Therefore, nocturnal urination might be not considered bothersome when subjects maintain sufficient levels of melatonin. As the third step, the effects of melatonin and the hypnotic, rilmazafone, on nocturia were compared in the elderly patients. After 4 weeks‘ treatment, the number of nocturnal urinations was decreased and the QOL score was improved in both groups. Melatonin and rilmazafone were equally effective for nocturia in the elderly, and the plasma melatonin level was increased in the melatonin-treated group. Therefore, the decrease of the plasma melatonin level may be one of the most important causes of nocturia, and sleep disturbance should be considered when choosing a therapy for nocturia. Chapter XI - In humans and other diurnally active mammals, melatonin acts as a sleeppromoting agent, but, for practical purposes, its short half-life in the circulation has been a major obstacle. Two different approaches have intended to overcome this problem, the development of slow-release pills and of other melatoninergic agonists, such as ramelteon and agomelatine, representing two non-indolic analogs of melatonin. With regard to sleep, melatonin and these analogs are acting in the same way, via the membrane-bound, highaffinity melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus, which controls the hypothalamic sleep switch. Ramelteon displays a considerably higher receptor affinity, in conjunction with a much longer lifetime in the circulation, plus a contribution of one of its metabolites, M-II, to the melatoninergic actions. The affinities of agomelatine are close to those of melatonin, but the half-life of the analog is longer. In addition, agomelatine was shown to inhibit the serotonin receptor subtype 5-HT2C, an effect associated with additional antidepressive actions. In spite of the similarities with regard to sleep, several profound differences between the three compounds may be of importance. The use of slow-release melatonin should exert a much broader spectrum of effects, since this indoleamine acts, in addition to MT1 and MT2, via other binding sites, too, such as subtypes of the nuclear receptors ROR and RZR, quinone reductase 2, calmodulin, calreticulin and mitochondrial binding proteins. The actions of ramelteon and agomelatonine seem to be much more specific for the membrane receptors, although binding to the last-mentioned proteins has not yet been tested. Another profound difference concerns the metabolism of the agonists. The non-indolic compounds are hydroxylated, dealkylated or further oxidized in positions not homologous to those of the natural indoleamine. The entire kynuric pathway of melatonin metabolism is absent in ramelteon and agomelatine. Since biological effects have been ascribed to the melatonin-derived kynuramines AFMK (N1-acetyl-N2-formyl-5-methoxykynuramine) and AMK (N1-acetyl-5-methoxykynuramine), this sector of melatonin‘s actions is missing. To date it is difficult to judge whether the full spectrum of melatonin‘s effects represents an
Preface
xiii
advantage of the parental compound, when only sleep promotion is intended, or whether the higher selectivity of the analogs for membrane receptors will turn out to be a favorable property. However, the poorly understood actions of metabolites from ramelteon and agomelatine, including disproof or proof of toxicity, may be relevant for a future decision on the most suitable compound. Chapter XII - Sleep disorders in childhood and adolescence are regarded as a common manifestation of symptoms of a disorder, mostly transitory in nature and in many cases caused by unsatisfactory sleep hygiene or maladjusted parent-child interaction during the falling asleep and sleeping through the night process. Furthermore, sleep disorders could exhibit comorbid symptoms with manifestations of psychiatric and neurological diseases [16, 17]. In these cases, they are often chronic and partially also serious in nature. In most cases, during consultation behaviorial therapeutic measues are indicated and are also sufficient. With manifestations of chronic disorders, medicinal measures play an important role [45]. Thus far, the use of an antihistamine, benzodiazepine or a neuroleptic can only be used with reservation or at least in the short term due to long-term side effects, the potential for dependency and substantial negative impacts on daytime alertness and memory functions [45]. With melatonin as an endogenous sleep-inducing hormone, for the first time a pharmacological treatment method essentially free of side effects could be offered for children. This paper summarizes the current, however still relatively narrow-based findings. The literature search is based on Medline-Search, in which substantial papers have been stored since 1985. Due to the still very provisional study status however, this could not consider exclusively randomized studies. Chapter XIII - Melatonin has been used to relief preoperative anxiety and stress. Several investigators reported that melatonin produces preoperatively anxiolysis and sedation. Patients undergoing laparoscopic cholecystectomy and pretreated with melatonin or midazolam exhibited less anxiety and increased sedation preoperatively compared with the controls. Similarly, patients undergoing gynecological laparoscopic surgery and premedicated with 5 mg of melatonin or with 15 mg of midazolam, or placebo were sedated in contrast to the control group. Psychomotor impairment after premedication was observed only in patients treated with midazolam. However, these effects are not reproducible by other studies. In elderly patients undergoing elective surgery 5 mg of melatonin or placebo given by mouth decreased anxiety scores to a similar degree. Melatonin premedication did not enhance the induction of anesthesia with sevoflurane as assessed by the bispectral index (BIS) monitor. Regarding the effect of sedative interventions and anesthesia on the endogenous melatonin release, acupuncture and acupressure may or may not affect melatonin levels. Also the inhalation anesthetic sevoflurane has been reported to decrease or to have no effect on endogenous melatonin. The different results may be attributed to the great variability associated with the measurements in melatonin levels, the different anesthetic techniques and co-administration of other agents, different populations in the relevant studies and other undetermined factors. Nevertheless, the interaction of sedative and anesthetic techniques with melatonin and vice versa is challenging and provocative in understanding the underlying mechanisms of sedation and anesthesia.
xiv
Yolanda E. Soriento
Chapter XIV - Introduction: Obsessive-Compulsive Disorder (OCD) is a common, chronic disorder which results in marked distress and impairment of social and occupational functioning. Sleep disturbance often accompanies mental disorders, but there have been few studies of sleep disturbance in OCD. These have produced contradictory findings, with some reporting sleep disruption, and others a normal sleep pattern. The aim of the present study is to examine sleep patterns in OCD, to establish the frequency of the different types of insomnia (early, middle and late insomnia) in a sample of patients with OCD. The study also intends to determine whether the presence of a comorbid mood disorder influence frequency and type of insomnia. Methods: all patients with a primary diagnosis of OCD (according to DSM-IV criteria) consecutively referred to the Mood and Anxiety Disorder Unit, Department of Neuroscience, University of Turin, from January 2003 to June 2008, were recruited. Frequency and severity of the different types of insomnia were evaluated on the basis of the Hamilton Depression Rating Scale (HDRS) specific items score (item 4-5-6). A statistical comparison between OCD patients with and without insomnia was performed to examine whether there was any difference in clinical features. Then a statistical comparison between patients with and without depressive comorbidity was performed to examine whether there was any difference in prevalence and type of insomnia. Results: The sample included 315 OCD patients. More than a half of the sample suffered from any type of insomnia. The most frequent type of insomnia was early insomnia (about 44,8%). We didn‘t find a positive correlation between the severity measured with total YBOCS score or obsessions and compulsions sub-score clinical and socio-demographic features and insomnia. The presence of any comorbid depressive disorder increased the frequency of insomnia. Chapter XV - It has been suggested that sunbathing may increase the amplitude of the sleep-wake rhythm and nocturnal serum melatonin secretion, and have effects on insomnia as well. A case report of a patients with epilepsy, cerebral palsy, and severe mental and intellectual disabilities (SMID) with severe behavioral disturbance is presented, in which the sleep-wake-cycle (SWC) was markedly improved by a sunbathing for seven months. The schedule included a sunbathing for 30 minutes in the morning, and a walk with a sunbathing for 10~30 minutes in the afternoon. Reduction of frequency of excitement and pyrexia was also observed, and the latter effect persisted for more than six months after the completion of this schedule. In the present case, being similar to the effects of light therapy for insomnia in elderly persons, low level of nocturnal melatonin level exhibited a tendency toward normalization. These findings show that a sunbathing is an effective and simple method for the treatment of insomnia and behavioral disturbance associated with severe mental retardation. The effects of light therapy and / or a sunbathing on insomnia and serum melatonin level, particularly in individuals with brain damages, are reviewed based on the literatures. Chapter XVI – Insomnia is a frequent symptom or syndrome defined by complaints of trouble in initiating or maintaining sleep or of nonrestorative sleep. This causes significant impairments in several areas of daytime functioning including mood, motivation, attention and vigilance.
Preface
xv
Significant advances in our neurobiological knowledge of insomnia have been brought by electrophysiological data (e.g. electroencephalography (EEG) and by functional neuroimaging data (e.g. single photon emission computed tomography (SPECT), positron emission tomography (PET) acquired during wakefulness, transition from waking to non rapid-eye-movement (NREM) sleep and REM sleep itself. Indeed it has been shown that idiopathic insomnia is characterized by a specific pattern of regional brain activity: (i) during the transition from waking to NREM sleep: failure to decrease brain activity in the ascending reticular activating system, medial prefrontal cortex, limbic/paralimbic areas (including insular cortex, amygdala, hippocampus, anterior cingulate), thalamus and hypothalamus, (ii) during NREM sleep: deactivation of the parietal and occipital cortices, and basal ganglia, and (iii) during wakefulness: deactivation in brainstem reticular formation, thalamus, hypothalamus, prefrontal, left superior temporal, parietal and occipital cortices. This specific distribution of brain activity might relate to (i) specific impairments in daytime functioning (e.g. hypoactivity in prefrontal cortex during wakefulness is consistent with reduced attentional abilities), (ii) hyperarousal hypothesis as a common pathway in the pathophysiology of insomnia (e.g. overall cortical hyperarousal characterized by an increase in EEG beta/gamma activity (14-35 / 35-45 Hz) at sleep onset and during NREM sleep) and (iii) the potentially overlapping pathophysiology with major depressive disorder as this illness has shown similarly altered cortical patterns (e.g. both illnesses have impairments in limbic/paralimbic areas as well as in basal ganglia). The goal of this chapter is to show that combining recent neurophysiological and neuroimaging data on human sleep offers new insights into the pathophysiological mechanisms of insomnia and potentially opens new therapeutic perspectives. Chapter XVII - Dreams are sensory, cognitive, and emotional experiences that occur spontaneously during sleep. Dream reports tend to be more frequent, vivid, and longer during rapid eye movement (REM) sleep than during non-REM sleep. This is why our current neurobiological knowledge about dreaming primarily derives from functional neuroimaging data acquired during REM sleep (e.g. electroencephalography, positron emission tomography, and functional magnetic resonance imaging). Recent neuroimaging results showed that REM sleep is characterized by a specific pattern of regional brain activity: (i) activation of the thalamus, pons, temporo-occipital and limbic/paralimbic areas (encompassing amygdala, hippocampal formation and anterior cingulate cortex), and (ii) deactivation of the dorsolateral prefrontal and inferior parietal cortices. This heterogenous distribution of brain activity might relate to some characteristic dream features (e.g. amygdala activation is consistent with frequent threat-related emotions in dream reports). Reciprocally, specific dream features suggest the activation of specific brain regions during sleep. Based on these observations, we previously proposed that a neuropsychological or cognitive neuroscience approach to dreaming can usefully contribute to the interpretation of neuroimaging maps of sleep. The goal of this chapter is to show that connecting recent neurophysiological and neuroimaging data on human sleep and the content of dreams offers new insights into the brain correlates of dreaming and possibly into dream functions.
In: Melatonin, Sleep and Insomnia Editor: Yolanda E. Soriento
ISBN: 978-1-60741-859-7 ©2010 Nova Science Publishers, Inc.
Chapter I
Conditioned Arousal in Insomnia Patients: Physiological, Cognitive, Cortical—An and/or Question? Aisha Cortoos, Elke De Valck and Raymond Cluydts Unit of Biological Psychology, Vrije Universiteit Brussel, Belgium
Abstract Insomnia has become fully recognized as one of the most prevalent sleep disorders in society with a profound impact on multiple aspects of daytime functioning and quality of life. Major advances in the non-pharmacological approach to insomnia include the work of Morin and colleagues on the behavioral and cognitive treatment of insomnia and the introduction of the behavioral model published by Spielman and Glovinsky (1991). Other researchers quickly followed resulting in an increasing amount of studies validating this perspective with its separate components. In the last 15 years, the nature of the conditioned arousal as one of the components in this model has been a major topic of interest. In this context, the neurocognitive model, published by Perlis and colleagues in 1997, argues for the extension of the arousal concept with a third component: cortical arousal. The latter is reflected by high frequency EEG activity during sleep, which is thought to mirror the lack of cognitive deactivation, resulting in a disruption of the normal sleep onset and maintenance processes. Some studies have shown the presence of high frequency EEG activity during the sleep onset period, NREM and REM sleep. Furthermore, beta and gamma EEG activity seem to be related to the subjective misperception of sleep, so often seen in insomnia patients. However, other studies revealed no significant differences in the sleep EEG between insomnia patients and controls. In addition to the theoretical overview, this chapter includes a study exploring the different arousal components in a group of selected insomnia patients with objective findings. 17 insomnia patients diagnosed according to DSM-IV criteria and 12 healthy controls were included in our study. Next to a general assessment of hyperarousal through the use of cortisol assay and questionnaires, a wake EEG and polysomnography
2
Aisha Cortoos, Elke De Valck and Raymond Cluydts were performed to evaluate the presence of cortical hyperarousal both during wakefulness and sleep. In comparison to a control group, insomnia patients experienced more cognitive and emotional arousal, but no increase in physiological arousal, both subjectively as well as objectively. Indications of cortical arousal were only present during the sleep onset period, reflected by a stable alpha EEG level and slower increase of delta power, related to longer sleep onset latencies. Furthermore, the cortical arousal variables were correlated significantly with objective sleep disruption, not with sleep perception. Together with previous studies, these results point to a large variability in insomnia patients as to the expression of hyperarousal and its different components.
Introduction Sleep is a behavior we engage in approximately one third of our lives. Falling asleep and staying asleep is a natural phenomenon for most people. However, approximately 10 to 20% of the population report difficulties initiating or maintaining sleep, accompanied by impairment of one or more aspects of daytime functioning [1]. When facing the fact that sleep initiation is delayed or has to be repeated several times during the night, the process of falling asleep loses its obvious characteristics and becomes a conscious and often frustrating task. Most people encounter this kind of situation at least once in their lives. Often a stressful or disruptive event causes the temporary sleep difficulties, which in turn will disappear when the stressor fades away. However, some people are more sensitive to a disruption of their sleep-wake rhythm and will continue having sleep problems even when the initial cause has disappeared. Often reported characteristics of sleep initiation or reinitiating problems are the presence of ‗racing thoughts, rumination and a state of alertness‘ at a time and place when relaxation is necessary [2, 3]. In reaction to the resulting sleep difficulties, behavioral coping strategies are developed, aiming at an increase of sleep time. When this process is repeated for a period of time, it becomes connected or linked to the specific environment within which it occurs; a phenomenon called conditioned arousal. The development of this subtype of insomnia is well described and widely known as the behavioral model [4]. Sleep is considered a complex behavior, partially dependant on daytime stimuli. The focus lies on the conditioned arousal, manifesting itself on different levels, such as anxiety, muscle tension, destructive and/or obsessive cognitions about sleep, and the consequences of sleep shortage. Within this model, the so-called 3 Ps (predisposing, precipitating and perpetuating factors) describe the 3 most important factors playing a key role in the development of insomnia [5]. First of all, it is suggested that insomnia patients are characterized by predisposing factors, making them more sensitive to sleep disruptive phenomena. These trait or predisposing factors can be related to personality traits, biological and/or psychological factors. At this point, however, a significant sleep disruption should not be present. It is only with the occurrence of a precipitating factor, mostly a stressful life event, that an interference of normal sleep processes takes place. As a reaction to the delayed and/or fragmented sleep period certain behavioral strategies, such as an extended time in bed, are employed as a way of ‗catching up‘ on sleep. These strategies or perpetuating factors, however, reinforce the relationship between wakefulness and the bedroom, which in turn will
Conditioned Arousal in Insomnia Patients
3
result in conditioned arousal, and finally in a more severe sleeping problem. At this point a negative vicious cycle is installed, maintaining the sleep disruption and its facilitating processes. Within this model it is assumed that the sleep disturbances in chronic insomnia are maintained because of these perpetuating factors, which in turn form the focus of attention for treatment interventions.
The Concept of Arousal: Validation of the Behavioral Model Arousal mechanisms are essential for surviving and have an adaptive function enabling our most basic behaviors, such as movement, sleep, rest, wakefulness, and danger orientation. As such, arousal is part of our daily life and makes it possible to perform certain physical and/or mental tasks. However, the perception of arousal may vary according to the possible presence of emotions related to the situation [6]. Performing sports after work will often not be recognized as a situation of arousal, although all characteristics of physical arousal are present, such as muscle activation, increased heart rate and ventilation. However, when confronted with a possible dangerous situation, we are more aware of the changes inducing a state of arousal. Together with the physical preparation, our cognitive system reacts as well, by scanning the environment for dangerous cues, and as such selective attentional processes are activated. Chronic insomnia patients tend to perceive sleep-related situations, such as the bedroom and bedtime, as stressors, as such inducing an arousal response, as proposed by the behavioral model. This theoretical perspective has given rise to a growing amount of research concentrating on the assessment of different arousal components in insomnia patients. One of the major difficulties in these studies, however, is the differentiation of the different arousal components involved, because of possible similarities in the underlying etiologies [7].
Physiological Arousal The process of falling asleep is accompanied by a series of events indicating a deactivation of several bodily systems, as such reflecting a state of physiological de-arousal [8]. During sleep onset, a decrease in muscle activation of the upper airway dilator muscles and respiratory pump muscles result in a fall in ventilation [9], which is also accompanied by a gradual decrease in heart rate [10]. Although EMG changes during sleep onset are not often studied in detail, findings regarding other related topics of sleep onset, such as passive behavioural sleep devices or changes in respiratory activity, suggest a decrease in overall EMG activity during sleep onset. In light of these findings, it is obvious that an interference of physiological deactivation can result in an impairment of sleep onset processes, a phenomenon called physiological arousal. This can be often observed in insomnia patients. One of the first studies assessing aspects of physiological arousal [11] showed that insomnia patients were characterized by elevated rectal temperature, skin resistance, and phasic vasoconstrictions. Hyperarousal was present half an hour before bedtime, as well as during sleep. This study was the starting point for many other researchers evaluating the
4
Aisha Cortoos, Elke De Valck and Raymond Cluydts
possible link between physiological arousal and sleep disturbances. Freedman and Sattler [12] and Freedman [13], for example, revealed that insomnia patients dominantly suffering from sleep onset problems, featured increased facial muscle activity during the sleep onset period, as well as increased beta and decreased alpha EEG activity during wakefulness, phase 1 and REM sleep. Other studies reported increased heart rate in insomnia patients during the night [14, 15], as well as in the morning when confronted with a stressful event [14]. Moreover, there appears to be a correlation between specific alterations in body temperature, related to impairments of the circadian rhythm, and different types of insomnia [16]. Sleep onset insomnia might partially be associated with a delay in temperature rhythm. As such, they try to fall asleep during their ―wake maintenance zone‖ [17] resulting in increased sleep latencies. Early morning awakening insomniacs, on the other hand, appear to be characterized by a phase advanced temperature rhythm, causing an early circadian wake up time. Sleep maintenance insomnia apparently is not associated with a temperature rhythm impairment, but with overall nocturnal elevated body temperature [18]. Finally, it is suggested that insomnia patients suffering from a combination of sleep-onset and maintenance problems are associated with a 24-hour elevated core body temperature [16]. The mediating role of the hypothalamic-pituitary-adrenal (HPA) axis has been another main focus in arousal studies in insomnia patients. Some studies have shown that insomnia patients have increased levels of evening cortisol, which are also correlated with the amount of awakenings during the night [19-21]. Backhaus et al. [22], on the other hand, only found decreased cortisol levels in the morning, negatively correlated with the reported subjective sleep quality. Although these studies report different results, they all mention some impairment of hormones related to the HPA axis. Therefore, it can be proposed that the hypothalamic-pituitary-adrenal (HPA) axis is overactivated, mostly due to stress and anxiety, keeping the cortisol levels high en thus interfering with normal sleep onset and maintenance processes [23, 24]. Despite these impressive results, other studies failed to find significant differences in the mentioned parameters of physiological arousal. Riemann and colleagues [25] for example, did not found elevated levels of evening cortisol, but only decreased levels of melatonin. No increased heart rate was found in the study by Monroe (1967). Varkevisser and colleagues [26] performed a 24-hour sleep deprivation protocol in insomnia patients and evaluated several indicators of physiological arousal (cardiovascular parameters, cortisol, and body temperature) but found no significant differences in comparison to healthy controls. These mixed results suggest a vast heterogeneity in regard to the presence and expression of physiological arousal in insomnia patients.
Cognitive Arousal As discussed above, falling asleep is accompanied by relaxation and deactivation of several bodily functions, which can be impaired at several levels in insomnia patients. However, a reduction in physiological processes is not the only requirement for a rapid sleep onset. The mind is a powerful and sometimes uncontrollable entity, processing all incoming information from external and internal stimuli during the day, which can also interfere with sleep onset. Increased presleep cognitive activity has been consistently associated with the
Conditioned Arousal in Insomnia Patients
5
maintenance of insomnia. Studies have repeatedly shown that insomnia patients experience intrusive thoughts, which are mostly negatively toned, as well as excessive worry, typically about sleep, the lack of sleep and its consequences on daytime functioning [27-29]. Studies evaluating self-reported attributions showed that insomnia patients report more presleep cognitive activity during the sleep onset period in comparison to healthy sleepers, and experience more sleep disturbances from presleep cognitive activity [30]. Furthermore, cognitive arousal appears to be more dominantly present as opposed to physiological arousal [3]. Besides the plain existence or presence of disruptive cognitive activity, it is also very interesting to evaluate its specific content in patients suffering from insomnia, especially in light of therapeutic interventions. Regarding the nature of cognitive activity, it has been reported that problem solving, worries and concerns, and listening to noises are a major focus of attention when trying to fall asleep [30]. Furthermore, thoughts about sleep shortage and re-evaluating the day are often reported. Another characteristic of insomniacs in comparison to healthy sleepers is the perceived control over presleep thoughts and worries. Whereas normal sleepers report that their presleep cognitive activity is intentionally, insomniacs describe this as being uncontrollable. Wicklow and Espie [31] conducted a study were they evaluated the content of intrusive thoughts and their relationship with actigraphic measured sleep and self report. Through the use of Principal Component Analysis, they were able to derive three major factors of intrusive thoughts. The first factor was referred to as ‗active problem solving‘, which correlated with objective sleep latency and was relatively unaffected by emotional tone. The second factor was ‗present state monitoring‘, reflecting selfawareness and self-monitoring. No connection was found with the objective sleep latency, but an inverse correlation was present with emotional tone. ‗Environmental reactivity‘ was the third factor, but no relations were found with any sleep parameter. Regarding the subjective sleep report, none of the factors apparently correlated with perception of sleep. The role of cognition in insomnia has been elegantly described by Harvey [32] in her paper ‗the cognitive model of insomnia‘. It is suggested that insomnia patients are overly worried about their sleep and the possible consequences of sleep shortage on daytime functioning, which results in ‗excessively negatively toned cognitive activity‘. This in turn leads to an arousal response and emotional distress, triggering selective attention towards all kinds of stimuli that are perceived as threads for a good night sleep. The combination of arousal and distress, as well as specific selective attentional processes cause a distortion in the perception of the sleep complaints and impairments in daytime functioning. This in turn fuels again the negatively toned cognitive activity, and is the starting point for a negative vicious cycle. In line with the behavioral perspective described earlier, this negative cognitive activity gives rise to certain beliefs about sleep and their sleep problem, as well as safety behaviors, comparable with the perpetuating factors of the behavioral model. Other researchers have also demonstrated the presence of a sleep related attentional bias. Taylor et al. [33] compared two groups of cancer patients with insomnia, the first group at 0-3 months and the second at 12-18 months after cancer diagnosis. All patients had been good sleepers before the diagnosis. Results from the Stroop paradigm showed that both groups presented an attentional bias for cancer words, but only the persistent insomnia patients who still experienced sleep disturbances a year after their diagnosis, demonstrated attention bias for sleep-related words. In a recent study, Spiegelhalder and colleagues [34] for example,
6
Aisha Cortoos, Elke De Valck and Raymond Cluydts
compared insomnia patients, sleep experts and healthy controls using an emotional Stroop task. They found significant higher attentional bias scores in the insomnia group in comparison to the sleep expert group, suggesting that the attentional bias for sleep-related words is due to specific emotional, cognitive or procedural processing rather than differences in habitual exposure to these concepts. In summary, these results suggest that insomnia patients are characterized by some form of cognitive arousal, mainly consisting of thoughts concerning problem solving and monitoring. As is shown by Harvey‘s cognitive model of insomnia, specific selective attentional processes play an important role in the maintenance of insomnia, which in turn has been repeatedly shown by studies who found an attentional bias in insomnia patients for sleep related words or cues. Espie and colleagues [35] reviewed literature about attentional bias in insomnia patients and introduced an important sleep inhibitory process, namely the attention-intention-effort pathway. They point out that the automaticity of the sleep system in insomnia patients is inhibited by three factors: first, the selective attention to sleep; secondly, the explicit intention to sleep; and finally, a dysregulation by both direct and indirect sleep effort. As such, when considering therapeutic intervention, the cognitive processes and attentional bias should be an important focus of attention.
Clinical Applications: Cognitive and Behavioral Interventions for Insomnia The growing literature regarding physiological and cognitive arousal in insomnia patients resulted in studies evaluating different interventions aiming at a reduction of these arousal components. Since the 1970‘s the impact of different relaxation techniques on physiological arousal and sleep quality were examined. Borkovec and Fowles [36] for example, evaluated three different relaxation trainings as well as a waiting list no-treatment control group. They used progressive relaxation, hypnotic relaxation and self-relaxation as a way to influence physiological arousal in insomnia patients. They hypothesized that only the progressive and hypnotic relaxation groups would demonstrate significant improvement after training. However, results showed an equal improvement in sleep onset latency, number of awakenings and waking up refreshed in all three training groups. Surprisingly, the reduction in physiological arousal reflected by skin conductance, heart rate and respiration was not related to treatment outcome. The authors suggested that the general instruction in all groups to relax and focus on pleasant internal feelings might be the mediating factor responsible for the general improvement in all groups. As such they hypothesized that attention focusing may be enough as treatment intervention for moderate insomnia patients. A similar study was performed by Nicassio and Bootzin [37] using progressive relaxation and autogenic training as active treatment groups, and a self-relaxation and waiting list group as control groups. In contradiction with Borkovec and Fowles [36] they only found significant improvement after progressive relaxation and autogenic training, suggesting that the mere instruction to relax at a scheduled time is not enough to result in significant improvements in sleep. As their sample of insomnia patients had more severe sleep problems, it was also suggested that the selfrelaxation instruction may lose its value with increasing severity of the sleep complaints.
Conditioned Arousal in Insomnia Patients
7
In addition to this line of research, much attention has been paid to other behavioral interventions, mostly based on operant or instrumental conditioning. The use of ‗stimulus control‘ [38], for example, was one of the first interventions successfully applied in insomnia patients, which is based on the fact that spending to much time in bed is an important perpetuating factor playing a key role in the maintenance of the sleep complaints [4]. It has been shown that avoiding wakefulness in bed during the night as well as daytime napping results in a significant improvement of total sleep time, wake after sleep onset, sleep efficiency and sleep onset. The main objective of this intervention technique is to reassociate the sleep environment with relaxation and fast sleep onset, resulting in a new conditioned response as opposed to the arousal response leading to the reported sleep complaints. The American Academy of Sleep Medicine has recommended stimulus control instructions as a ‗standard‘ treatment for primary insomnia [39]. A second behavioral intervention that has received much attention is the use of ‗sleep restriction therapy‘ [40] were the time in bed is restricted to the reported total sleep time, as such that a mild sleep deprivation results in fast sleep onset latencies and increased sleep efficiency. In addition to these two major behavioral interventions, sleep hygiene instructions [29, 41] are recommended to ensure that poor sleep habits do not interfere with the beneficial effects of other interventions. Finally, in the 1990‘s cognitive therapy was introduced in order to directly intervene on the level of dysfunctional beliefs and attitudes about sleep [29]. These different components were then integrated into a multi-component treatment for insomnia, widely known as Cognitive Behavioral Therapy for Insomnia (CBT-I) [42]. The use of these different components in one integrated training program results in better outcome in comparison to single component treatment, and the addition of cognitive restructuring to the behavioral components causes slightly greater benefits than behavioral treatment alone [43]. Furthermore, it has been shown that CBT-I does induce a greater decrease in maladaptive beliefs and attitudes about sleep in comparison to relaxation therapy and placebo [44]. This effect is maintained at follow-up 6 months after completing the training program. Morin and colleagues [45] performed a similar study comparing a CBT-I group, pharmacotherapy, combined therapy of CBT-I and pharmaco and a placebo medication group. Again they showed that CBT-I or the combination of CBT-I with medication resulted in greater improvements of beliefs and attitudes about sleep. Furthermore, both studies showed that a decrease in maladaptive beliefs and attitudes were correlated with objective and subjective sleep improvement. Although CBT-I is regarded the gold standard for psychological management of insomnia, there are limitations, suggesting that a further exploration of additional interventions or treatments is still required [46]. First of all, the majority of insomnia patients following CBT-I show an average improvement that does not bring them into the good sleeper range, which means that they still show some impairment after treatment [46-48]. Secondly, the effect sizes after CBT-I training are markedly lower in insomnia patients in comparison to the effect sizes resulting from CBT in other psychophysiological disorders [46]. Thirdly, although the combination of CBT-I with pharmacotherapy might result in better improvements on the short term, Hauri [49] also showed that the progress obtained after a combined therapy are not maintained over a follow-up period of 10 months in
8
Aisha Cortoos, Elke De Valck and Raymond Cluydts
comparison to the use of CBT-I alone. Fourthly, the different components of CBT-I, such as sleep restriction and stimulus control, require a certain amount of dedication and the will to make some changes in habitual life style to produce the desired effects, which is not always obvious [48]. Finally, it has to be noted that about 19% to 26% of patients do not respond to CBT-I [46, 48]. These observations suggest that a focus on physiological and/or cognitive/behavioral components of arousal might not be enough for a substantial group of insomnia patients, and other factors may be in play causing sleep disruption.
The Neurocognitive Model: Introduction of a New Arousal Component As a theoretical perspective on insomnia the behavioral model has been dominantly used since the 1980‘s, and it has given rise to new and efficient therapeutic interventions. However, some characteristics or paradoxes observed in insomnia patients can not be fully explained by this model [50]. A first paradox refers to the phenomenon perceiving ‗sleep‘ as ‗wakefulness‘. There appears to be a misperception of sleep resulting in a discrepancy between polysomnographically measured sleep and the subjective report through sleep logs [51-54]. Secondly, insomnia patients tend to overestimate the time needed to fall asleep and underestimate their total sleep time [11, 52, 55]. Thirdly, when using hypnotic medication there appears to be a discrepancy between the benefits reported by the patients and the objective gains [53, 56]. Furthermore, it has been shown that the administration of benzodiazepines does not normalize sleep; in fact it decreases SWS, while insomnia patients tend to report great benefits of them. In 1997, Perlis and colleagues introduced the neurocognitive perspective, an extension of the previous discussed behavioral model, which focuses on a third arousal component, namely cortical arousal [50]. They hypothesize that the presence of high frequency EEG activity during sleep reflects a state of hyperarousal, interfering with the normal sleep onset and maintenance processes. The presence of cortical arousal makes it possible to explain some of the mentioned paradoxes as cognitive alterations may result from high frequency EEG activity. It is suggested by the authors that cortical arousal results in heightened sensory and information processing. These cognitive alterations in turn are able to clarify certain characteristics of insomnia, such as the complaint of not falling asleep, the perceived misperception between wakefulness and sleep and the overestimation of wakefulness. The past decade research concerning cortical arousal in insomnia patients has received much attention and suggests that this sleeping disorder is characterized by the presence of high frequency EEG activity during sleep onset and sleep. Nevertheless, results are still inconsistent, probably due to different methodologies and inclusion criteria. On the other hand, literature shows that the presence of physiological and/or cognitive arousal is not a uniform phenomenon as well. Indeed, the insomnia population appears to be quite heterogeneous, which might also be the case for cortical arousal.
Conditioned Arousal in Insomnia Patients
9
Cortical Arousal As discussed in the previous sections, the concept of arousal in insomnia patients has traditionally been explained in terms of physiological and/or psychological processes. However, arousal can also be seen as a brain process reflected by changes in specific EEG frequency rhythms, referred to as cortical arousal. A state of arousal or high vigilance means that the brain is open to signals from the outside world, ready to process and react on these stimuli [57]. One of the most important structures in the brain involved in the control of information flow to the cerebral cortex is the thalamus. During sleep, synaptic inhibition occurs, blocking the incoming signals of being processed by the thalamus, as such the brain closes of from irrelevant external cues. The specific functions of the thalamus can be related to the EEG frequencies produced by this structure and measured on the scalp. The process of falling is asleep is normally characterized by a decrease of high frequency and an increase of slow frequency EEG activity [58, 59], reflecting the inhibition of incoming stimuli by the thalamus resulting in a slowing down of general brain EEG activity. Several studies have shown a different EEG pattern in insomnia patients during sleep onset and sleep, suggesting higher arousal levels in comparison to healthy sleepers. Freedman [13] was the first to investigate possible differences in EEG frequencies between insomnia patients and healthy controls. He examined the first minute of every sleep stage and found increased beta and decreased alpha EEG activity during wakefulness, stage 1 and REM sleep. Since possible EMG interferences were not taken into account, and patients were not screened for psychiatric disorders, these results should be interpreted with caution. Two other studies evaluated the specific EEG changes during sleep onset in insomnia patients [60, 61] and found decreased delta and alpha EEG power, as well as increased beta EEG power in comparison to healthy controls and even psychiatric insomniacs [60]. These results suggest an impairment of normal sleep onset processes, possible related to heightened cortical arousal. Moreover, the authors posit that the presence of beta EEG activity during sleep onset might also be related to the tendency in insomnia patients of overestimating sleep onset latency [60]. Finally, Staner et al. [62] assessed the sleep onset period and first NREM cycle in 21 controls, primary insomniacs and depressives. In contrast to the other studies, they found that insomnia patients were characterised by lower beta1 (13-21.5 Hz) EEG activity at the beginning of sleep onset, resulting in a relatively stable evolution during the sleep onset period. However, in line with the research of Lamarche and Ogilvie [60] they found decreased levels of alpha power. Both EEG frequencies however, are supposed to show a progressive decline during sleep onset. As such these results are interpreted as reflecting an impairment of the wakefulness propensity or a state of hyperarousal, interfering with normal sleep onset processes. Besides the EEG differences during the sleep onset period, there have also been some studies evaluating sleep EEG profiles during NREM and REM sleep. Merica, Blois and Gaillard [63] examined the first 4 NREM/REM cycles and found significant EEG difference in NREM, as well as in REM sleep. Decreased delta and theta and increased beta EEG activity were present in both NREM and REM stages. For alpha power a different pattern was found: this EEG rhythm was reduced during NREM and elevated during REM sleep. It is suggested that these results indicate on the one hand presence of cortical arousal reflected by
10
Aisha Cortoos, Elke De Valck and Raymond Cluydts
heightened levels of beta activity during sleep, and on the other hand a slow wave sleep deficiency reflected by the lack of slow frequencies during NREM sleep, more specifically delta power. They proposed a neurophysiological interpretation combining two related theories, namely the neuronal group theory of sleep function [64] and the Neuronal Transition Probability (NTP) model [65] to clarify and combine both results. First of all, the neuronal group theory posits that alertness and sleepiness are two concepts of a continuum, in which the varying degree of these two states are dependent on the amount of sleep intensity. The perception of sleep, in turn, is dependant on the amount of neuronal groups being in a sleep (or disjunctive) state. As such, a lesser number of neuronal groups entering the disjunctive state might be a characteristic of insomnia patients, resulting in a part of the brain that remains alert or awake, reflected by higher levels of beta EEG activity. Secondly, the Neuronal Transition Probability model [65] makes use of the work of Steriade et al. [57] who showed that the hyperpolarisation of thalamocortical neurons produce delta oscillatory modes, resulting in SWA and deep sleep, and subsequent depolarization creating a disappearance of the delta oscillations leading to a transition to light sleep. This process is accompanied by oscillation changes of the neurons, following a sequence: beta – sigma – delta – sigma – beta [65]. In light of this model, their observation of a broader sigma peak and delayed delta peak in insomnia patients would suggest that the thalamocortical neurons become hyperpolarized at a slower rate, resulting in a slower transition from the sigma to the delta oscillatory mode [63]. Two more studies performed by Perlis and colleagues [66, 67] found increased beta1 (1420 Hz), beta2 (20-35 Hz) and gamma (35-45 Hz) EEG power during NREM sleep, as well as heightened levels of beta2 activity during REM sleep in insomnia patients compared to psychiatric insomniacs and good sleepers. Furthermore, the increased beta activity was correlated with the tendency to underestimate total sleep time. By analyzing the temporal and stagewise distribution of high frequency activity, they found an inverse relationship between delta and beta EEG activity in healthy controls, which disappeared in insomnia patients during the second part of the night. All these studies, however, did not take into account the amount of discrepancy between objective and subjective sleep complaints and thus possible subtypes of primary insomnia. Krystal et al. [68] evaluated NREM sleep EEG spectral analysis between ―subjective‖ and ―objective‖ insomnia patients and healthy controls. Results showed distinctive different EEG patterns between both insomnia groups. Diminished delta and greater alpha, sigma and beta EEG relative spectral power during NREM sleep were observed and more prominent in the ―subjective‖ insomnia patients. These EEG differences were also correlated with the subjective sleep complaints of the ―subjective‖ group, but not with the ―objective‖ insomniacs. A correlation was found between the lower relative delta power during NREM sleep and the discrepancy between subjective and objective sleep measures. This result seemingly contrasts the finding of Perlis et al. [67] who found a positive correlation between the presence of beta power and the underestimation of TST. However, the authors suggest that since delta and beta EEG power appear to be negatively correlated, both findings might be related. Finally, a very recent study by Buysse and coworkers [69] performed an interesting study on EEG profiles during NREM sleep, examining the possible effects of gender on sleep EEG. Surprisingly, they did found a significant impact of gender on the sleep EEG profiles, namely women were characterised by elevated high
Conditioned Arousal in Insomnia Patients
11
frequency EEG activity, as well as increased low frequency EEG activity. These differences were not found in men suffering from insomnia compared to healthy men. These results raise the question whether the earlier findings on heightened beta EEG activity might be related to gender as opposed to the sleep complaints, especially since insomnia complaints are more prevalent in woman? Moreover, they found no relationship between high frequency EEG activity and clinical characteristics of insomnia in both men and woman. Overall, it is obvious that although certain studies report evidence for cortical arousal during sleep in insomnia patients, the results are still inconclusive. There have been reports of increased beta EEG activity in primary insomniacs [63, 66, 67, 70] or only in subjective insomniacs [68] or only in women suffering from insomnia [69] or even no differences during NREM [13]. The same picture is found for the sleep onset period. Further research is necessary to clarify these mixed results on cortical arousal during sleep in insomnia patients.
The Concept of Arousal: Interrelationships between the 3 Components By reviewing the literature on the presence of arousal in insomnia patients, it is clear that there exists a certain amount of variability. Hyperarousal, if present, can manifest itself in different ways, such as elevated heart rate, EMG, cortisol levels, cognitive activity, high frequency EEG activity, but as to why it expresses itself in different manners has not been explained yet. The neurocognitive model [50] posits that conditioned arousal can present itself in three different modalities, being physiological, cognitive and/or cortical. However, few studies have evaluated the expression of hyperarousal in these three systems at the same time. Furthermore, one can ask to what extend these three components are (in)dependent of each other and what are their interrelationships? An important question not yet received much attention. In a recent review by Perlis and colleagues [71] the same question has been put forward. In line of the neurocognitive perspective, they posit that the three arousal components are relatively distinct and rather independent from one another, as such that heightened arousal in one component does not necessarily lead to an increase in the other components. One of the arguments put forward to ground this hypothesis, is the disconnection between the peripheral nervous system and the brain during REM sleep; muscle activity is practically shut down at the same time that the brain shows signs of arousal in the EEG. On the other hand, it has been shown that the sympathetic activation during wakefulness reflected by heart rate, decreases entering NREM sleep, and rises again towards mean awake levels during REM sleep [72]. Interestingly, here we see an example were two parameters reflecting physiological (de)arousal suggesting different states of arousal. A second consequence of viewing arousal as a three-construct system with limited interrelations, is the lack of knowledge to know which component might be elevated reflected by which parameter and under which conditions? This might also explain the mixed results concerning the different arousal components in insomnia. To clarify this rather complex question can be seen as a challenge. A few studies have tried to clarify the interrelationship between different arousal components. One of the main objections against the presence of high frequency EEG activity in insomnia patients is the possible influence of increased EMG levels on the EEG spectrum.
12
Aisha Cortoos, Elke De Valck and Raymond Cluydts
Indeed, it has been suggested that the raise of beta EEG activity under stress or arousal conditions, might be related to the raise in muscle tension, as such not exclusively reflecting a change in brain activity [73], but rather a expression of physiological arousal. Bonnet and Arand [74] targeted this question by evaluating the effect of different states of physiological arousal and increased EMG upon spectral EEG measures in healthy sleepers. The different conditions used were sitting, standing, walking, a mathematical task, gritting teeth and clenching fists. Indeed, it was shown that the production of physiological arousal resulted in an increase in high frequency EEG activity. Heightened levels of EMG produced EEG changes above 24 Hz, which includes the beta EEG band often referred to in insomnia studies. At the same level, an increase in heart rate was observed during arousal condition, which in turn was related to changes in the EEG spectrum. As such, it is hypothesized that increased high frequency EEG activity may not be a sign of cortical arousal, but might just be a reflection of physiological arousal such as heart rate or tension. A second study by De Valck et al. [75] evaluated the effect of experimentally induced cognitive arousal on the subsequent physiological and cortical arousal components in healthy sleepers. The unannounced visit of a camera crew filming a documentary on sleep and related issues was used as a trigger for cognitive arousal. Cognitive, physiological and cortical arousal were assessed using respectively the POMS tension subscale, heart rate (HR) and HRV, and beta EEG activity during the first and last 5 minutes of an MSLT. All subjects were exposed to an arousal and neutral condition during a 2-day partial sleep deprivation protocol. The arousal condition resulted in significant increases in cognitive subjective arousal and physiological arousal reflected by higher scores on the POMS and an increase in heart rate, which in turn gave rise to increased sleep latency during the MSLT. In regard to the impact on cortical arousal, a trend was found for increased beta2 (20-35 Hz) EEG activity during the first and last 5 minutes of the MSLT. None of these changes were observed during the neutral condition. Surprisingly, none of the arousal parameters correlated with objective sleep latency. These findings suggest a partial interrelationship between the three arousal components, with a more pronounced connection between cognitive and physiological arousal, as opposed to cortical arousal. Furthermore, since the increase in physiological arousal did not result in a similar magnitude of increased cortical arousal, this might suggest that heightened levels of beta EEG activity are not solely the result of increased physiological arousal. Methodological difference between the former and latter study are related to the experimentally provoked arousal component used. Bonnet and Arand induced physiological arousal and evaluated its impact on cortical arousal, whereas De Valck and colleagues used cognitive arousal as a starting point. Thirdly, Tang and Harvey [76] performed two napping experiments in order to clarify the different effects of physiological versus cognitive and emotional arousal, and their impact on perception of sleep. The first experiment aimed at evaluating the specific influence of presleep cognitive arousal on the distortion of sleep perception, reflected by the SOL and TST discrepancy, during an afternoon nap. Secondly, the cognitive arousal group was divided in two subgroups, the first being the anxious cognitive arousal and the second the neutral cognitive arousal group. It was hypothesized that both anxious and neutral cognitive arousal would lead to a prolonged sleep latency and an increase in the discrepancy between self reported sleep and actigraphy-defined sleep in comparison to a ‗no manipulation‘ group.
Conditioned Arousal in Insomnia Patients
13
Indeed, analysis showed an increase in self reported cognitive arousal in both groups, but only the anxiety group reported a significant increase in anxiety during the sleep onset period. Regarding the objective sleep parameters, only the cognitive anxious arousal group showed a significant increase in sleep onset latency, as opposed to the neutral cognitive arousal group. However, both arousal groups did show an overestimation in reported sleep onset latency compared to the no manipulation group, supporting the hypothesis that the amount of presleep cognitive arousal is related to the discrepancy in sleep perception. A second experiment compared the relative effects of an anxious cognitive arousal group with a physiological arousal group, induced by caffeine intake, in relation to the objective measures of sleep quality by means of actigraphy, as well as distortion of sleep perception. Results showed that both arousal groups resulted in a distorted perception of sleep. In regard to the objective sleep parameters, only the anxious cognitive arousal group showed increased sleep latencies. Summarizing, these studies have resulted in some preliminary insights into the different arousal components and their specific influences on sleep parameters, perception and other arousal dimensions. Inducing physiological arousal by means of physical activity and additional raises in EMG level, results in parallel increases in beta EEG activity, probably due to the specific effects of EMG on the EEG spectrum. On the other hand, when using a protocol that induces cognitive arousal, a similar increase in physiological arousal is produced, but not in cortical arousal, suggesting that this methodology might avoid to some extent the confounding effect of muscle tension on the EEG. Furthermore, when using an experimentally induced cognitive arousal protocol, attention must be paid to the possible occurrence of emotions, such as anxiety. As Tang and Harvey [76] showed, combined occurrence of emotion and cognitive arousal, will have a greater impact on objective sleep variables.
Conditioned Arousal or a Predisposing Factor? Based on the many studies regarding this topic during the last decade, hyperarousal is recognized as an important characteristic in primary insomnia today. However, the specific nature of this arousal remains unclear: is it a conditioned response or a predisposing factor? Furthermore, the two are not mutually exclusive. More specifically, the basic level of arousal that predisposes people to develop insomnia may be another key factor [7]. According to the neurocognitive perspective [50], arousal in insomnia patients is a conditioned response as a results of the presence of predisposing factors in combination with a precipitating event and perpetuating factors. As such, arousal responses should only occur in situations that have become associated with threatening sleep-related environments or contexts or as a result of such responses. Most studies on arousal assessed its presence in sleep-related contexts or environments, such as the bedroom, the sleep onset period, during the entire night or in the morning. Indeed, indications for hyperarousal such as increased muscle activity, beta EEG activity, cortisol levels, temperature or HR during the sleep onset period or during sleep could be interpreted as being a conditioned arousal in response to the sleep environment. However, if considered a conditioned response, these increases in arousal should not be present in situations not related to sleep. As mentioned before, there exists a
14
Aisha Cortoos, Elke De Valck and Raymond Cluydts
certain amount of variability and not all studies found the same increased arousal in insomnia patients, suggesting that the arousal response may vary between subjects. Another explanation is that the conditioned response is triggered in different situations, being bedtime or during awakenings or in the morning after a bad night sleep, which might clarify to some extend the mixed results mentioned before. A way of examining this is to evaluate specific measurements of arousal during a longer period, such as 24 hour protocol. Indeed, Bonnet and Arand [77] performed a study targeting these limitations of previous studies by arguing that the mixed results concerning hyperarousal in insomnia might be related to the fact that the involved physiological systems differ between insomnia patients and that the measurements were limited in time to a specific moment. As such, a more general measure of physiological arousal, for example metabolic rate reflected by whole body oxygen use, would give more consistent and accurate results. Insomnia patients showed increased metabolic rate during the day and the night, suggesting a general 24-hour hyperarousal disorder, which in turn is responsible for the reported sleep impairments. This surprising result lead to the suggestion that the presence of such a general hyperarousal could also be considered as a predisposing factor, making a person more prone to emotional and/or cognitive arousal and the resulting sleep impairments, and not as a conditioned arousal response. This conclusion can be considered a very important and topical subject. The presence of a predisposing arousal factor is not present in all insomnia patients however, as was shown by the study of Varkevisser et al. [26] who found no significant difference in 24-hour cardiovascular parameters, free cortisol, and body temperature. It was suggested that their insomnia sample was not characterised by a general hyperarousal disorder on the level of physiological arousal. These results imply the possible presence of two distinct categories of insomnia patients, namely a group characterised by a predisposing arousal disorder, and a second group distinguished by specific conditioned arousal responses related to sleep and sleep difficulties. Recent research on the possible influence of specific genes on sleep propensity and waking performance has given preliminary evidence for a predisposing factor with an impact on the sleep and wake EEG in healthy sleepers [78]. The presence of PER34/4 or PER35/5 in healthy sleepers results in different SWS, SWA and waking performance. It has been shown that people with PER35/5 are characterised by a greater sleep propensity during NREM sleep, reflected by faster sleep onset and higher SWA during NREM sleep, in comparison to subjects characterized by PER34/4. The differential effects of both genes was even more apparent after sleep deprivation, since the presence of PER34/4 resulted in less inhibition of REM sleep during recovery, no increase in theta EEG power and less decrements in waking performance during sustained wakefulness. Future research evaluating PER3 VNTR polymorphism in insomnia patients might clarify some of the unanswered questions regarding arousal and predisposing factors.
Arousability and Habituation A final relevant question regarding arousal and its role in the development of insomnia, is related to the degree of arousal that insomnia patients develop when confronted with new or emotional stimuli [7]. It has been shown that a higher arousability reflected by higher
Conditioned Arousal in Insomnia Patients
15
scores on the Arousal Predisposition Scale (APS) in healthy individuals is associated with stronger electrodermal and EMG responses, e.g. physiological arousal [79]. Lundh et al. [80] performed a study evaluating personality profiles as an indication of predisposing factors in the development of insomnia. Their patient sample was characterized by higher emotional sensitivity, slow recuperation after stress, and worrying. When confronted with new/emotional stimuli, a greater arousal response is produced, which in combination with the slow recuperation will remain present for a longer period in comparison to healthy sleepers. This situation in turn, might increase the possibility of creating negative associations or conditioned responses to sleep related cues. Furthermore, the predisposition of excessive worry will lead to more negative cognitions about the sleep disruption. The presence of these predisposing factors can be the starting point for the onset of the behavioral/neurocognitive model, resulting in a negative vicious cycle. In this situation, it is a matter of being prone to react with higher arousal levels on a stressful or emotional situation and the slow habituation from stress that make up the predisposition to insomnia, and not per se the presence of a general 24-hour hyperarousal.
Current Study The aim of the current observational study is to assess the presence of physiological, cognitive and/or cortical arousal within a sample of primary insomnia patients in comparison to healthy controls. In line of current knowledge, we hypothesize that insomnia patients are characterized by some form of hyperarousal, being physiological, cognitive and/or cortical. As to which component of the arousal system will be elevated, no hypotheses are put forward. Furthermore, possible correlations between hyperarousal and subjective or objective sleep parameters will be explored. In addition to differences in sleep macrostructure, we hypothesize to find significant differences in microstructural parameters of sleep, as well as reported sleep reflected by the sleep logs. In accordance with the literature, we hypothesize that our insomnia group will show greater discrepancy between objective and subjective sleep variables than good sleepers.
Method Subjects Primary insomnia patients were recruited through clinical sleep centers and primary care physicians. After a short screening interview by phone to check for possible medical conditions and medication use, eligible candidates were invited for a full screening session. In addition to a comprehensive sleep history and the Mini International Neuropsychiatric Interview (M.I.N.I.) [81], the following questionnaires were used: Pittsburgh Sleep Quality Index (PSQI) [82], Epworth Sleepiness Scale (ESS) [83], Athens Insomnia Scale (AIS) [84], State Trait Anxiety Index (STAI) [85], Beck Depression Inventory (BDI) [86], Presleep Arousal Scale (PSAS) [87] with a somatic (PSAS SOM) and a cognitive (PSAS COG)
16
Aisha Cortoos, Elke De Valck and Raymond Cluydts
subscale. Once enrolled in the study subjects received an explanation of the complete procedure and signed an informed consent. Of the 158 subjects with sleep complaints who wanted to join the study, 56 subjects were invited for an interview. 27 insomnia patients fulfilled the in- and exclusion criteria (see below) and came to our lab for a polysomnography. 20 insomnia patients were enrolled in this study, but 3 more patients cancelled their participation. A total of 17 insomnia patients, 11 men and 6 women (mean age 42.6) were finally included in this study. 13 of them already underwent a polysomnography in a clinical sleep centre the past year. 16 out of 17 insomnia patients reported a combination of sleep onset and sleep maintenance problems with a dominance of the latter type. Only 1 patient reported an exclusive sleep onset disruption. Twelve healthy sleepers, 7 men and 5 women (mean age 44.4), participated in the study as a control group for baseline sleep comparisons. They underwent a similar screening session. This study was evaluated and approved by the Medical Ethics Committee of the Brussels University Hospital.
Inclusion and Exclusion Criteria Insomnia patients between 18 and 60 years of age had to present either a sleep onset problem (latency > 30 minutes) or a sleep maintenance problem (wake after sleep onset > 30 minutes) based on a polysomnography. In addition they had to report sleep complaints with a minimum of 3 times per week, and duration of the insomnia complaints of more then 6 months. Impairment in daytime functioning had to be present and all participants had to be medication-free for at least 4 weeks before the start of the study, as well as during the whole study. All psychiatric or medical disorders were excluded, except for a positive response in the M.I.N.I. on dysthymia and/or generalized anxiety disorder when it was clearly related to their sleep complaints. Table 1. Clinical characteristics Insomnia
Duration insomnia (years) Age STAI 1 STAI 2 BECK AIS PSQI PSAS SOM PSAS COG ESS
n=17 ♂=11;♀=6) 12.41 (10.15) 42.65 (9.35) 34.12 (5.56) 42.18 (7.19) 5.65 (5.23) 12.24 (3.53) 11.53 (2.00) 11.41 (4.58) 20.88 (8.53) 7.65 (4.96)
Controls n=12 (♂=7;♀=5) 0 (0) 44.42 (7.68) 27.67 (6.3) 34.58 (9.03) 2.67 (3.08) 2.17 (1.47) 4.00 (1.76) 9.50 (1.62) 11.75 (2.30) 7.08 (2.35)
*indicates significant difference with control group (p. < .05)
Effect size (r)
0.85* 0.09 0.52* 0.39* 0.25 0.83* 0.83* 0.15 0.41* 0.11
Conditioned Arousal in Insomnia Patients
17
Further exclusion criteria for all subjects: students, shift workers, pregnancy, consumption of more than two alcohol units/ day for woman and three alcohol units/day for men, consumption of more than five caffeine beverages/day, phase delayed or phase advanced syndrome, abnormal bedtime hours (< 09:30 PM) or irregular sleep-wake schedule, parents with newborns, excessive daytime sleepiness (ESS>13 and subjective report of difficulty staying awake during the day), presence of other primary sleep disorders (RLL, PLM, sleep apnea,…), BMI > 30.
Sleep Diary and Actigraphy Before the polysomnography, participants were asked to fill in a sleep diary and wear an actigraphy during the night for 2 weeks, to check for irregular sleep-wake schedules. The morning after the polysomnography, all participants were asked to fill in a morning questionnaire evaluating their night in the sleep lab, consisting of the Brussels Indices of Sleep Quality (BISQ) and a PSAS. Following variables were calculated from the sleep diary: Total Sleep Time (TST), Sleep Latency (SOL), Wake after sleep onset (WASO), Sleep Efficiency (SE), and Time in Bed (TIB).
Wake EEG All participants underwent a full-cap EEG measurement using the Cognitrace (A.N.T.) the evening they came to the laboratory for their sleep night. 19 electrodes were placed according to the international 10-20 system (Fp1, Fp2, F3, F4, F7, F8, Fz, C3, C4, Cz, P3, P4, Pz, T3, T4, T5, T6, O1, O2) and were averaged referenced online. An EOG and EMG submentalis were added to exclude artifacts of eye movements or muscle activity. Sampling rate was 256 Hz and impedances were kept below 10 kOhm. A 5 minute measurement with eyes open and eyes closed was performed. A Fast Fourier Transformation (FFT) Analysis was performed on the wake EEG on a minimum of 90 seconds artefact-free data using Neuroguide software (Applied Neuroscience, Inc.). The spectrum was divided into the following EEG frequency bands: delta (1-3.5 Hz), theta (4-7.5 Hz), alpha (8-12 Hz), beta1 (12-15 Hz), beta2 (15-17.5 Hz), beta3 (18-25 Hz), and high beta (25.5-30 Hz). Both absolute and relative values were calculated and a log transformation was performed to counter normality issues.
Polysomnography A polysomnography was performed at the experimental sleep laboratory at the Vrije Universiteit Brussel. In accordance with the studies of Perlis et al. [66, 67] analysis were performed on the first screening night. The recording montage consisted of 3 EEG electrodes referenced to a single mastoid (F3-A2, C4-A1, O1-A2), 2 EOG electrodes referenced to a single mastoid (LOC, ROC), a bipolar submentalis EMG, tibialis EMG, and EKG. A 32
18
Aisha Cortoos, Elke De Valck and Raymond Cluydts
channel Embla N7000 recording system was used (Medcare) with a DC offset of 500 mV max and a fixed DC low cut filter at 0.3 Hz. The signal was digitized at a sampling rate of 500Hz using Somnologica Software. The EEG and EOG signals were high pass filtered at 0.5 Hz and low pass filtered at 40 Hz, EMG channels were high pass filtered at 5 Hz and low pass filtered at 70 Hz. All data was scored in 30-second epochs according to the Rechtschaffen & Kales [88] rules by a trained specialist, unaware of group allocation. Outcome variables were Total Sleep Time (TST), Sleep Onset Latency (SOL) defined as lights out to the first minute of stage 1 sleep, Wake After Sleep Onset (WASO), Sleep Efficiency (SE), % Slow Wave Sleep (SWS) of the Sleep Period Time (SPT), % REM sleep of the SPT, % Stage 1 sleep (S1) of the SPT and % Stage 2 sleep (S2) of the SPT. Furthermore, the arousal index defined as the amount of arousals (3-15 seconds) per hour and number of awakenings was calculated. Additionally, the EMG level (Root Mean Square µV) of the first period of wakefulness during the sleep onset period was also analyzed as a measure of baseline tension level. Movement artefacts were excluded from analysis. Spectral analysis was performed on C4-A1 to evaluate both the sleep onset period (SOP) and NREM and REM sleep. SOP was defined as lights-out to the first 5 minutes of stage 2 sleep [60]. Artefacts were removed and the SOP was divided into four quartiles to evaluate the EEG dynamics. FFT analysis was performed using Neuroguide software (Applied Neuroscience, Inc.), in which standard EEG frequency bands were defined: delta (1-3.5 Hz), theta (4-7.5 Hz), alpha (8-12 Hz), beta1 (12-15 Hz), beta2 (15-17.5 Hz), beta3 (18-25 Hz), and high beta (25.5-30 Hz). Regarding the sleep EEG, all epochs containing movements, EMG artefacts, sleep stage transitions or arousals (3-15sec) were excluded from analysis. All artefact-free epochs underwent high-pass filtering and hanning windowing followed by Fast Fourier Transformation in 2-second epochs. Delta (0.5 – 3.5 Hz), theta (4 – 8 Hz), alpha (8.5 – 12 Hz), sigma (12.5 – 16 Hz), beta (16.5 – 30 Hz) and gamma (30.5 – 60 Hz) were the analysed frequency bands. Analyses were performed using Somnologica Science software and data was exported to an excel file. The definition of NREM and REM cycles was adopted from the study of Perlis and colleagues [67]. Relative power spectra were calculated by dividing each frequency band by the calculated total power (sum of power of all frequency bands).
Arousal Parameters The somatic subscale of the PSAS will be used as a measure of subjective physiological arousal, both retrospective, as well as during their stay in our sleep laboratory. Secondly, EMG levels during sleep onset, as well as a cortisol sample the evening of the scheduled polysomnography will be used as an objective measure of physiological arousal. The cognitive subscale of the PSAS will be used as a measure of subjective cognitive arousal. Finally, an evaluation of cortical arousal reflected by the spectral profile of the wake and sleep EEG (SOP-NREM-REM) will be performed.
Conditioned Arousal in Insomnia Patients
19
Procedure Before the polysomnography, participants were asked to fill in a sleep diary and wear an actigraphy during the night for 2 weeks, to check for irregular sleep-wake schedules. Subjects came to our sleep lab for the first PSG measurement at the Vrije Universiteit Brussel. They came in around 8:00 pm and received information on the procedure of the evening and purpose of the measurement. Around 8:15 pm the EEG measurement in an experimental room was started. During the eyes open condition, subjects were asked to keep their eyes fixed on a white dot on the floor, approximately 1.5 m from their seat to minimize eye movements. In the eyes closed condition, subjects were asked to visualize the same white dot and try to keep their eyes as still as possible. Afterward the electrodes for the night were applied. Around 10:30 pm cortisol measurement was performed through a saliva sample. Subjects went to bed between 10:30 pm and 12:00 pm, depending on their usual bedtime. Time in bed was approximately 7 hours and 30 minutes and was kept stable for every subject. The next morning they were asked to fill in the Brussels Indices of Sleep Quality (BISQ) and PSAS to monitor their subjective sleep quality.
Statistical Analysis Statistical analysis was performed using STATISTICA 8.0 software. Normality and homogeneity of variances were checked before analysis. To evaluate differences regarding clinical, demographical, PSG and sleep diary data an independent samples t-test was performed. If one of the assumptions was violated, a Mann-Whitney U test was used. The wake EEG was evaluated using a 2x19 repeated measures ANOVA for every EEG frequency band, using group (insomnia vs. controls) as a between subject variable and electrode location (19 locations) as a within subject variable. A 2x4 repeated Measures ANOVA was used for the SOP, with group (insomnia vs. controls) as a between subject variable and quartile as a within subject variable. The first 3 NREM and REM cycles were also examined using an 2x3 repeated measures ANOVA with group (insomnia vs. controls) as a between subject variable and NREM/REM cycle as a within subject variable. The calculated effect size for the repeated measures ANOVA is partial-eta squared (ηp2). Finally, in order to examine possible associations between sleep and arousal, a Spearman Rank correlational analysis was performed.
Results Clinical Characteristics In addition to the data presented in table 1, our insomnia subjects reported significantly more anxiety, both as a state and trait characteristic (STAI-1: z = 2.81; p.<.005; STAI-2: z = 2.13; p.<.05). They reported increased presleep cognitive arousal during the past month in comparison to the control group (z = 2.24; p.<.05). No difference was found for somatic
20
Aisha Cortoos, Elke De Valck and Raymond Cluydts
presleep arousal. Furthermore, state anxiety correlated significantly with PSAS-SOM (rs=.60) and PSAS-COG (rs=.51) in insomniacs, which was absent in healthy sleepers.
Objective and Subjective Sleep Parameters Results from the polysomnography and sleep diaries are displayed in Table 2 (A). Objective sleep parameters show that the group of insomnia patients was characterized by significant objective disruptions of sleep. Table 2. Objective and subjective sleep parameters A. PSG
Insomnia n=17 (♂=11;♀=6) 22.11 (15.48) 78.44 (48.17) 373.01 (47.03) 82.74 (10.5) 14.98 (5.11) 18.31 (4.16) 6.38 (3.13) 42.98 (8.34) 11.29 (7.56) 14.30 (5.24) 473.57 (21.71)
SL (min.) WASO (min.) TST (min.) SE (%) SWS (%SPT) REM (%SPT) F1 (%SPT) F2 (%SPT) Awakenings (#) Arousal index (#/hour) TIB (min.) B. Sleep diary SL (min.) 76.17 (97.36) WASO (min.) 119.70 (92.86) TST (min.) 300.00 (102.81) SE (%) 63.68 (21.52) C. Discrepancy between objective and subjective sleep SOL (min.) 54.05 (94.14) WASO (min.) 41.26 (68.45) TST (min.) -73.01 (74.23)
Controls n=12 (♂=7;♀=5) 9.24 (4.54) 32.7 (21.55) 412.25 (31.51) 92.8 (4.74) 16.86 (8.27) 23.03 (4.74) 5.77 (1.61) 42.70 (13.39) 6.00 (2.69) 6.94 (2.90) 454.19 (38.8)
Effect size (r)
10.75 (8.04) 18.66 (17.24) 421.66 (32.49) 92.73 (5.25)
.80* .73* .71* .77*
1.50 (6.13) -14.03 (16.92) 9.41 (28.11)
.50* .52* .67*
.51* .50* .43* .50* .13 .47* .11 .01 .38* .68* .22
*indicates significant difference with control group (p. < .05)
It took them longer to fall asleep (z = 2.79; p.<.01; r = .51), they spend more time awake during the night (t(27)=3.06; p.<.005; r = .50), had less TST (t(27)=-2.51; p.<.05; r = .43) and a decreased SE (t(27)=-3.07; p.<.005; r = .50). Regarding sleep architecture, no significant differences were observed, except for a decreased REM sleep % (t(27)=-2.83; p.<.01; r = .47) in comparison to the group of healthy sleepers. Sleep was more fragmented in insomnia patients reflected by more awakenings (z = 2.09; p.<.05; r = .38) and a higher arousal index (z = 3.70; p.<.0005; r = .68). The morning after the PSG, subjects were asked to evaluate their sleep by filling in the BISQ, which revealed significant differences between both groups (Table 2 B). Insomnia patients reported longer SOL (z = 4.13; p.<.00005; r = .80), more WASO (z = 3.96; p.<.0001; r = .73), less TST (z = -3.85; p.<.0005; r = .71) and a decreased SE (z = -4.18; p.<.00005; r = .77). As was hypothesized, insomnia patients were characterized by a greater discrepancy between objective sleep parameters and perception of sleep (Table 2 C). They overestimated SOL by approximately 55 minutes (z = 2.74; p.<.01; r
Conditioned Arousal in Insomnia Patients
21
= .50) and WASO by an average of 41 minutes (z = 3.96; p.<.005; r = .52), while TST was underestimated by an average of 73 minutes (z = -3.63; p.<.0005; r = .67).
Cognitive and Physiological Arousal To evaluate the two arousal components described by the behavioral model, our subjects completed the PSAS the morning after the PSG recording as a measure of subjective cognitive and physiological arousal. Results show that our insomnia sample reported significantly more cognitive arousal (z = 2.91; p.<.005; r = .54) during the SOP, but no increased physiological arousal was indicated. Markers for objective physiological arousal were obtained by a cortisol sample the evening of their stay in our laboratory, and analysis of the EMG level during the SOP. No indications of objective physiological arousal were found (table 3). Table 3. Cognitive and physiological arousal. Cognitive arousal PSAS COG Physiological arousal PSAS SOM EMG (RMS µV) Cortisol
Insomnia n=17 (♂=11;♀=6) 15.52 (5.26)
Controls n=12 (♂=7;♀=5) 10.50 (1.97)
9.70 (2.36) 3.76 (1.18) 2.34 (1.89)
8.58 (1.08) 3.48 (1.11) 1.74 (0.46)
Effect size (r) .54* .24 .01 .02
*indicates significant difference with control group (p. < .05)
Cortical Arousal: Wake EEG, SOP and NREM/REM Wake EEG To assess the possibility of increased cortical arousal in the evening outside the bedroom, a wake EEG was performed. A 2x19 repeated measures ANOVA revealed no differences between insomnia patients and healthy controls. The SOP The SOP defined starting from lights-off to the first 5 minutes of stage 2 sleep was divided into 4 quartiles to evaluate the specific EEG dynamics between insomniacs and healthy controls. A 2x4 repeated measures ANOVA was performed for both relative and absolute power in 7 frequency bands. For all frequency bands, a main effect for quartile was observed. Absolute delta (F(27)=105.74; p.<.0000001; ηp2 = .79) and theta (F(27)=41.67; p.<.0000001; ηp2 = .60) and beta1 (F(27)=13.27; p.<.0000001; ηp2 = .32) power increased from the first to the last quartile, alpha (F(27)=9.20; p.<.00005; ηp2 = .25) , beta2 (F(27)=8.29; p.<.0001; ηp2 = .23), beta3 (F(27)=40.10; p.<.0000001; ηp2 = .59) and high beta (F(27)=26.26; p.<.0000001; ηp2 = .49) decreased. A small but significant group x quartile
22
Aisha Cortoos, Elke De Valck and Raymond Cluydts
interaction effect was found for absolute delta (F(27)=3.64; p.<.05; ηp2 = .11) and alpha (F(27)=3.12; p.<.05; ηp2 = .10) EEG power (figure 1 and 2).
Figure 1. Evolution of the absolute delta power during the sleep onset period. A log transformation (ln) was performed.
Post-hoc Tukey showed that the controls had a steeper and faster increase in delta power (quartile 2 vs. quartile 3: p.<.0005; no significant difference between third and fourth quartile) in comparison to the insomnia group (significant difference between quartile 2 and 3: p.<..005; quartile 3 and 4: p.<.0005). In regard to the absolute alpha power, no significant difference between all quartiles was found for the insomnia group, whereas the controls showed a gradual significant decrease (quartile 1 versus quartile 3 and 4: p.<0005). No significant differences were found for the beta EEG frequency bands. Regarding the relative power, similar results were found: a significant main effect for quartile were delta (F(27)=74.44; p.<.0000001; ηp2 = .73) and theta (F(27)=17.17; p.<.0000001; ηp2 = .39) power increases during SOP, while all other frequencies showed a decrease (alpha: F(27)=53.70; p.<.0000001; ηp2 = .67; beta1: F(27)=3.91; p.<.05; ηp2 = .13; beta2: F(27)=45.14; p.<.0000001; ηp2 = .63; beta3: F(27)=81.28; p.<.0000001; ηp2 = .75; high beta: F(27)=57.62; p.<.0000001; ηp2 = .68). Again, a significant interaction effect was found for relative delta (F(27)=3.35; p.<.05; ηp2 = .11) and alpha (F(27)=5.17; p.<.005; ηp2 = .16) EEG power (figure 3 and 4).
Conditioned Arousal in Insomnia Patients
23
Figure 2. Evolution of the absolute alpha power during the sleep onset period. A log transformation (ln) was performed.
Figure 3. Evolution of relative delta power (%) during the sleep onset period. Log transformation (ln) was performed.
24
Aisha Cortoos, Elke De Valck and Raymond Cluydts
Post-hoc Tukey analysis showed a faster and steeper increase in relative delta power in the healthy sleepers (quartile 2 vs. 3: p.<.0005) in comparison to insomniacs (quartile 3 vs. 4: p.<.005). The results for the relative alpha power show a gradual decrease for both groups, but this process is faster and steeper for controls (quartile 2 vs. 3: p.<.0005) in comparison to the insomnia group (quartile 3 vs. 4: p.<.05). The difference between absolute and relative alpha power, suggests that the decrease in relative alpha power is due to an increase in absolute power of one of the other frequency bands, as opposed to an actual decrease of absolute alpha power.
Figure 4. Evolution of relative alpha power during the sleep onset period. Log transformation (ln) was performed.
No significant interaction effects were found for the other frequency bands. The Sleep EEG: NREM/REM First, the average of all the previously defined relative frequency bands during NREM and REM sleep of the entire night was calculated (figure 5). No significant differences were found between both groups.
Figure 5. Relative spectral power profiles during NREM and REM sleep. An average of the entire night was calculated for each frequency band. Error bars denote standard error.
Conditioned Arousal in Insomnia Patients
25
Since the number of sleep cycles was not equal for all participants, an average of NREM and REM sleep was calculated for the first three sleep cycles. Again, no significant differences were found between insomnia patients and healthy sleepers. Furthermore, an assessment was made of the evolution of all described EEG frequencies from the first to the third NREM and REM cycle, but no significant differences were found.
Correlational Analysis of Arousal and Sleep Parameters As previous studies have shown that arousal and sleep disruptions are interrelated, a correlational analysis was performed to evaluate possible links between objective and subjective sleep parameters and arousal components. Given the risk for multiple comparisons and chance hits, only the following correlations were analyzed: objective SOL and arousal components, discrepancy between objective and subjective SOL and arousal components, and cortisol and sleep fragmentation parameters. More specific it was hypothesized that specific sleep EEG frequencies are related to objective sleep disruption and sleep misperception: delta and beta EEG activity during the SOP and NREM sleep were compared to the arousal index and TST discrepancy. Objective Sleep Parameters and Arousal A Spearman Rank correlational analysis was performed for each group to evaluate the possible associations between objective sleep parameters and arousal components. The objective SOL was negatively correlated with the average absolute delta (rs=-.77) EEG activity during the SOP in insomnia patients. Evening cortisol level was positively correlated with the arousal index (rs=.55) and number of awakenings (rs=.70) during the night. Relative beta EEG activity during NREM sleep was positively correlated with WASO (rs=.66) and the arousal index (rs=.55), and negatively correlated with TST (rs=-.49) and SE (rs=-.68). Relative beta power during REM sleep was also positively correlated with the arousal index (rs=.64) (all p‘s <.05). Within our group of healthy sleepers, the objective SOL was negatively correlated with absolute delta power (rs=-.64). Furthermore, a positive correlation was found between cortisol and PSAS-SOM (rs=.66). Relative beta EEG activity during NREM sleep was positively correlated with WASO (rs=.59), number of awakenings (rs=.64), and the discrepancy of TST (rs=.60) (all p‘s <.05). The only correlation observed in both groups, as well as in the total sample of subjects (insomnia and controls as one group) was the negative correlation between objective SOL and the amount of absolute delta power (rs=-.70). Subjective Sleep Parameters and Arousal A Spearman Rank correlational analysis was performed for each group to evaluate the possible associations between subjective sleep parameters and arousal components. The SOL discrepancy in insomnia patients was positively correlated with the PSAS-SOM (rs=.49) and cortisol level (rs=.51).
26
Aisha Cortoos, Elke De Valck and Raymond Cluydts
The SOL discrepancy in the control group was positively correlated with the EMG level (rs=.60) during the SOP. Relative beta EEG activity during NREM sleep was positively correlated with the discrepancy of TST (rs=.60) (all p‘s <.05).
Conclusion Clinical Data In this study, a relatively homogenous group of ‗objective‘ insomnia patients was targeted and compared to a matched control group of good sleepers. Indeed, our insomniacs were clearly characterized by sleep disruption as reflected by the PSG data. They tended to take more time to fall asleep, were more awake during the night, had less TST and a decreased SE. Moreover, both the macro- and microstructure of sleep were significantly fragmented, reflected by more awakenings and a higher arousal index in comparison to controls. Interestingly, when evaluating the effect sizes for all objective sleep parameters, the highest effect was found for the arousal index, which is a strong argument for including this parameter in standard sleep evaluation. An often reported phenomenon in insomnia patients is the fact that perception of sleep quality is not in accordance with objective findings, a result also present in our insomnia group. In line with former research [51-53, 56], our group of insomniacs—although characterized by objective sleep disruption—tended to overestimate SOL and WASO, as well as underestimate TST and SE. The discrepancy between perception and polysomnography has been related to the occurrence of arousals [89]; however, our results did not show a positive correlation between the arousal index and perception of sleep within the insomnia group, suggesting that another factor might be in play. The insomnia patients were also characterized by higher levels of trait and state anxiety, as well as more cognitive arousal instead of physiological arousal, a finding previously reported by Lichstein and Rosenthal [3]. Furthermore, trait anxiety was related to the perception of the SOL, while this was not the case in the control group. Moreover, there appeared to be a relationship between state anxiety and presleep arousal in insomnia patients. Tang and Harvey [76] showed in a napping experiment that the presence of both anxiety and cognitive arousal have a greater impact on sleep and perception of sleep. Indeed, in their study only the anxious cognitive arousal group showed a greater discrepancy in TST, as opposed to a neutral cognitive arousal group in comparison to a no manipulation group.
Arousal in Insomnia: A Dynamic and Transitional Concept? Our results confirm the presence of arousal in insomnia patients. First of all, the heightened scores on the trait anxiety subscale of the STAI questionnaire suggests that our insomnia patients were characterized by a predisposition to react with an emotional arousal response in stressful situations, which corresponds with the behavioral perspective and neurocognitive model of insomnia. Furthermore, the results of the STAI-2 subscale confirm the presence of anxiety in stressful situations. During the presleep period, they also reported
Conditioned Arousal in Insomnia Patients
27
more cognitive arousal, a result in line with previous studies [27, 28, 30, 42]. As in the study of Lichstein and Rosenthal [3], presleep physiological arousal was also absent in our study sample. As discussed previously, research regarding the presence of physiological arousal reflected by EMG levels or cortisol show mixed results. Besides the subjective physiological arousal, muscle tension during the SOP and evening cortisol were measured to evaluate the objective physiological arousal related to the sleep environment and sleep time, but no effects were found. This corresponds to the studies performed by Riemann et al. [25], as well as Varkevisser et al. [26], who also found no indication of physiological arousal whatsoever. As the insomnia group also failed to report a significant increased physiological presleep arousal over the last month during the screening period, it could be suggested that this was just a characteristic of this patient sample. Next, an indication was found for an impairment of cortical sleep initiation processes during the SOP. The absence of a decrease in alpha power in combination with the slower increase in delta power, suggests that normal sleep onset processes were delayed, resulting in longer sleep onset latencies. This result is in agreement with previous studies evaluating the sleep onset period [60, 61]. We did not find, however, any significant differences for beta EEG activity, both during wakefulness and sleep. Again, these results emphasize the fact that hyperarousal in all three systems studied is apparently not always simultaneously present in insomnia. Arousal most probably should not be seen as a static phenomenon. When reviewing the process of falling asleep at the level of EEG changes, we see that two shifts need to occur before sleep onset is achieved. First, high frequency EEG activity needs to decrease, and secondly low frequency EEG activity needs to increase [58, 59]. According to the neuronal group theory [64, 90] maximal alertness and maximal sleepiness are part of a continuum, suggesting that transitional states are possible as well. Furthermore, the Neuronal Transition Probability model [65] posits that oscillatory modes of the thalamocortical neurons responsible for the beta, sigma and delta oscillations clearly show this transitional character of arousal and sleepiness. Therefore, it might be suggested that maximal alertness is equal to hyperarousal, reflected by both increased levels of beta EEG activity and decreased levels of slow wave activity in the delta range. A second phase could be referred to as arousal; it is a condition in which hyperarousal is not present anymore, but complete de-arousal is still not reached, reflected by normal levels of beta EEG activity and slower increase of delta power. Finally, when complete de-arousal is reached, a normal transition from wake to sleep can occur. In light of this perspective, it can be assumed that our insomnia patients were characterized by a lack of complete de-arousal, reflected by impairment in sleep initiation processes as seen in the slower EEG frequencies during the SOP. The strong correlation found between the sleep onset latency and the amount of delta power both in healthy sleepers and insomnia patients strengthens the hypothesis that the depolarization to the delta mode of the TC neurons, and thus the speed of transition from wake to sleep is the key factor, and not the beta EEG power. This perspective can also be used to explain the lack of hyperarousal during NREM and REM sleep. If, according to this theory, our insomniacs were not characterized by hyperarousal, but by a lack of complete dearousal, heightened levels of beta EEG activity were not expected. Moreover, the frequent awakenings and arousals may be an indication of a certain degree of instability of the sleep system because of the arousal condition, since these intrusions are defined by the presence of
28
Aisha Cortoos, Elke De Valck and Raymond Cluydts
higher frequencies such as alpha or beta EEG activity. When arousal is considered as a varying construct on a continuum, the mixed results regarding hyperarousal in insomnia can be better interpreted. Assuming that the maximal state of hyperarousal is accompanied by increased levels on all 3 components of the multidimensional arousal construct, the gradual decrease in hyperarousal will lead to a normalization of some arousal components. For example, our insomnia patient sample apparently was only characterized by presleep cognitive arousal, state anxiety, impairment of sleep initiation processes and instability of the sleep maintenance processes. As such, it could be hypothesized that physiological and cortical hyperarousal will be more apparent when reaching the upper level (hyperarousal) of the continuum, while cognitive arousal is a sign of a minimal arousal level. Indeed, cognitive arousal is much more prevalent in insomnia studies than physiological arousal [3] and is often regarded as the starting point for the development and maintenance of insomnia and related arousal changes [32, 35]. Of course, the recruitment of our patient sample on the basis of their polysomnographical sleep distortions might have influenced the cortical arousal data, given the fact that Krystal and coworkers [68] found that specific EEG correlates of cortical arousal were more pronounced within a group of ‗subjective‘ insomnia patients in comparison to ‗objective‘ insomniacs and controls. However, our insomnia patient group showed a high degree of underestimation of TST (19.5%), but this was not accompanied by increased high frequency EEG activity, as would be expected by the theory posited by Krystal and colleagues. Furthermore, Buysse et al. [69] found that only women are characterized by heightened levels of beta EEG activity during sleep. Given that our insomnia and control groups consisted of more men than women, it is possible that cortical arousal reflected by beta EEG activity was not a predominant feature.
Sleep and Arousal Based on these results and recent literature, we propose to conceptualize arousal as a multidimensional construct, expressing itself in different systems with varying degrees. To what extent is arousal associated with the specific sleep impairments, both objectively and subjectively? Previous studies have found different correlations between arousal and sleep disruption, again pointing out the heterogeneity of this construct and its role in sleep. On the one hand, we found a correlation between evening cortisol and number of awakenings and arousal index, a finding in accordance with Vgontzas et al. (1998, 2001) and Rodenbeck et al. (2002). Also, cortisol levels were associated with the misperception of the SOL. These results suggest that physiological arousal reflected by evening cortisol is associated with a significant fragmentation of sleep macro- and microstructure, as well as a misperception of the time needed to fall asleep. On the other hand, the subjective physiological presleep arousal component seemed to be related with the discrepancy of SOL. Although our insomnia patients were not characterized by increased levels of beta EEG power during wakefulness and sleep, correlations have been found with objective sleep parameters. It seems that the presence of beta EEG power, both during NREM and REM sleep, is related to sleep fragmentation, reflected by the arousal index. An important remark related to this issue is the
Conditioned Arousal in Insomnia Patients
29
fact that all awakenings and arousals were excluded from spectral analysis, which means that this correlation can not be due to the mere presence of arousals in insomnia patients. Furthermore, NREM beta EEG activity was also correlated with objective WASO, TST and SE. This seems not to be in accordance with previous research suggesting that beta EEG activity is specifically related to subjective insomnia and the perception of sleep [66-68]. Our insomnia sample seemed to be characterized by a discrepancy of sleep perception, in combination with a lack of cortical hyperarousal reflected by high frequency EEG activity. Could it be that this was a specific subtype of arousal-related insomnia, in which the beta EEG activity is more associated with objective PSG disruption both at the level of macroand microstructure? Misperception of TST was associated with the amount of alpha EEG power during REM sleep, a result not mentioned before. Furthermore, misperception of SOL in our study was related to the somatic component of the PSAS, and not the cognitive arousal component as was previously shown by Tang and Harvey [76]. The fact that they experimentally induced arousal in healthy sleepers might be an important factor. However, De Valck et al. [75] did not find any correlations between the experimentally induced arousal and increased sleep onset latencies measured by an MSLT. Could it be due to individual differences in predisposing factors? In summary, the insomnia group was characterized by more cognitive presleep arousal, but no association was found with any sleep variable. Instead, the physiological component of arousal appeared to play an important role in influencing both objective and subjective sleep, reflected by the correlation between cortisol and sleep fragmentation and somatic presleep arousal and perception.
Conclusion In this study we used a relatively homogenous sample of insomnia patients characterized by objective sleep distortions as shown by a polysomnography. They reported sleep maintenance problems in combination with sleep onset difficulties with a dominance of the first type. In accordance with previous studies evaluating NREM/REM EEG profiles in insomnia patients [66, 67], analyses were performed on the first PSG recording. Summarizing, this group experienced more cognitive and emotional arousal, but no increase in physiological arousal, both subjectively as well as objectively, in comparison with a control group. Indications of cortical arousal were only present during the sleep onset period, reflected by a stable alpha EEG level and slower increase of delta power, resulting in longer sleep onset latencies. Correlational analysis on the other hand, revealed a stronger association between physiological parameters of arousal with sleep, in comparison to the cognitive arousal component. Furthermore, the cortical arousal variables were correlated with objective sleep disruption, not with sleep perception. Together with literature, these results point to a large variability in insomnia patients as to the expression of hyperarousal and the different arousal components. It is suggested to regard hyperarousal as a more transitional state that can vary on a continuum going from maximal alertness/hyperarousal to maximal sleepiness/de-arousal. Future research should take into account the possible variation within the insomnia population of this construct and the role of specific predisposing factors, and
30
Aisha Cortoos, Elke De Valck and Raymond Cluydts
examine the specific effects of different degrees of hyperarousal through experimentally induced arousal studies as to further clarify the role of this concept in insomnia and its different subtypes.
References [1]
[2]
[3] [4] [5] [6] [7]
[8] [9] [10] [11] [12] [13] [14] [15] [16] [17]
Ohayon, M.M., Prevalence of DSM-IV diagnostic criteria of insomnia: Distinguishing insomnia related to mental disorders from sleep disorders. Journal of Psychiatric Research, 1997. 31(3): 333-346. Wicklow, A. and C.A. Espie, Intrusive thoughts and their relationship to actigraphic measurement of sleep: towards a cognitive model of insomnia. Behav Res Ther, 2000. 38(7): 679-93. Lichstein, K.L. and T.L. Rosenthal, Insomniacs' perceptions of cognitive versus somatic determinants of sleep disturbance. J Abnorm Psychol, 1980. 89(1): 105-7. Spielman, A.J., L.S. Caruso, and P.B. Glovinsky, A behavioral perspective on insomnia treatment. Psychiatr Clin North Am, 1987. 10(4): 541-53. Spielman, A.J., Assessment Of Insomnia. Clinical Psychology Review, 1986. 6(1): 1125. Thayer, R.E. (1989). The biopsychology of mood and arousal, New York: Oxford University Press. Lundh, L.G. and J.E. Broman, Insomnia as an interaction between sleep-interfering and sleep-interpreting processes. Journal of Psychosomatic Research, 2000. 49(5): 299310. Ogilvie, R.D., The process of falling asleep. Sleep Med Rev, 2001. 5(3): 247-270. Worsnop, C., et al., Activity of respiratory pump and upper airway muscles during sleep onset. J Appl Physiol, 1998. 85(3): 908-20. Pivik, R.T. and K. Busby, Heart rate associated with sleep onset in preadolescents. J Sleep Res, 1996. 5(1): 33-6. Monroe, L.J., Psychological and physiological differences between good and poor sleepers. J Abnorm Psychol, 1967. 72(3): 255-64. Freedman, R.R. and H.L. Sattler, Physiological and psychological factors in sleep-onset insomnia. J Abnorm Psychol, 1982. 91(5): 380-9. Freedman, R.R., EEG power spectra in sleep-onset insomnia. Electroencephalogr Clin Neurophysiol, 1986. 63(5): 408-13. Stepanski, E., et al., Heart-Rate Changes In Chronic Insomnia. Stress Medicine, 1994. 10(4): 261-266. Bonnet, M.H. and D.L. Arand, Heart rate variability in insomniacs and matched normal sleepers. Psychosomatic Medicine, 1998. 60(5): 610-615. Lack, L.C., et al., The relationship between insomnia and body temperatures. Sleep Medicine Reviews, 2008. 12(4): 307-317. Morris, M., L. Lack, and D. Dawson, Sleep-onset insomniacs have delayed temperature rhythms. Sleep, 1990. 13(1): 1-14.
Conditioned Arousal in Insomnia Patients
31
[18] Lushington, K., D. Dawson, and L. Lack, Core body temperature is elevated during constant wakefulness in elderly poor sleepers. Sleep, 2000. 23(4): 504-510. [19] Rodenbeck, A., et al., Interactions between evening and nocturnal cortisol secretion and sleep parameters in patients with severe chronic primary insomnia. Neurosci Lett, 2002. 324(2): 159-63. [20] Vgontzas, A.N., et al., Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: Clinical implications. Journal of Clinical Endocrinology And Metabolism, 2001. 86(8): 3787-3794. [21] Vgontzas, A.N., et al., Chronic insomnia and activity of the stress system: A preliminary study. Journal of Psychosomatic Research, 1998. 45(1): 21-31. [22] Backhaus, J., K. Junghanns, and F. Hohagen, Steep disturbances are correlated with decreased morning awakening salivary cortisol. Psychoneuroendocrinology, 2004. 29(9): 1184-1191. [23] Roth, T., T. Roehrs, and R. Pies, Insomnia: Pathophysiology and implications for treatment. Sleep Medicine Reviews, 2007. 11(1): 71-79. [24] Van Reeth, O., et al., Interactions between stress and sleep: from basic research to clinical situations. Sleep Medicine Reviews, 2000. 4(2): 201-219. [25] Riemann, D., et al., Nocturnal cortisol and melatonin secretion in primary insomnia. Psychiatry Research, 2002. 113(1-2): 17-27. [26] Varkevisser, M., H.P.A. Van Dongen, and G.A. Kerkhof, Physiologic indexes in chronic insomnia during a constant routine: Evidence for general hyperarousal? Sleep, 2005. 28(12): 1588-1596. [27] Borkovec, T.D., Insomnia. Journal of Consulting and Clinical Psychology, 1982. 50(6): 880-895. [28] Borkovec, T.D., et al., Relaxation Treatment Of Pseudo-Insomnia And Idiopathic Insomnia - Electroencephalographic Evaluation. Journal of Applied Behavior Analysis, 1979. 12(1): 37-54. [29] Morin, C.M. (1993). Insomnia: psychological assessment and mangement, New York: Guilford press. [30] Harvey, A.G., Pre-sleep cognitive activity: a comparison of sleep-onset insomniacs and good sleepers. Br J Clin Psychol, 2000. 39 (Pt 3): 275-86. [31] Wicklow, A. and C.A. Espie, Intrusive thoughts and their relationship to actigraphic measurement of sleep: towards a cognitive model of insomnia. Behaviour Research and Therapy, 2000. 38(7): 679-693. [32] Harvey, A.G., A cognitive model of insomnia. Behaviour Research and Therapy, 2002. 40(8): 869-893. [33] Taylor, L.M., C.A. Espie, and C.A. White, Attentional bias in people with acute versus persistent insomnia secondary to cancer. Behav Sleep Med, 2003. 1(4): 200-12. [34] Spiegelhalder, K., et al., Sleep-related attentional bias in patients with primary insomnia compared with sleep experts and healthy controls. J Sleep Res, 2008. 17(2): 191-6. [35] Espie, C.A., et al., The attention-intention-effort pathway in the development of psychophysiologic insomnia: A theoretical review. Sleep Medicine Reviews, 2006. 10(4): 215-245.
32
Aisha Cortoos, Elke De Valck and Raymond Cluydts
[36] Borkovec, T.D. and D.C. Fowles, Controlled Investigation of Effects of Progressive and Hypnotic Relaxation on Insomnia. Journal of Abnormal Psychology, 1973. 82(1): 153-158. [37] Nicassio, P. and R. Bootzin, A comparison of progressive relaxation and autogenic training as treatments for insomnia. J Abnorm Psychol, 1974. 83(3): 253-60. [38] Bootzin, R.R., Epstein, D., Wood, J.M., "Stimulus control instructions", In: Case studies in insomnia, P.J. Hauri, Editor. 1991, Plenum Press: New York. p. 19 - 28. [39] Chesson, A.L., et al., Practice parameters for the nonpharmacologic treatment of chronic insomnia. Sleep, 1999. 22(8): 1128-1133. [40] Spielman, A.J., P. Saskin, and M.J. Thorpy, Treatment of chronic insomnia by restriction of time in bed. Sleep, 1987. 10(1): 45-56. [41] Hauri, P.J., Sleep hygiene, relaxation therapy, and cognitive interventions, In: Case studies in insomnia, P.J. Hauri, Editor. 1991, Plenum press: New York. [42] Morin, C.M., et al., Cognitive-Behavior Therapy For Late-Life Insomnia. Journal of Consulting and Clinical Psychology, 1993. 61(1): 137-146. [43] Lichstein, K.L. and B.W. Riedel, Behavioral-Assessment and Treatment of Insomnia A Review with an Emphasis on Clinical-Application. Behavior Therapy, 1994. 25(4): 659-688. [44] Edinger, J.D., et al., Does cognitive-behavioral insomnia therapy alter dysfunctional beliefs about sleep? Sleep, 2001. 24(5): 591-599. [45] Morin, C.M., F. Blais, and J. Savard, Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behaviour Research and Therapy, 2002. 40(7): 741-752. [46] Harvey, A.G. and N.K. Tang, Cognitive behaviour therapy for primary insomnia: can we rest yet? Sleep Med Rev, 2003. 7(3): 237-62. [47] Morin, C.M., J.P. Culbert, and S.M. Schwartz, Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry, 1994. 151(8): 117280. [48] Morin, C.M. and V. Wooten, Psychological and pharmacological approaches to treating insomnia: Critical issues in assessing their separate and combined effects. Clinical Psychology Review, 1996. 16(6): 521-542. [49] Hauri, P.J., Can we mix behavioral therapy with hypnotics when treating insomniacs? Sleep, 1997. 20(12): 1111-8. [50] Perlis, M.L., et al., Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. J Sleep Res, 1997. 6(3): 179-88. [51] Borkovec, T.D., T.W. Lane, and P.H. Vanoot, Phenomenology of Sleep among Insomniacs and Good Sleepers - Wakefulness Experience when Cortically Asleep. Journal of Abnormal Psychology, 1981. 90(6): 607-609. [52] Coates, T.J., et al., Cognitive activity, sleep disturbance, and stage specific differences between recorded and reported sleep. Psychophysiology, 1983. 20(3): 243-50. [53] Mendelson, W.B., Effects of flurazepam and zolpidem on the perception of sleep in insomniacs. Sleep, 1995. 18(2): 92-6. [54] Mendelson, W.B., et al., Effects of flurazepam on sleep, arousal threshold, and the perception of being asleep. Psychopharmacology (Berl), 1988. 95(2): 258-62.
Conditioned Arousal in Insomnia Patients
33
[55] Edinger, J.D. and A.I. Fins, The distribution and clinical significance of sleep time misperceptions among insomniacs. Sleep, 1995. 18(4): 232-9. [56] Mendelson, W.B., Pharmacological Alteration of the Perception of Being Awake or Asleep. Sleep, 1993. 16(7): 641-646. [57] Steriade, M., D.A. McCormick, and T.J. Sejnowski, Thalamocortical Oscillations. In: The Sleeping and Aroused Brain. Science, 1993. 262(5134): 679-685. [58] De Gennaro, L., M. Ferrara, and M. Bertini, The boundary between wakefulness and steep: Quantitative electroencephalographic changes during the sleep onset period. Neuroscience, 2001. 107(1): 1-11. [59] Merica, H., R.D. Fortune, and J.M. Gaillard, Hemispheric Temporal Organization during the Onset of Sleep in Normal Subjects. Phasic Events and Dynamic Organization of Sleep, 1991. 7: 73-83. [60] Lamarche, C.H. and R.D. Ogilvie, Electrophysiological changes during the sleep onset period of psychophysiological insomniacs, psychiatric insomniacs, and normal sleepers. Sleep, 1997. 20(9): 724-33. [61] Merica, H. and J.M. Gaillard, The EEG of the sleep onset period in insomnia: a discriminant analysis. Physiol Behav, 1992. 52(2): 199-204. [62] Staner, L., et al., Sleep microstructure around sleep onset differentiates major depressive insomnia from primary insomnia. J Sleep Res, 2003. 12(4): 319-30. [63] Merica, H., R. Blois, and J.M. Gaillard, Spectral characteristics of sleep EEG in chronic insomnia. Eur J Neurosci, 1998. 10(5): 1826-34. [64] Krueger, J.M. and F. Obal, A neuronal group theory of sleep function. J Sleep Res, 1993. 2(2): 63-69. [65] Merica, H. and R.D. Fortune, A neuronal transition probability model for the evolution of power in the sigma and delta frequency bands of sleep EEG. Physiol Behav, 1997. 62(3): 585-9. [66] Perlis, M.L., et al., Temporal and stagewise distribution of high frequency EEG activity in patients with primary and secondary insomnia and in good sleeper controls. J Sleep Res, 2001. 10(2): 93-104. [67] Perlis, M.L., et al., Beta/Gamma EEG activity in patients with primary and secondary insomnia and good sleeper controls. Sleep, 2001. 24(1): 110-117. [68] Krystal, A.D., et al., NREM sleep EEG frequency spectral correlates of sleep complaints in primary insomnia subtypes. Sleep, 2002. 25(6): 630-40. [69] Buysse, D.J., et al., EEG spectral analysis in primary insomnia: NREM period effects and sex differences. Sleep, 2008. 31(12): 1673-82. [70] Altena, E., et al., Prefrontal hypoactivation and recovery in insomnia. Sleep, 2008. 31(9): 1271-1276. [71] Perlis, M.L., et al., Beta EEG activity and insomnia. Sleep Med Rev, 2001. 5(5): 363374. [72] Baharav, A., et al., Fluctuations in Autonomic Nervous Activity during Sleep Displayed by Power Spectrum Analysis of Heart-Rate-Variability. Neurology, 1995. 45(6): 1183-1187.
34
Aisha Cortoos, Elke De Valck and Raymond Cluydts
[73] Bastien, C.H. and M.H. Bonnet, Do increases in beta EEG activity uniquely reflect insomnia? A commentary on "Beta EEG activity and insomnia" (M. L Perlis et al.). Sleep Medicine Reviews, 2001. 5(5): 377-379. [74] Bonnet, M.H. and D.L. Arand, Impact of activity and arousal upon spectral EEG parameters. Physiol Behav, 2001. 74(3): 291-8. [75] De Valck, E., R. Cluydts, and S. Pirrera, Effect of cognitive arousal on sleep latency, somatic and cortical arousal following partial sleep deprivation. Journal of Sleep Research, 2004. 13(4): 295-304. [76] Tang, N.K.Y. and A.G. Harvey, Effects of cognitive arousal and physiological arousal on sleep perception. Sleep, 2004. 27(1): 69-78. [77] Bonnet, M.H. and D.L. Arand, 24-Hour metabolic rate in insomniacs and matched normal sleepers. Sleep, 1995. 18(7): 581-8. [78] Viola, A.U., et al., PER3 polymorphism predicts sleep structure and waking performance. Current Biology, 2007. 17(7): 613-618. [79] Coren, S. and K.B. Mah, Prediction of physiological arousability: a validation of the Arousal Predisposition Scale. Behav Res Ther, 1993. 31(2): 215-9. [80] Lundh, L.G., J.E. Broman, and J. Hetta, Personality-Traits in Patients with Persistent Insomnia. Personality and Individual Differences, 1995. 18(3): 393-403. [81] Sheehan, D.V., et al., The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSMIV and ICD-10. Journal of Clinical Psychiatry, 1998. 59: 22-33. [82] Buysse, D.J., et al., The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res, 1989. 28(2): 193-213. [83] Johns, M.W., A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep, 1991. 14(6): 540-5. [84] Soldatos, C.R., D.G. Dikeos, and T.J. Paparrigopoulos, Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res, 2000. 48(6): 555-60. [85] Spielberger, C. (1983). Manual for the State-Trait Anxiety Inventory STAI (form Y). Palo Alto, CA: Mind Garden. [86] Beck, A.T., R.A. Steer, and M.G. Garbin, Psychometric Properties of the Beck Depression Inventory - 25 Years of Evaluation. Clinical Psychology Review, 1988. 8(1): 77-100. [87] Nicassio, P.M., et al., The phenomenology of the pre-sleep state: the development of the pre-sleep arousal scale. Behav Res Ther, 1985. 23(3): 263-71. [88] Rechtschaffen, A. and A. Kales. (1968). A manual of standardized terminology, techniques and scoring sytem for sleep stages of human subjects, Los Angeles, UCLA: Brain Information Service/Brain Research Institute. [89] Smith, S. and J. Trinder, The effect of arousals during sleep onset on estimates of sleep onset latency. J Sleep Res, 2000. 9: 129-135. [90] Krueger, J.M., et al., Brain Organization And Sleep Function. Behavioural Brain Research, 1995. 69(1-2): 177-185.
In: Melatonin, Sleep and Insomnia Editor: Yolanda E. Soriento
ISBN: 978-1-60741-859-7 ©2010 Nova Science Publishers, Inc.
Chapter II
Neuropathology of Insomnia in the Adult: Still an Enigma! Jean-Jacques Hauw*1 and Chantal Hausser-Hauw2 APHP, Hôpital de la Salpêtrière, Université Pierre et Marie Curie, Laboratoire de 1 Neuropathologie Raymond Escourolle, Paris, France Laboratoire du sommeil, Hôpital Foch, Suresnes, France2
Abstract Insomnia Insomniais a very frequent symptom, usually due to non organic brain diseases. In some organic brain disorders, however, sleep impairment occurs through a series of mechanisms: structures responsible for need for sleep are lesionned ; the biological clock doesn‘t give the start for sleep; sleep networks responsible for inhibition of waking structures are not efficient; mechanisms carrying on sleep or responsible for waking stages are damaged. In each case, examples of those brain disorders leading to insomnia (tumors, strokes, traumas, neurodegenerative disorders) are reviewed, focusing on the neuropathological description of structures involved in sleep network. When possible, clinicopathological correlates are suggested.
Introduction Whatever the cause, insomnia is usually related to a stress-induced hyperarousal state thought to be mainly mediated by the limbic system and forebrain areas. This hyperarousal state leads to an over-stimulation of the hypothalamo-hypophyseal axis, inducing chronic *
Correspondence: Pr J.-J. Hauw, Laboratoire de Neuropathologie Raymond Escourolle, La Salpêtrière, 47 Bd de l‘Hôpital, 75651, Paris Cedex 13, Tel :33 1 42 16 1881, FAX :-33 1 42 16 1899,
[email protected]
36
Jean-Jacques Hauw and Chantal Hausser-Hauw
insomnia. (Vgontzas A, 2001; Buckley R et al, 2008). No organic brain lesion is seen, but functional neuroimaging shows an increased brain metabolism associated with inability to get asleep. In contrast, it has been suggested that decreased activity in the prefrontal cortex may be related to sleep deprivation effect (Nofzinger EA et al, 2004). In a few occurrences, however, insomnia is associated with identified brain lesions. This may occur when the hypothalamic suprachiasmatic nucleus doesn‘t give the start for sleep, when waking structures are not inhibited by sleeping structures, when thalamocortical bundles that carry on sleep are lesionned, or even when some waking structures are impaired. In addition, it may be due to a dysfunction of structures responsible for need for sleep. Some strategically located brain tumours, strokes, and consequences of brain traumas are characterized by insomnia. Several neurodegenerative diseases such as Steele-Richardson, Alzheimer, Parkinson or Huntington diseases may also lead to insomnia. A series of different disorders, Fatal insomnia, rare cases of Creutzfeldt-Jakob disease, Morvan‘s chorea, limbic encephalitis and delirium tremens, often associated with severe insomnia, have been grouped together under the name ―agrypnia excitata‖(Montagna P and Lugaresi E, 2002). Most of the time, on the other hand, when recognised, the lesions in these disorders are widespread, making definite correlations difficult. In addition, combined factors (organic, psychic, cognitive or therapeutic) are often associated. In some cases, however, the lesions involve various regions, some of which are responsible for sleep organisation, which makes clinico-pathological correlations possible. In addition, in a few selected cases, organic brain lesions are localized enough to throw light on the mechanism of associated sleep disorders.
1. The Biological Clock Hypothalamic suprachiasmatic nucleus is supposed to start sleep. Cells of this ―pacemaker‖ contain a series of clock genes with rhythmic expression. It is influenced by light stimulation from the retina through the retinohypothalamic tract (glutamatergic), and indirectly from the geniculohypothalamic tract (GABAergic) and projects widely (among other regions) towards the pineal gland which secretes melatonin. Circadian synthesis of melatonin in the pineal gland is part of the rhythmic controls set up by the suprachiasmatic nucleus. The neuronal inputs originate in the retina which project fibers to the suprachiamatic nucleus; then the signal passes through the paraventricular nucleus, follows the medial forebrain bundle, and ends in the intermediolateral cell column of the upper thoracic spinal cord, from where it projects to the superior cervical ganglion, which sympathetic neurons innervate the pineal gland (Møller M and Baeres FM, 2002). The signal to the pineal gland is mediated by norepinephrine, which is inhibited by light. Melatonin is implicated in numerous physiological processes, including circadian rhythms, stress and reproduction, many of which are mediated by the hypothalamus and pituitary gland. Melatonin receptors MT1 immunoreactivity is seen in the suprachiasmatic nucleus, paraventricular nucleus, periventricular nucleus, supraoptic nucleus, sexually dimorphic nucleus, the nucleus of the diagonal band of Broca and the nucleus basalis of Meynert, infundibular, tuberomamillary nuclei and the mamillary body, thalamic ventromedial, dorsomedial nuclei and paraventricular nuclei (Wu YH et al, 2006).
Neuropathology of Insomnia in the Adult: Still an Enigma!
37
The suprachiasmatic nucleus, optic tracts, retinohypothalamic pineal gland and MT1 receptors are crucial to induce sleep. Lesions of this circuit may induce insomnia characterized by delayed sleep onset, eventually leading to day-night reversal : a) Tumors of the anterior hypothalamus occur more frequently in children. The anterior hypothalamic syndrome consists of insomnia and loss of thirst regulatory mechanisms (Carmel PW 1980). In occasional larger lesions which interrupt the output from the supraoptic and paraventricular nuclei, diabetes insipidus is noticed. Tumors or cyst of the pineal gland may also lead to delayed sleep onset (Etzioni A et al, 1996; Taraszweska A et al, 2008). A 17-year-old boy, presented with severe headaches, associated with insomnia. Preoperative MR imaging suggested tumour of the pineal gland. Histopathological and immunohistochemical examination of the specimens from this surgical case revealed a characteristic pattern of cystic structures within the pineal gland, surrounded by layers of a dense fibrillar glial tissue and pineal parenchyma, consistent with non-neoplastic glial cysts (Taraszweska A et al, 2008). b) Delayed sleep phase syndrome is also frequently associated to brain injury. It probably results from alterations either of the suprachiasmatic nucleus, or of its connecting fibers (Quinto C et al, 2000), which could imply basal contusion or diffuse axonal injury (Wang JY et al, 2008 ; Kumar R et al, 2009) c) In the ―normal old‖aged persons, who pathologically may correspond to pre-clinical stages I and II of Braak‘s classification of abnormal tau-associated lesions of Alzheimer disease (Braak H and Braak E, 1991), sleep initiation can be much delayed. In Alzheimer disease (AD), sleep disorders consist mainly in hypersomnia at the onset of the disease. Then, insomnia and inversion of circadian rhythm take place, the patient wandering during the night and sleeping during the day. Melatonin, which inhibits neurons mediated by receptor MT1, may regulate neuronal sensitivity to stimuli that set biological clock in phase with environmental pressures (Wu YH et al, 2006). Melatonin has been reported to be low in old persons, but much variations were found: some have high levels, others have low levels and a few have even no evidence of melatonin secretion, whatever the differences in self reported quality of sleep (Baskett et al, 2001). It may be emphasized, however, that these data have been found in aged persons in the absence of neuropathological data. Melatonin levels in the cerebrospinal fluid decrease during the progression of AD associated tau neuropathology, tightly linked to neuronal loss (as assessed by the Braak‘s stages), and this is already observed in cognitively intact subjects with the earliest AD neuropathology (Braak stages I-II), the so-called preclinical AD (Wu YH et al, 2003). It has been shown that dysfunction of the sympathetic regulation of pineal melatonin synthesis by the suprachiasmatic nucleus is responsible for melatonin changes during the early AD stages (Wu YH, 2005). In neuropathologicaly assessed Alzheimer‘s disease, two main lesions (already found in some aging ―normal‖ brain) are seen: essentially extracellular deposits of Abeta (diffuse and focal deposits, including the core of senile plaques) and mostly intraneuronal inclusions of hyperphosphorylated tau, including neurofibrillary tangles, neuropil threads and the corona of
38
Jean-Jacques Hauw and Chantal Hausser-Hauw
senile plaques. The latter are highly linked to neuronal loss (Duyckaerts C, 2008 ; Dixon DW, 2008). The regions implicated in circadian rhythms (hypothalamus and pineal gland) have been thoroughly studied in AD by Dick Swaab‘s group (2004) using early postmortem samples from the Amsterdam tissue bank. In 68 pineal glands, some clock genes (hBmal1, hCry1and hPer1) were found rhythmically expressed in aged control cases (stage 0 of Braak), and there were some correlations between hPerl expression and adrenergic beta1 (hbeta1ADR) receptors. These data were linked to the hour of death. In AD (late stages V-VI of Braak), and even at pre-clinical stages I-II, (―old aged‖persons), rhythmic expression of clock genes was no longer found and the correlations disappeared. Surprisingly, hCryl mRNA was increased in AD. The authors suggest that brain control upon pineal gland is lost, in reference to similar results obtained in the pineal gland of de-afferented rats (Wu YH et al, 2006). These data may be match up to the reduction of the hypothalamic neurons that express melatonin MT1 receptors, vasopressin and VIP (vasoactive intestinal peptide) at stages V-VI of Braak, whereas in aged controls (Braak‘s stage 0) and at early stages I-II, the reduction of neurons concerns only those expressing melatonin receptors. d) In Parkinson disease (PD), characterised by a synucleinopathy (Lewy bodies and Lewy neuritis) involving progressively some selected areas of the peripheral and the central nervous system (Hauw JJ et al, 2008 ; Braak H and Del Tredici K, 2008), as expanded later on, insomnia is the most common of the sleep disorders: 67% of patients have problem initiating sleep and 88% have sleep maintenance impairment (Factor SA et al, 1990). The number of neurons expressing melanoconcentrating hormone (MCH) is reduced from 12% at stage I to 74% at stage V, at the same time as their size increases significantly. Hypothalamic neuronal loss may play a more significant role in this disease than previously thought (Braak H and Del Tredici K, 2008). e) Huntington disease (HD) is characterized by dementia, chorea and a dominant mode of inheritance. It is caused by an abnormal expansion of CAG repeats in the gene encoding Huntingtin. Sleep disturbances have been described in about 20% of patients with late-onset HD. Insomnia with impaired initiation and maintenance of sleep is a common complaint particularly in moderate to severe cases. With progression of the disease, sleep fragmentation increases (Myers RH et al, 1985). Sleep records used to show increased spindle density (Emser W et al, 1988). More recent sleep records showed low sleep efficiency, increased stage 1, delayed and shortened REM sleep and increased periodic leg movements (Arnulf I et al, 2008). On cerebral imagery, global cerebral atrophy did not significantly correlate with sleep parameters while atrophy of caudate nuclei was associated with reduced slow wave sleep and increased periods of awakeness (Wiegand M et al, 1991). Hypothalamic atrophy occurs at early stages, associated with loss of orexin (hypocretin) and somatostatin-containing cell populations. Endocrine changes including increased cortisol levels, reduced testosterone levels and increased prevalence of diabetes are also found in HD patients. In HD mice, alterations in the hypothalamic-pituitary-adrenal axis occurs, as well as pancreatic beta-cell and adipocyte dysfunction (Petersen A and Björkqvist M, 2006).
Neuropathology of Insomnia in the Adult: Still an Enigma!
39
2. The Structures Inhibiting Waking Systems Sleep is set on only when structures responsible for waking state are inhibited: the ventrolateral preoptic area, which is in charge of sleep, inhibits the lateral hypothalamus (orexin/hypocretin system), Meynert nucleus, posterior hypothalamus and periaqueductal grey matter (Mignot E et al, 2002; McGinty D and Szymusiak R, 2003; Swaab D, 2004; Saper C et al, 2005; Sakurai T, 2007). Stress, which stimulates CRF and orexin/hypocretin system is the usual cause of lack of inhibition of the waking structures. Lesions of the ventrolateral preoptic area or its connecting fibers to the waking structures may also impair the setting of sleep and lead to initiation of sleep insomnia: a) Tumors of the anterior hypothalamus that impair biological clock, may also impair ventrolateral preoptic areas, when they are large enough. b) In Parkinson‘s disease, ventrolateral preoptic areas is involved at an early stage (Braak H and Del Tredici K, 2008). That could account for the severe insomnia occurring in this disease. c) Whipple disease is a rare infectious disease that typically infects the bowel. It is caused by a bacteria named Tropheryma whippelii. It can affect any system of the body. At times, brain is the only organ affected. Symptoms include diarrhea, intestinal bleeding, abdominal pain, loss of appetite, weight loss, fatigue, weakness, arthritis and neurological signs and symptoms. Patients could suffer from hypersomnia or insomnia. Hypothalamic manifestations occur in 31% of Whipple encephalopathies, including polydipsia, hyperphagia, change in libido and insomnia (Papadopoulou M et al, 2005). Cerebral lesions of Whipple disease are disseminated throughout hemispheric and brain stem grey matter much more than in the white matter. They are more prominent in the hypothalamo-hypophyseal region and the upper brain stem especially in the periaqueductal grey matter (Powers J and Rawe SI, 1979). In a well-studied case of Whipple disease, progressive and almost complete sleep loss was the initial and predominant symptom. Polysomnographic recording over 24 h, and during several consecutive nights, showed a complete abolition of the sleep-wake cycle with nocturnal sleep duration of less than 15 min. Hypothalamic dysfunction occurred, with flattening of circadian rhythmicity of cortisol, TSH, GH and melatonin, and hypocretin was reduced in CSF. However, FDG-PET scan revealed hypermetabolic zones in cortical and subcortical areas, including the brainstem. In this case, hypothalamic dysfunction was probably not the only cause of insomnia (Vodeholzer U et al, 2002).
40
Jean-Jacques Hauw and Chantal Hausser-Hauw
3. The Structures Carrying on Sleep 3.1 Slow Wave Sleep After the two previous steps have been achieved, thalamus switches to sleep (Akire MT et al, 2000). Slow sleep is the product of synchronized rhythmic activity of the thalamic reticular nuclei projecting to the cortex (thalamocortical activity) and hyperpolarizing cortical layer V. Sleep spindle and delta waves are thought to be due to these thalamocortical networks (Steriade M et Timofeev I, 2003). The main neurotransmittor is GABA. Deactivation of the orbital, dorsolateral prefrontal and inferior parietal cortices occurs during slow wave sleep and REM sleep, as shown by PET study (Braun AR, 1997). Various brain lesions may involve the thalamocortical network and induce insomnia: stroke, trauma, normal aging and Alzheimer disease, and prion infection, a) Insomnia is associated with acute stroke, whatever the location, and sleep duration is reduced proportionally to the size of the stroke (Müller C et al, 2002). When stroke involves the middle cerebral artery territory, stages 2 and 3 and spindle density decrease during the few days following stroke. Following a thalamic infarct involving postero-lateral, ventral postero-lateral, dorso-medial and centromedial nuclei (a mixture of reticular/intralaminar, limbic and specific sensory nuclei) a 48hour insomnia has been reported (Garrel S et al, 1966). Surprisingly, thalamic infarcts are seldom reported as a cause of insomnia, since thalamus plays an important role in generating sleep spindles. As thalamocortical activity is also involved in waking state, patients are frequently neither asleep nor totally awake. Actually, thalamic infarcts are more responsible for hypersomnia or altered states of consciousness than for insomnia (Castaigne P et al; 1981; Schmahmann JD, 2003). The clinical presentations of thalamic stroke is not specific to individual nuclei because even small, focal ischemic lesions are seldom confined within nuclear boundaries. For instance, there is nothing such as an ―infarct of the reticular/intralaminar nuclei‖, that would be the best candidate to produce insomnia (De Girolami U et al, 2009). b) Insomnia is a frequent consequence of brain injury. It is attributed to shearing mechanism that induces diffuse axonal injury, as already mentionned. Most of the time it is associated to depressive mood and is usually reversible (Fichtenberg NL et al, 2002). Very few cases of localised brain injury leading to persistent insomnia are available. A case of total insomnia during 6 days was reported after right thalamotomy in a Parkinsonian patient who had benefited from a left sided alcoholic thalamotomy in the past (Bricolo A,1967). The right lesion involved ventral lateral, ventral intermedial and anterior part of the ventral intermedial nuclei, medial center and the subthalamic area, the dento-rubro-thalamic bundle and the H1 Forel region. The left sided lesion involved the medioventral part of the lateral ventral nucleus, ventral intermedial nucleus and anterior part of the ventral intermedial, median center and dorsal subthalamic bundles.
Neuropathology of Insomnia in the Adult: Still an Enigma!
41
c) In old persons, sleep is interrupted by frequent awakenings. There is age-dependent changes in sleep EEG, with a shift of power from the anterior towards the central regions (Landolt HP and Borbély AA, 2001). In Alzheimer‘s disease, sleep records show reduced sleep efficiency, increased amounts of stage I and increased numbers of awakenings. The typical lesions of tauopathy in clinical AD involve limbic, then hemispheric cortex with associative areas being predominantly injured. A number of nuclei that give projections to the cortex (involving mainly cholinergic, serotoninergic and histaminergic systems), are also injured (Duyckaerts C and Dickson DW, 2003), although initial tauopathy occurs in the peri-rhinal and entorhinal areas in presymptomatic patients. As a matter of fact, the development of abnormally phosphorylated tau occurs typically as described by Braak (I and II: preclinical stages, thus including ―normal aged people‖; III and IV: limbic stages: Ammon horn involvement ; V and VI : isocortex involvement) (Braak H and Braak E, 1991). The ventro-medial amygdala (Tsuchiya K and Kosaka K, 1990), and the basal nucleus of Meynert are involved precociously (Sassin I et al, 2000). On the contrary, the striatum and the thalamus are usually spared, with the exception of thalamic limbic nuclei which are also affected early (Braak H and Braak E, 1991). d) Prion diseases, or transmissible spongiform encephalopathies (Creutzfeldt-Jakob diseases, fatal insomnias, Gerstmann-Strausler-Scheinker disease…) are due to a misfolded isoform enriched in beta-sheet of a normal protein (PrP). We will call PrPres this abnormally conformed protein for it is partly resistant to proteinases. In addition, it is transmissible to some animal species, including human. In PrP knockout mice devoid of prion protein, there is an alteration in both circadian activity rhythms and patterns. This could imply that prion protein is strongly involved in sleep regulation (Tobler I et al, 1996). However, in humans affected by Prion disorders, sleep disturbances are related more to the localisation of lesions than to prion infection by itself. For instance, in fatal insomnias, insomnia is constant; in Creutzfeldt-Jakob diseases, sleep disorders are a variable feature and in GerstmanSträussler-Scheinker disease, sleep is usually normal. These different phenotypes are likely related to different conformations of PrPres. The distinct localization of neuronal loss or systems that could explain the different phenotypes may be difficult to assess, however, unless specific markers (such as enzymes of neurotransmitter metabolism) allow numerating definite neuronal classes. The classical triad of lesions in prion diseases is not always easily recognisable: in contrast to spongiform change and gliosis involving both astrocytes and, at a lesser degree, microglial cells, neuronal loss is often difficult to detect in the early lesions. However, it is conspicuous in the severe lesions where it induces gross atrophy. Early, severe, and selective neuronal loss affects a subset of parvalbumin positive GABAergic inhibitory interneurons both in human and experimental prion diseases, except in FFI (Guentchev M et al., 1997; Budka H et al, 2003). Electron microscopy does not disclose any known infectious agents, but tubulovesicular structures, particles of unknown origin and chemical composition which seem to occur only in prion diseases (Liberski PP et al, 2008). These lesions are associated with various types of
42
Jean-Jacques Hauw and Chantal Hausser-Hauw PrPres deposits seen by immunohistochemistry (Privat N et al, 2008) or immunobloting. Western blotting provides most sensitive, but less precise data.
Fatal insomnia (FI) is a rare prion disease which affects as well men as women, at an age ranging from 36 to 62 years (Lugaresi E et al, 1986 ; Manetto V et al, 1992 ; Krasnianski et al, 2008). Most FI have a genetic autosomic dominant aetiology (Montagna P et al, 1998), usually linked to a mutation at codon 178 (D178N) of the gene of prion protein (PRNP). Interestingly enough, in the very same family, fatal familial insomnia (FFI) phenotype usually occurs only when there is a methionine (M) on the mutated allele at the polymorphism methionine-valine (MV) of codon 129 of the PRNP. When a valine (V) is present on this allele, a genetic disease with Creutzfeldt-Jakob phenotype occurs. Variants of this scheme have been reported, however, including typical Creutzfeldt-Jakob disease, FFI, and what was thought to be an autosomal dominant cerebellar ataxia in the same family (McLean CA et al, 1997) and different involvement of thalami and frontal lobes on PET scan in half-brothers (Johnson MD et al, 1998), suggesting that other genetic or environmental factors may play a role in the disease process. Mutations at codon 200 (E200K-129M), classified usually as familial Creutzfeldt-Jakob disease (Parchi P et al., 2003) have also lead to FFI phenotypes in cases with homozygoty VV at codon 129 (Taratuto AL et al, 2002). In sporadic fatal insomnia (sFI), also called the MM2-T subtype of sporadic Creutzfeldt-Jakob, PRNP shows no mutation. MM homozygosity at codon 129 polymorphism is also found (Scaravilli F et al, 2000). In FI, disease onset is characterized by subtle personality changes, indifference and unability to express emotions and feelings, hallucinations and depression (87%). Cognitive dysfunction (87%) is characterized by lack of attention and hypovigilance. Myoclonus (70%), ataxia, dysarthria (61%), dysphagia (13%), pyramidal (43%) and extra-pyramidal (35%) signs occur. Profuse vegetative signs including perspiration and salivation, tachycardia, hypertension, fever, impotence, are present at the onset or a few weeks later (83%) (Krasnianski A et al, 2008). Hypovigilance is often prominent. Peudohypersomnia could also happen with profound alteration in the sleep-wake cycle (Dauvilliers Y et al, 2004). However, the hallmark of the disease is sleep loss with inability to produce the physiological patterns of slow sleep and REM sleep (96%) as well as hormonal and vegetative circadian fluctuations. Sleep records in 5 cases showed REM sleep reduction (100%), reduced efficiency of sleep (80%), deep sleep reduction (80%), periodic limb movements (60%), central apneas (40%) (Krasnianski A et al, 2008). Hypnograms of an italian case fluctuated between stage 1 and REM sleep (Provini F et al, 2008). CT and MRI are normal except for slight atrophy of the cerebrum and the cerebellum in the most advanced cases. A mild hypometabolism initiating in the thalamus, then extending to the mesial frontal areas and the whole hemispheres and basal ganglia, could be observed as soon as 13 months before the disease onset in a longitudinal 18FDT-PET scan study performed in carriers of the D178N mutation of PRNP (Cortelli P et al, 2006). Magnetic resonance spectroscopy combined with the measurement of apparent diffusion coefficient of water in different brain areas were performed 4 days before death in a 55-year-old man with familial fatal insomnia linked to D178N mutation. They showed an increase of apparent
Neuropathology of Insomnia in the Adult: Still an Enigma!
43
diffusion coefficient of water, and a metabolic pattern indicating gliosis in the thalamus but not in the other brain regions studied (Haïk S et al, 2008). In FI, the neuropathological lesions include mainly gliosis and neuronal loss, due to apoptosis (Daurandeu A et al., 1998) which is difficult to detect, as mentioned, in the early lesions. It is associated with gross atrophy in the severe lesions only. Spongiform change is mild or lacking, except in cases with very long duration (Hirose K et al, 2006). Some gliosis of the hypothalamus and periaqueductal gray matter is a common finding. In contrast, there is a severe bilateral and symmetrical thalamic degeneration with marked gliosis, neuronal loss, and usually lack of spongiform change. Gross atrophy is seen in the most affected areas, i. e. the anteroventral, mediodorsal and pulvinar nuclei. Other thalamic nuclei are usually less damaged, but intralaminar nuclei can be severely injured, especially in long duration cases. A morphometric investigation showed, indeed, that most thalamic nuclei had severely degenerated in two patients with FFI. Associative and motor nuclei lost 90% neurons, and limbic-paralimbic, intralaminar and reticular nuclei lost 60%. Although PrP immunohistochemistry shows various demonstrable deposits of PrP, biochemical studies usually detect PrPres at highest levels in the thalamus, and at lower levels in the brain stem and limbic structures (Gambetti P et al, 2003 ; Sazaki K et al, 2005 ; Ironside JW and Head MW, 2008). Serotoninergic neurons are selectively decreased in the raphe nuclei (Wanschitz J et al, 2000). It may be mentioned that in mutations at codon 200 (E200K-129M), which may also lead to FFI phenotype, the usual lesions are alike those of sporadic Creutzfeldt-Jakob of the MM1 type (Parchi P et al, 1999; Parchi P et al, 2003), affecting the cerebral cortex, striatum, medial thalamus, and cerebellum. There is severe gliosis and moderate to severe neuronal loss in the thalamic nuclei and the inferior olivary nuclei, and spongiform change is particularly evident in the medio-dorsal nucleus of the thalamus, with rare and coarse spongiform degeneration in the isocortex and the putamen in a case with severe insomnia. In a E200K-129M case of CJD with thalamic involvement, insomnia occurred as the initial symptom, and was severe and intractable. Polysomnographic studies showed an absence of deep sleep and of REM sleep. On neuropathological examination, there was major involvement of the thalamus and of the inferior olivary nucleus, as could be seen in D178N mutation. Spongiform changes were mild in the neocortex and not patent in the cerebellum (Taratuto AL et al, 2002). ). In sporadic fatal insomnia (sFI), also called the MM2-T subtype of sporadic CreutzfeldtJakob, there is a marked atrophy of the thalamus and inferior olive, with mild lesions in other areas (Scaravilli F et al, 2000, Piao YS et al, 2005). In summary, thalamus is always involved in FI and thalamic lesions appear responsible for disappearance of deep stages of sleep, delta waves and spindles. Degeneration of mediodorsal, anteroventral and pulvinar nuclei of the thalamus is prominent. The disorganization of most thalamic circuits is a condition necessary for the sleep-wake rhythm being affected (Macchi G et al, 1997). This could be confirmed when comparing with the mild hypometabolism initiating in the thalamus observed as soon as 13 months before the disease onset when sleep was normal (Cortelli P et al, 2006). Mediodorsal nucleus has important connections both with reticular nucleus of the thalamus and cerebral cortex. Its lesion, or the frequent lesions of the intralaminar nuclei, are thus likely responsible for disappearance of spindles and delta sleep. By contrast, REM sleep often (but not always)
44
Jean-Jacques Hauw and Chantal Hausser-Hauw
persists because the tegmentum pontis sublaterodorsal nucleus and precoereuleus area, ventrolateral periaqueductal grey matter and tegmentum latero-pontis are not always severely affected. Hypovigilance and sleepiness could depend on damage of other thalamic structures, i.e. reticular nuclei for instance. In sporadic Creutzfeldt-Jakob disease (sCJD), PrPres seems to occur in the brain for no obvious reason (―natural stochastic conversion‖) and the disease manifests as a rapidly evolving dementia. A number of clinical criteria for suspicion of sCJD have been proposed (Brandel JP et al., 2000; Zerr I, 2008); every one includes myoclonus, cerebellar signs, pyramidal or/and extrapyramidal signs, and some akinetic mutism or lower motor neuron involvement. None of them, however, mention insomnia or other sleep alteration. Typical EEG (pseudoperiodic sharp waves) and detection of 14-3-3 protein in the CSF are also considered in some criteria. Even if insomnia is rare, sleep disturbances are frequent, however, and night-time behaviour disorders have been noted in 37% of 30 cases of sCJD (Zerr I, 2008). Sleep disorders can sometimes be similar to those found in FFI (Landolt HP et al, 2006). These authors followed seven consecutive patients with definite sCJD who underwent a systematic assessment of sleep-wake disturbances, including clinical history, video-polysomnography, and actigraphy. Sleep-wake symptoms were observed in all patients, and were prominent in four of them. All patients had severe sleep EEG abnormalities with loss of sleep spindles, vertex sharp waves, K-complexes, and slow sleep, very low sleep efficiency, and virtual absence of REM sleep. The EEGs were similar to that of wakening state, at times interrupted by muscular atonia without the other characteristics of REM sleep. Neuropathological examination (Budka H et al., 2003; Landolt HP et al., 2006; Ironside JW and Head MW, 2008) show that, macroscopically, there may be either no gross alteration or a diffuse cerebral and cerebellar atrophy. The lesions typical of sCJD are patent spongiform change, gliosis, neuronal loss, and deposits of PrP. In about 10% of cases, these deposits aggregate into amyloid plaques of the ―kuru‖ type. Several regional involvements could occur, in relation to the type of mutation or, in sporadic cases, to the M/V distribution at polymorphic codon 129 of the PrP gene in combination with the migration pattern of PrPres on Western blotting:1 or 2 following the classification of Parchi P et al. (1999). Six main molecular subtypes can thus been recognized (Parchi P et al., 1999; Zerr I, 2008). Whatever either the prominent types of lesions (spongiform change, gliosis, marked neuronal loss, plaques, type of immunodeposit) or their localisation (cortical, basal ganglia, cerebellum, brain stem nuclei), no insomnia was expressly described (Zerr I, 2008), but insomnia is not a systematically noticed symptom. It must be stressed upon that in Landolt HP et al (2006) patients with definite sCJD who underwent a systematic assessment of sleep-wake disturbances, and had severe sleep EEG abnormalities with loss of sleep spindles, very low sleep efficiency, and virtual absence of REM sleep, autopsy revealed prominent changes in cortical areas, and only mild changes in the thalamus. A severe involvement of the thalamus can be observed in some cases of CJD (Nagashima T et al, 1999, Yamashita M et al, 2001). The MV2 subtype, where the thalamus is predominantly affected, is easily distinguished from FI, always MM at codon 129 polymorphism.
Neuropathology of Insomnia in the Adult: Still an Enigma!
45
Studies concerning hypothalamus have mainly concerned pituitary infectivity. Hypothalamus per se is seldom mentioned. In summary: In CJD, insomnia is frequent, but is not a constant symptom. It appears to be associated with involvement of the thalamus in some cases, of the cortex in others. Variant CJD (Ironside JW and Head MW, 2008), iatrogenic CJD (Brown P et al, 2001) and Gerstman-Sträussler-Scheinker disease (GSS) have quite different clinical and pathological characteristics, but in none of them insomnia is a salient feature even if variant CJD is characterised by severe thalamic lesions. A few exceptions are provided, however, for example by P102L GGS, where two sisters showed protracted awakenings, reduced sleep efficiency, brief daytime naps. Slow wave sleep and REM sleep were preserved (Provini F et al, 2008), or in a case of variant CJD (Limousin N et al, 2008). e) In Progressive supranuclear palsy (PSP), insomnia is a frequent and important feature (Petit D et al., 2004; Sixel-Döring F et al., 2008; Hauw JJ et al., 2008). Polysomnographic studies show short total sleep time, lower sleep efficiency, drastic reduction in sleep spindles, atonic slow-wave sleep. Standard EEG shows slowing in the frontal lobes (Montplaisir J et al., 1997). Although described as normal in the seminal descriptions, the isocortex is commonly affected by lesions of glial cells and neurons predominating in the motor and temporal cortex (Hauw JJ and Agid Y, 2003; Dickson DW, 2008). Some degree of neuronal loss is seen in the striatum and thalamus, especially ventral anterior and lateral thalamic nuclei. Thalamic intralaminar caudal nuclei are often involved (Henderson J et al, 2000).Other lesions will be described later on.
f)
In Huntington disease (HD), there is usually a cortical atrophy in the frontal lobes, and significant neuronal loss has been found by morphometric studies, notably in layer VI of HD brains at stages 3 or 4 of the disease. These cells project principally to the thalamus, the claustrum and other regions of cerebral cortex. Layer V neurons have also be found in decreased densities (Hedreen JC et al, 1991). Using anti huntingtin and antipolyglutamin immunohistochemistry, neuronal intranuclear ubiquitinated inclusions can be detected long before the onset of symptoms. An increase of CD15 (carbohydrate epitope 3-fucosyl-N-acetyl-lactosamine)-positive astrocytes has been described in the lateral part of the nucleus basalis of Meynert (Morres SA et al, 1992). The most striking neuronal loss and astrocytic gliosis in the brains of HD occurs in the striatum, predominant in the caudate nucleus. However only 1-4% of striatal neurons in all grades of HD have huntingtin nuclear inclusions (Gutekunst CA et al, 1999). Medium spiny projection neurons containing GABA colocalized with substance P and especially with enkephalin degenerate first. The most severe lesions of the thalamus are seen in the centrum medianum. In seven cases, the ventrolateral thalamus was studied by quantitative cytometry. A selective 50% atrophy of microneurons (internuncial cells) was found while the macro neurons did not show significant atrophy (Dom R et al, 1976). There is also a loss of neurons of the substantia nigra and the subthalamicus nucleus.
46
Jean-Jacques Hauw and Chantal Hausser-Hauw
In summary: In HD, insomnia seems to be related to the involvement of the thalamus and even more to the involvement of the layers V and VI of the cortex. The role of the caudate nuclei in the occurrence of sleep disorders in HD is unknown.
3.2 REM Sleep REM sleep system remains hypothetical. It is also due to thalamocortical activity, like slow wave sleep, but in a desynchronised pattern, as it occurs during waking state (McCormick DA and Bal T, 1997; Wehrle R et al, 2007), under the influences of several upper brain stem nuclei. Mechanisms for tonic REM sleep and phasic REM sleep are probably somewhat different : during phasic REM periods, thalamocortical network includes basal forebrain, limbic and parahippocampal areas activity (Nofzinger EA et al, 1997; Wehrle R et al, 2007). The mechanisms that set on and set off REM sleep have been recently debated, their dysfunction being responsible for several disorders. Reciprocal inhibitory interactions between cholinergic brain stem neurons promoting REM (« REM-on ») and monoaminergic inhibitors « REM-off ») were up to now largely accepted (Siegel J, 2004). Selective lesions of these systems, however, do not seem to affect significantly REM sleep. Cholinergic system may, in fact, modulate rather than initiate this stage. Actually, recent studies in rats showed the existence of mutually inhibitor neurons, « REM-on » in the tegmentum pontis sublaterodorsal nucleus and precoereuleus area, and « REM-off » in ventrolateral periaqueductal grey matter and tegmentum latero-pontis. Each of these two neuronal populations contains interconnected GABAergic neurons. This system of reciprocal inhibition has been called ― flip-flop switch ‖, from electronic binar switch used to proceed quickly from a state to the other (Lu J et al, 2006). The existence, in human, of similar structures as ―REM-on‖ and ―REM-off‖ found in rats is highly probable. Their precise topography remains hypothetical. However, it has been possible to suggest a human equivalent of the rat sublaterodorsal nucleus and precoeruleus area « REM-on » which needs to be confirmed. The ventrolateral regions of the periaqueductal grey matter and tegmentum lateroponti may correspond to « REM-on » regions (Boeve B et al, 2007). Two ―REM-on‖ glutamatergic neuronal groups may be activated, one projecting toward the basal telencephalon, setting EEG pattern ; the other one projecting to the ventromedial medulla and spinal cord, setting muscle atonia. Ponto-geniculo-occipital sharp waves (PGO) which precede and accompany rapid eye movements are related to neurons of the mesencephalon tegmentum (rostral part of the alpha locus coeruleus and of the mesopontine nuclei). They project on the lateral geniculate nucleus of the thalamus which is a cortical relay. In human, they are assumed to be located at the pedunculopontine nucleus (Lim AS et al, 2007). Two motor systems appear implicated. One is responsible for muscular atonia, the other for suppression of motor activity (the last relay being the bulbar gigantocellularis nucleus). The former is characterised by the activation of two neuronal groups, some bearing cholinergic receptors in the locus coeruleus/subcoeruleus areas, the other glycinergic receptors in the magnocellular reticular nucleus (Fuller P et al, 2007; Luppi H et al, 2007).
Neuropathology of Insomnia in the Adult: Still an Enigma!
47
Sublaterodorsal nucleus could be at the origin of the common final pathway towards spinal interneurons which inhibit muscular tonus. This hypothesis remains to be confirmed (Boeve et al, 2007). The latter system responsible for suppression of nocturnal movements appears to be influenced by indirect pathways linking midbrain dopamine neurons with pre-motor structures in the mesopontine tegmentum and ventromedial medulla (Rye DB, 2004). Descending dopaminergic neurons from the telencephalon (A11) to the spinal cord may contribute to abnormal movements during sleep. Schematically, during REM sleep, cholinergic system is active, as it is during waking state, whereas monoaminergic systems are silent, as they are during slow stages of sleep. In summary: Lesions, in the brain stem, of sublaterodorsal nucleus, rostral part of the alpha locus coeruleus and of the mesopontine nuclei, could affect REM sleep organisation. (Dysfunction of thalamocortical loops or limbic system may also play a role in reducing the amount of REM sleep). Lesions of the noradrenergic locus coeruleus/subcoeruleus, cholinergic pedunculo-pontine nucleus and tegmentum laterodorsal, impair atonia during REM sleep. Lesions are mainly neurodegenerative in nature: progressive supra-nuclear palsy (PSP), Parkinson disease (PD) and Alzheimer disease (AD): a) In Progressive supra-nuclear palsy (PSP), apart from insomnia, the other sleep disorders include REM sleep behaviour disorder (RBD), and, less frequently, hypersomnia and pseudo-narcolepsia. On sleep records there is a lower percentage of REM sleep (Montplaisir J et al, 1997). Neuropathological gross findings include severe atrophy in midbrain where it predominates on the tectum, extending to a lesser degree to the pons. Other lesions include loss of pigment in the substantia nigra, and atrophy of the subthalamic nucleus and the superior cerebellar peduncle. Microscopic lesions, which are tauopathies, affect as well some neurons (neurofibrillary tangles in the cell body, neuropil threads in the dendrites) as some glial cells (tufted astrocytes and oligodendrocytic coiled bodies). They widely spread in brain stem and basal telencephalon where they involve several systems implicated in sleep organisation. were unchanged compared with controls. Regions severely involved include substantia nigra (more than 80% of the reported cases), then periaqueductal grey matter, locus coeruleus, and central pontine nuclei (more than 50% of reported cases). Pedunculopontine nuclei involvement is variable (Verny M et al, 1996 ; Hauw JJ et Agid Y, 2003). Other injured nuclei are superior colliculi, oculomotor nuclei, locus ceruleus, pontine nuclei, vestibular nuclei, medullary tegmentum, inferior olives and cerebellar dentate nucleus. Nuclei responsible for autonomic regulation, intermediate zone of bulbar reticular formation and gigantocellularis nucleus are the most lesionned area. Other very markedly affected regions include the pontine reticular formation, medial parabrachial nucleus, and nuclei raphe magnus and obscurus. Lateral parabrachial nucleus is less injured (Rüb U et al, 2002a). Meso-cortico-limbic dopaminergic projections are relatively spared, which contrasts with the extreme severity of nigro-striatal system lesions, especially for its ventral part (Oyanagi K, 2001). The lesions of REM ―on‖ and ―off‖ systems in the brain stem, could explain the
48
Jean-Jacques Hauw and Chantal Hausser-Hauw
reduction of REM percentage on sleep records and REM sleep behaviour disorders and episodes of pseudo-narcolepsy, occurring in the late stages of the disease (Boeve B et al, 2001; Arnulf I et al, 2005). b) In Parkinson‘s disease (PD), REM sleep is often reduced. Other sleep disorders include REM sleep behaviour disorders (RBD), restless legs and periodic limb movement syndrome, hypersomnia and pseudo-narcolepsy (Arnulf I et al, 2005 ; Park M et al, 2006 ; Hausser-Hauw C, 2007). PD is a synucleinopathy (Duyckaerts C et Hauw JJ, 2003), the spectrum of which comprises Parkinson disease and dementia with Lewy bodies, according to the predominance of signs and topography of the lesions. The lesions (Lewy bodies and fibers immunolabelled by synuclein directed antibodies) involve preferentially the brain stem in Parkinson disease, and the cortex in Lewy body dementia. Immunohistochemistry of alpha-synuclein allowed Heiko Braak et al (2003) to suggest that the synucleinopathy occurs according to a stereotyped hierarchic temporo-spatial fashion, similar to that described for neurofibrillary degeneration and other tau-associated lesions in Alzheimer disease. They first studied the topography of lesions labelled by antisynuclein antibody in two series of autopsied cases: i.: clinically characterized Parkinson disease, and ii. brains from people free from neurological symptoms and signs. The synucleinopathy could be restricted either to the olfactory bulb and peduncle or to the medulla. In the former case, the lesions remained confined to the olfactory bulb and had no tendency to spread to adjacent regions. At the opposite, brain stem synucleinopathies always involved the medulla, from which they seemed to spread progressively toward the pons, then ventral mesencephalon, diencephalon, and antero-medial mesocortex of the temporal lobe. The brain stem is affected very early: At stage I, besides dorsal nucleus of IXth and Xth nucleus, dorsal spinal cord intermediolateral horn, gastro-intestinal nervous system are involved; at stage II, inferior raphe nuclei, magnocellularis reticular formation, among which bulbar gigantocellularis nucleus, and coeruleus-precoeruleus complex are involved. Substantia nigra and ventral tegmental area are involved at stage III (Braak H et al, 2008). In summary: in PD, Pedunculo-pontine nuclei, Meynert basal nucleus, tubero-mamillary nucleus and oral raphe nuclei involvement could explain REM sleep disorders. c) In Alzheimer‘s disease (AD), REM sleep alterations may not be present early in the disease, and a relationship between the severity of sleep disturbance and the severity of dementia is found (Montplaisir J et al, 1995). Superior and dorsal brain stem regions involvement could explain REM sleep disorders (Parvizi J et al, 2001).
4. The Structures Responsible for Waking State Sleep-wake organisation depends on oscillatory connections between sleep and arousal structures through feedback and reentry mechanisms. Thus lesions of structures related to arousal may impair sleep.
Neuropathology of Insomnia in the Adult: Still an Enigma!
49
The waking state is the result of a depolarisation of thalamocortical and thalamic reticular neurons and enhanced excitability in many pyramidal cells under the release of several different neurotransmitters from limbic system and brain stem nuclei (Steriade M and Timofeev I, 2003). The cholinergic systems are issued from two main pathways: the basal forebrain (magnocellular formations of the base, among which the basal nucleus of Meynert is the best known), and from the brain stem, originating from the tegmentum laterodorsal and pedunculo-pontine nuclei (also called ―meso-pontine‖ or ―peri-brachial‖) and from the bulbar gigantocellularis nucleus. It stimulates the cortex directly or through the mesencephalon reticular formation or the thalamocortical diffusely projecting nuclei, i.e. intralaminar formations (aspartate/glutamate). It could also stimulate the hypothalamic tubero-mamillary nucleus. Monoaminergic systems include: histaminergic pathways from the hypothalamic tuberomamillary nucleus, noradrenergic projections from the locus coeruleus, and serotoninergic pathways from the pontine raphe nuclei. They project directly to the cortex. The role of dopamine is uncertain. However pharmacological, biochemical and physiological studies suggest that mesocorticolimbic dopamine may help maintain wakefulness (Rye DB, 2004). Pharmacological evidence suggests the involvement of dopamine neurons, especially in the ventral tegmental area (A10), for the control of alertness (Lu J et al, 2002). On the other hand, L-DOPA and dopamine agonists induce sleepiness! Orexin/hypocretin system: Orexin (or hypocretin) is secreted in neurons of the lateral and posterior hypothalamus, and this system gives projections to the locus coeruleus, tuberomamillary nucleus and raphe nuclei, among others. They are highly excitatory neuropeptide hormones. They strongly stimulate the various brain nuclei including dopamine, norepinephrine, histamine and acetylcholine systems and appear to play an important role in stabilising wakefulness and sleep (Mignot E et al, 2002). All these systems also give descending projections for control in variations of breathing and muscle tonus associated with the different stages of sleep and wakefulness. During wakefulness, cholinergic afferent system to the thalamus, monoaminergic afferent systems to the cortex, orexin/hypocretin system widespread afferences, are active ; during slow stages of sleep, they are supposed to be inactive, or strongly inhibited. Lesions of the waking structures may produce hypersomnia, insomnia or both disorders. Some strokes, brain trauma, limbic encephalitides and Morvan‘s fibrillary chorea, several neurodegenerative disorders and prion diseases are examples of sleep and wake disorders occurring after arousal system lesions. a) Insomnia has been reported, though rarely, with ventral pons and mesencephalon strokes (Garrel S, 1966; Baldy-Moulinier M et al, 1977).Insomnia and hallucinations were also present in 7 patients in association with small vascular lesions of the pontine tegmentum. Insomnia affected both non-REM and REM sleep, appeared in the acute phase and tended to improve with time. Autopsy of one case revealed lesions of the pontis centralis caudalis and pontis centralis oralis nuclei (Forcadas MI and Zarraz JJ, 1994). In another case, sleep and dream suppression followed a lateral medullary infarct (Hobson A J 2002). As a matter of fact, medullary infarcts are
50
Jean-Jacques Hauw and Chantal Hausser-Hauw exceptionally responsible for insomnia. To our knowledge, it is the only reported case. b) In severe brain injury responsible for lesions located caudally to the mesencephalon, there is no longer any EEG activity corresponding to sleep (Mangin P et al, 1979). If patients recover from coma, they may suffer from insomnia. A case of insomnia related to post-traumatic pontine lesions was reversed by 5HTP(Guilleminault C et al,1973). c) Limbic encephalitis is a clinico-pathologic complex of symptoms which merged half a century ago, and the aetiology of which progressively diversified. Initially characterized by symptoms and signs indicating lesions predominant in the limbic system (memory and behaviour troubles, temporal seizures) and by neuropathological lesions suggesting an immunopathologic mechanism in the same territory, it went through many, diversely intricated, periods: viral, paraneoplasic and dysmetabolic.
Corsellis JAN et al (1968) described a paraneoplastic encephalitis of the limbic system developing in patients with systemic cancers, among encephalitides affecting mainly the temporo-cingular areas, the large majority of which were necrotic and of herpetic aetiology. Soon, however, the lesions revealed to be more diffuse than initially thought (extending to other brain areas, and mostly to the diencephalon, cerebellum, brain stem and spinal cord), which allowed to unify a number of clinico-pathologic descriptions («paraneoplastic polioencephalomyelitides ») (Goldbert GJ and Norton AR, 1968 ; Dubas F et al, 1982 ; Rosenfeld MR et al, 2001 ; Dalmau J et al, 2004). Lymphoid cells were found in the cerebral tissue where necrotic lesions were rare or absent. Multiple antibodies against onco-neural antigens (neuromuscular junction proteins, nerve terminal/vesicle-associated proteins, neuronal RNA binding proteins, or neuronal signal-transduction proteins) were found in the blood and the CSF, and were called for example anti HU, anti Yo … (Seeger RC et al, 1979 ; Darnell RB, 1996). On neuropathologic criteria, these encephalitides were grouped together with similar disorders arising in the absence of cancer (Dubas F et al, 1982). In 2004, indeed, Vincent A et al. showed that analogous encephalitides, often unrelated to systemic cancers, were associated with antibodies against either voltage-gated potassium channel or other neuronal membrane antigens. In most cases, MRI abnormalities were seen in the temporal lobe only. In a few cases, however, more diffuse lesions (frontal lobes, insula, cerebellum) were seen. These affections could be improved by reduction of the antibody levels. More recently, it was shown that encephalitides related to ovarian cancer were associated with antibodies to some membrane receptors of N-methyl-D-aspartate, NR1 and 2, and had a favourable outcome under plasma exchange and corticosteroids (Seki M et al, 2008). Limbic encephalitis, which could be linked also to the as yet not understood Rasmussen‘s encephalitis and maybe Morvan‘s fibrillary chorea, is an expanding concept (Graus F et al, 2008). Among 130 000 suspected paraneoplastic autoimmunity patients, 80 cases were positive for voltage-gated potassium channel (VGKC) autoantibodies (Tan KM et al, 2008). The
Neuropathology of Insomnia in the Adult: Still an Enigma!
51
pathogenic role of anti VGKC IgG is well known and intravenous immunoglobulins or plasmapheresis are most of the times efficient treatments. For these patients, clinical signs and symptoms included: cognitive alteration, with or without hallucinations, agitation and depression (71%); temporal lobe seizures or extra-temporal seizures, partial or generalized (38%); hypothalamic involvement: hyponatremia and hyperphagia (38%); dysautonomia (33%); myoclonus (29%); peripheral nervous system involvement (neuromyotonia, myokimia, cramps, sensitive or motor neuropathy, Morvan‘s syndrome (25%) ; extrapyramidal signs, tremor, rigidity, akinesia, chorea (21%); cranial nerves involvement, diplopia, dysarthria, dysphagia, facial palsy, facial hemispasm (19%). A cancer occurred in 33% of the cases, another autoimmune disorder in 33% (thyroïditis and diabetes). Sleep disorders occurred in 26% of the cases, including hypersomnia (13%) and insomnia (14%).Brain MRI showed T2/FLAIR hyperintensity in mesial temporal regions, unilateral in 8 cases or bilateral (12 cases), hyperintensity of the corpus callosum (1 case) and multifocal cortical hyperintensity (1 case) or generalised cortical atrophy (4 cases). The lesions of limbic encephalitis, whatever the mechanism (paraneoplastic or not) may be quite inconspicuous at gross examination, but, when severe, they can induce brain atrophy. They are often most pronounced in the limbic system, being bilaterally located in the hippocampus, medial temporal lobes, amygdaloid nuclei, mamillary bodies and orbital cortex. Histologic study reveals an interstitial infiltration of T-cells which can be grouped into clusters, cuffing the small vessels or dispersed in the grey mater. The T cells may be immunolabelled with antibodies against various antigens. The white matter is characteristically spared, and demyelination is not conspicuous. The remainder of the hemispheres is usually spared. (for review, see Dalmau J, 2008 ; Graus F et al, 2008) Other causes of limbic encephalitis, such as viral encephalitis (herpesvirus 6) in stem cell transplant recipients have been observed also. In five cases, clinical signs were short-term memory loss, insomnia and seizure activity in the temporo-basal areas. MRI showed increased hippocampal T2 and FDG-PET showed increased hippocampal glucose uptake (Wainwright MS et al, 2001). In summary: In limbic encephalitis, insomnia seems to be related to involvement of the limbic system, but the exact mechanism remains unexplained. d) Morvans‘s fibrillary chorea is a rare autoimmune disorder clinically characterized by acute and severe insomnia associated with anxiety, tachycardia, profuse perspiration and neuromyotonia (Serratrice G and Azulay JP, 1994 ; Hudson LA et al., 2008). The clinical course is benign in about 90% of the cases. In the remainder, the disease evolves into death in several weeks or months. Sleep is absent in the four months preceding death in malignant cases (Fisher-Perroudon et al, 1974) or is severely impaired if the evolution is more benign (Silber et al, 1995). A case of Morvan‘s syndrome occurred in a 76-year-old patient suffering from pulmonary adenocarcinoma and antibodies to VGKC. He was confused, restless and disoriented in time and space. When left alone, he would slowly lapse into a stuporous state with dreamlike episodes (enacted dreams) but was never asleep. Marked hyperhidrosis and excessive salivation and lacrimation were present as well as diffuse muscle twitching and spontaneous myoclonus. A 24-hour-video polysomnography showed
Jean-Jacques Hauw and Chantal Hausser-Hauw
52
that spindles, K complexes and delta waves were absent. EEG was dominated by ―wakefulness‖ and ―subwakefulness‖ alternating or intermingled with short atypical REM sleep phases, characterized by loss of muscle atonia (Liguori R et al, 2001). Actually, sleep records show similarities between Morvan‘s chorea and fatal familial insomnia (Provini F et al, 2008). Fundamentally, the neuropathology of Morvan‘s chorea is not understood. It could be related to an humoral immunopathologic disorder. In the case of Liguori R (2001) the brain was grossly unremarkable. Histological examination was also unremarkable. Direct immunohistochemistry on frozen sections of the post-mortem brain tissue showed areas of substantial leakage of IgG in the thalamus and striatum and diffusion into the parenchyma of antibodies bound to neuronal cells. In sections of cortex, there was evidence of antibodies in the blood vessels with only mild leakage into the surrounding tissue. However, these findings are non specific, and no control case was studied (Liguori R et al, 2001). e) In Fatal Insomnia, involvement of the cortex, when seen, is remarkably mild. When present, it includes slight spongiform change and gliosis often confined to the limbic cortex: orbitofrontal cortex, anterior gyrus cingulus and the entorhinal cortex, in short duration cases. In long duration cases, isocortical spongiform change and gliosis may be widespread, and even seen in the cerebellum, but they are always most prominent in the corticolimbic regions, including hippocampus and entorhinal cortex. According to Lugaresi E (1998), the degeneration of the thalamic nuclei, involved in the circuit of gyrus cinguli and orbitofrontal cortex to hypothalamus and reticular brainstem formation, releases hypothalamus and brainstem from corticolimbic control, and may result in loss of sleep. f)
In neurodegenerative disorders, waking structures as well as sleeping structures are involved so that hypersomnia as well as insomnia are frequent. The part played by lesions of the waking structures is difficult to assess. In PSP lesions of waking network, either cholinergic (Javoy-Agid F, 1994) or adrenergic, are precocious. Cholinergic nuclei of the brain stem are severely affected (Warren NM et al, 2005). In PD there is massive neuronal loss in intra-laminar thalamic nuclei, which are important relays of the cholinergic network for waking state (Henderson J et al., 2000) and in the thalamo-limbic nuclei (Rüb U et al, 2002b). The limbic system is affected earlier, at Braak‘ stage III, where the amygdala, the limbic cortex (entorhinal cortex and ammonian fields) are involved. In contrast, the cingular cortex is spared until stages V and VI. Lateral hypothalamic areas are involved at a precocious stage with orexin/hypocretin neuronal loss, as seen by immunohistochemistry, starting at stage I (23%) and being at its zenith at stage V (62%) (Thannickal TC et al, 2007). In AD, various structures in the brain stem implicated in waking network and ―allostatic‖ influences are precociously injured : initial tauopathy occurs in the peri-rhinal and entorhinal areas, locus coeruleus (German DC et al, 1992),
Neuropathology of Insomnia in the Adult: Still an Enigma!
53
raphe pontine nuclei (Rüb U et al, 2000), medial part of the substantia nigra (Uchihara T et al, 1992), and tegmento-pontine reticular nuclei. In HD, in the limbic system, the neuronal density in the granule cells of the CA1 area of the hippocampus is significantly reduced (Braak H and Braak E, 1982 ; Spargo E et al, 1993). The cellular expression of dopamine D1 and D2 receptor mRNAs was investigated in the post-mortem human caudate nucleus of control cases and pathologically confirmed cases of HD. For D2 receptor mRNA, the number of detectable D2-positive medium-sized cells decreased with increasing pathology. By contrast, for D1 receptor mRNA, despite a decrease in the number of D1 mRNA-positive cells detected, the average cellular expression of D1 mRNA was markedly reduced only in grade 1 HD and then increased with increasing pathology, presumably reflecting the relative survival of D1expressing striatal interneurons (Augood SJ et al, 1997). In the brain stem, in situ hybridation revealed extensive loss of tyrosine hydroxylase (TH) mRNA, the rate-limiting enzyme for dopamine biosynthesis, and decreased dopaminergic cell size in the substantia nigra. TH-immunoreactive protein was reduced in human grade 4 HHD substantia nigra by 32% compared to agematched controls (Yohrling GJ et al, 2003). In summary, in HD limbic system involvement and reduced striatal and nigral dopamine may play a role in insomnia.
4.1 The Structures Responsible for “Need for Sleep” There is a representation of motivational drives, especially for sleep and food intake, in mesial cortex, medial thalamus, hypothalamus and midbrain (Sewards RV and Sewards MA, 2003). Motivational drives could be impaired by numerous allostatic factors and by organic lesions. Actually we don‘t know why we need to sleep but there is an homeostatic system that fix sleep-wake cycles. The homeostatic facet of sleep-wake regulation correspond to regulation of ―sleep need‖ which increases during wakefulness and decreases during sleep. The neurochemical mechanisms underlying sleep homeostasis are poorly understood, but there is compelling and convergent evidence that adenosinergic neurotransmission plays a role in nonREM homeostasis in human (Landolt HP, 2008). Adenosine release in the brain may occur when energy-storing molecules containing adenosine triphosphate (ATP) are broken down to provide energy for cell activity. When brain cells burn ATP, adenosine builds up. During long sleep deprivation periods, the over regulation of A1 adenosine receptors takes place not only at the basal telencephalon level but also over the whole cortex (McCarley R, 2007). Some other regions react to sleep deprivation. These structures, the lesions of which causes insomnia in rats (Lu J et al, 2000), include ventrolateral preoptic area, as shown in rats and cats using the c-fos protein immunohistochemical method (Semba K et al, 2001). It has to be recalled that when a gene called c-fos, present in people and mice, is knocked out by genetic engineering, the mice act like human insomniacs, they have difficulty getting to sleep and staying asleep. Ventrolateral periacqueductal grey matter (Landis CA et al, 1993) and an
54
Jean-Jacques Hauw and Chantal Hausser-Hauw
area within anterior cingulated/medial prefrontal cortex are also activated after prolonged sleep deprivation (Cirelli C et al, 1995). In human, sleep deprivation causes the activation of a site within area 32 of medial prefrontal cortex (Clark CP et al, 2001). The thalamic representation of the need for sleep is probably located in the posterior part of the paraventricular thalamic nucleus, since neurons in this part of the nucleus are activated by sleep deprivation (Cirelli C et al, 1995; Semba K et al, 2001). In rats, this nucleus receives afferent projections from the suprachiasmatic nucleus, ventrolateral preoptic area, and ventrolateral periacqueductal grey matter (Krout KE et al, 2000). The regions responsible for need for sleep in human are not totally established. Some of them correspond to structures involved in sleep onset and maintenance, other to structures more related to waking state (limbic system and frontal cortex). They may thus give explanation for the occurrence of insomnia related to waking state related structures lesions. Some frontal tumors, maybe restless legs syndrome and basal ganglia disorders responsible for a reduction in adenosine could be cited as examples of insomnia related to loss of need for sleep. a) Rare cases of insomnia related to frontal tumors have been described. A 53-year-old man presented with insomnia for the previous 3 months. Psychological tests showed regression and schizophreniform and moderate organic deterioration signs. Neuropsychological testing revealed no deficit. MRI disclosed a presumed low-grade glioma or a dysgenetic tumor in the posterior part of the left gyrus rectus extending to the subcallosal area and the septal region, displacing the anterior cerebral artery. Polysomnography showed fragmented sleep with short deep slow wave sleep and no or little REM sleep. K-complexes and sleep spindles were present. Majority of sleep was unstable with high rate of cyclic alternating pattern (Szücs A et al, 2001). In another case, a right frontal lobe gliosarcoma induced sleep disturbance for 4 months and some headache and memory changes in a 79 year-old woman. The precise localisation of the tumor is unknown (Paueksakon P et al, 2003). In a case of nasalsubfrontal giant schwannoma, the patient presented with a year-long history of increasingly severe headache associated with insomnia. No neurological deficit was recorded except for anosmia (Bezircioglu H et al, 2008). b) Restless legs syndrome (RLS) is a sensorimotor disorder with a profound impact on sleep, inducing refractory insomnia, fatigue and sleepiness during the day. It affects both men and women, with a prevalence in the general population of 5% to10% (Berger K et al, 2004). RLS is characterized by an urge to move the legs or other parts of the body, accompanied by uncomfortable sensations. Symptoms occur during periods of rest and have a circadian peak of expression in the evening and at night. RLS is at times genetic autosomal dominant.The pathophysiology of RLS remains unclear, but there is evidence that impairment of brain iron availability and hypofunctioning of the brain dopaminergic system, play an important role. MRI metrics are suggestive of subnormal iron content in the substantia nigra (SN). T2 relaxation time values are higher in SNr than in SNc suggesting a higher iron content in SNc. The whole brain fMRI study evaluating patients with RLS during active
Neuropathology of Insomnia in the Adult: Still an Enigma!
55
dorsiflexion-plantar flexion of the foot show that only patients, and not controls, activate the thalamus, putamen, middle frontal gyrus and cingulated gyrus. Patients have higher activation of the dorso-lateral prefrontal cortex (Astrakas LG et al, 2008).TEMP and SPECT brain imagery did not show difference in presynaptic dopamine fixation in basal ganglions in RLS patients as compared to control group (Mrowkra M et al, 2005). TEP scan showed only slight reduction of presynaptic dopamine in the caudate nucleus and putamen (Ruottinen HM et al, 2000) or no difference at all (Trenkwalder C et al, 1999). The diencephalo-spinal dopaminergic pathway A11 is probably more important than the striatal dopamine in RLS physiology (Trenkwalder C et al, 2005).The genetic studies showed the association of several variants of the NOS1 (located at the level of the locus RLS1) with RLS. This result implicates that the system NO/arginine plays a role in RLS physiopathology. NOS1 gene is involved in the control of sleep-wake cycles and in the modulation of dopaminergic transmission (Winkelmann J et al, 2008).Autopsy studies in patients with early-onset RLS have demonstrated decreased H-ferritin and normal L-ferritin (usually stocked in oligodendrocytes) in the SN. Moreover transferrine fixation is increased in neuromelanine cells at the same times as transferrine receptors are reduces in theses cells, which suggests redistribution of iron toward cells that do not feed neurons (Connor JR and al, 2003). No autopsy in patients with late-onset RLS are available.In summary, insomnia occurring in RLS syndrome may be due to the activation of the dorso-lateral prefrontal cortex. It also could be related to an hypofunction of brain dopamine which is probably involved in sleep-wake cycles. c) A case of bilateral globus pallidus lesion due to hypoxia induced severe chronic insomnia. Acute mountain sickness occurs when someone move quickly to high altitude. Low oxygen partial pressure induces cerebral oedema responsible for loss of consciousness and coma. In one case, a 56-year-old female patient suffered severe chronic insomnia as the unique symptom following acute mountain sickness. MRI showed bilateral pallidus lesions (Shiota J et al, 1990). Globus pallidus is a part of the basal ganglia mainly involved in motor control, it is not traditionally associated with sleep organisation. Bilateral globus pallidus lesion usually change emotional and motivation but not sleep (Vijayaraghavan L et al, 2008). However, it may play a role in motor control of non-REM sleep through its connection with the frontocentral cortex during sleep (Salih F et al, 2009). The distribution of adenosine A2A, involved in sleep homeostasis is restricted in the basal ganglia (Kase H, 2001) so that a lesion to globus pallidus may theoretically reduce need for sleep.
5. General Influences (« Allostatic ») Various factors could overwhelm these regulatory systems. They include multiple stimuli, the best known being stress. Depression, systemic diseases and illness-related discomfort, drugs, alcohol, lack of light, are other very frequent factors inducing insomnia.
56
Jean-Jacques Hauw and Chantal Hausser-Hauw
Visceral sensory systems and autonomic regulatory neurons are clearly implicated, but a lot remains to be clarified in this field. Projections toward supra-chiasmatic nucleus, ventrolateral preoptic nucleus and orexin neurons of the cortical limbic system, for instance, have been advocated (Saper C et al, 2005). The role of the thalamic limbic system (anterior and dorso-medial areas), part of the ―central autonomic network‖ is also obvious. It is especially important in FFI (Provini F et al, 2005). Hormonal influences, the network of hypnogenic substances (VIP, somatostatine, CLIP or ACTH 18-39) and other molecules (prostaglandine D2, adenosine) (Huang Z et al, 2007; Bennaroch E, 2008) are implicated in these regulatory systems. These influences are not easy to illustrate but may play an important role in the occurrence of insomnia in normal persons and in those suffering from brain lesions, making clinicopathological correlations difficult.
Discussion and Conclusion Insomnia is theoretically induced by lesions of the structures implicated in sleep. However, structures involved in sleep and wake are so intimately interconnected that insomnia related to a brain lesion is rare and almost never an isolated symptom (Autret A et al, 2001). One methodological problem related to insomnia is the lack of sleep records. Sleep records are more often prescribed for hypersomnia or parasomnias than for insomnia. The symptom of insomnia is even not mentioned in many patients charts. Insomnia is considered as a ―soft sign‖, related to so many allostatic factors that its description doesn‘t bring much interest. At the opposite, hypersomnia, REM-sleep behaviour disorders, periodic limb movements are much more taken into consideration. Clinicopathological correlations are done according to the current knowledge about sleep and wake mechanisms. This knowledge is far from being accurate and is in constant evolution. For instance, the discovery of orexin/hypocretin system, few years ago, modified the known pathways of waking network and threw light on narcolepsy mechanisms. In the present paper, several levels or sleep organisation were considered in a classical hierachic manner : hypothalamus that sets schedule for sleep, thalamocortical bundles that set slow waves sleep, limbic system and frontal areas more involved in waking state and need for sleep, and brain stem nuclei responsible for REM-sleep organisation. With hypothalamic lesions, insomnia and delayed sleep syndrome occur when anterior hypothalamus is lesionned. Thalamo-cortical activity is modulated by limbic system and by several nuclei of the hypothalamus and brain stem, involved in sleep or in wakefulness. Thalamo-cortical activity is thus involved in alertness, waking state, slow sleep, and REM sleep, so that lesions involving thalamus, cortex, or thalamocortical bundles could induce altered states of consciousness, as well as insomnia and/or hypersomnia. Thalamic lesions, whether infectious, degenerative, ischemic, tumourous or others, never keep within the boundaries of selective thalamic nuclei, so that sleep related clinicopathological correlations are variable from patients to patients.
Neuropathology of Insomnia in the Adult: Still an Enigma!
57
The hypothesis of Lugaresi is that limbic cortex exerts an inhibitory control on the entire neuronal network regulating sleep and wakefulness (Lugaresi et al, 2004). According to the literature, the role of the limbic system is not so clear. It seems more involved in arousal and in phasic REM sleep than in sleep organisation. However fMRI shows significant BOLD signal changes in relation to slow wave sleep in specific brain areas including inferior and medial frontal gyrus, parahippocampal gyrus, precuneus, posterior cingulated cortex, pontomesencephalic tegmentum and cerebellum (Dang-Vu TT et al, 2008). Limbic system, inferior and medial frontal gyrus, and cerebellum may thus be implicated in sleep organisation, or at least, be strongly inhibited during slow wave sleep. Actually fMRI changes are dependant upon an hypermetabolism which could be inhibitory or excitatory in nature. The lesions of the limbic system could disorganise the sleep-wake circuit and induce insomnia (or hypersomnia). In the brain stem, the density of nuclei or tracts involved in sleeping or waking is so high that the risk that a lesion could impair only one group of nuclei is low. In Steele-Richardson‘s and Parkinson‘s diseases, insomnia is frequent but patients may also suffer from daytime hypersomnia and from several other sleep disorders. Strokes of the ventral pons and mesencephalon could lead to insomnia, probably by a dysfunction of the raphe nuclei (involved in arousal). With regard to traumatic lesion, clinicopathological correlations are poor for lesions are widespread and seldom localised. This schematic division is probably a caricature of genuine sleep organisation. A lot remains to discover. For instance, the role in sleep organisation of the striatum, and of several other structures, is still unknown.
References Akire MT, Haier RJ, Fallon JH. Toward a unified therory of narcosis : Brain imaging evidence for a thalamocortical switch as the neurophysiologic basis of anesthetic-induced unconsciousness. Conscious Cogn 2000; 9:370-386. Arnulf I, Merino-Andreu M, Bloch F, et al. REM sleep behavior disorder and REM sleep without atonia in patients with progressive supranuclear palsy. Sleep Med Rev 2005; 28: 349-54. Arnulf I, Nielsen J, Lohmann E, Schiefer J, Wild E et al. Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 2008; 65(4):482-488. Astrakas LG, Konitsiotis S, Margariti P, Tsouli S et al. T2 relaxometry and fMRI of the brain in late-onset restless legs syndrome. Neurology 2008; 71: 911-916. Autret A, Lucas B, Mondon C, et al. Sommeil et lésions cérébrales: revue critique de la littérature et cas cliniques additionnels. Neurophysiol Clin Clin Neurophysiol 2001; 31: 356-375. Augood SJ, Faull RL, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington‘s disease. Ann Neurol 1997; 42(2): 215-221. Baldy-Moulinier M, Billard M, Escuret E, Roquefeuil B, Fuentes J, Passouant P. A polygraphic, haemodynamic and metabolic study of 2 cases of the ―locked-in‖ syndrome. Rev Electroencephalogr Neurophysiol Clin 2001; 31: 356-375.
58
Jean-Jacques Hauw and Chantal Hausser-Hauw
Baskett JJ. Melatonin in older people with age-related sleep maintenance problems: a comparison with age matched normal sleepers. Sleep 2001; 24(4): 418-424. Bennaroch E. Adenosine and its receptors. Multiple modulary functions and potential therapeutic targets for neurologic disorders. Neurology 2008; 70: 231-236. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004;164: 196-202. Bezircioglu H, Sucu HK, Rezanko T, Minoglu M. Nasal-subfrontal giant schwannoma. Turk Neurosurg 2008; 18(4): 412-414. Boeve B, Silber M, Ferman T, et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001;16: 622-630. Boeve B, Silber M, Saper C, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007;130: 2770-2788. Braak H, Braak E Allocortical involvement in Huntington‘s disease Neuropathol Appl Neurobiol 1982 ;16:539-547. Braak H, Braak E. Alzheimer‘s disease affects limbic nuclei of the thalamus. Acta Neuropathol 1991; 81(3):261-268. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82(4):239-259. Braak H, Rüb U, Braak E. Staging of brain pathology related to sporadic Parkinson‘s disease. Neurobiol Aging 2003; 24:197-211. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007;113(4): 421-9. Braak H, Del Tredici K. Nervous system pathology in sporadic Parkinson disease. Neurology 2008;70(20):1916-25. Brandel JP, Delasnerie-Lauprêtre N, Laplanche JL, Hauw JJ, Alpérovitch A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology 2000;54(5):1095-9 Braun AR, Balkin TJ, Wesentern NJ, Carson RE et al. Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)O PET study. Brain 1997; 120 (Pt7):11731197. Bricolo A. Insomnia after bilateral stereotactic thalamotomy in man. J Neurol Neurosurg Psychiatry 1967; 30:154-158. Brown P Preece M, Brandel JP, Sato T, McShane L et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2001; 56(7):987. Buckley R, Duggal V, Schatzberg AF. The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study. J Clin Sleep Med 2008; 4(3):235-241. Budka H, 2003 Neuropathology of prion diseases. Br Med Bull 2003; 66:121-30. Budka H, Head MW, Ironside JW, Gambetti P, Parchi P, Zeidler M, Tagliavini F. Sporadic Creutzfeldt-Jakob disease. In: Dickson DW, Neurodegeneration : The Molecular Pathology of Dementia and Movement Disorders, ISN Neuropath Press, Basel 2003, pp 287-297.
Neuropathology of Insomnia in the Adult: Still an Enigma!
59
Carmel PW. Surgical syndromes of the hypothalamus. Clin Neurosurg 1980; 27:133-159. Castaigne ¨P, Lhermitte F, Buge A ; Escourolle R, Hauw JJ, Lyon-Caen O. Paramedian thalamic and midbrain infarct : clinical and neuropathological strudy. Ann Neurol 1981; 10(2):127-148. Cirelli C, Pompeiano M, Tononi G. Sleep deprivation and c-fos expression in the rat brain. J Sleep Res 1995; 4 : 92-106. Clark CP, Frank LR, Brown GG. Sleep deprivation, EEG and functional MRI in depression: preliminary results. Neuropsychopharmacology 2001; 25: S79-S84. Connor JR, Boyer PJ, Menzies SL et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome (RLS). Sleep Med 2004; 61:304-309. Corsellis JAN, Goldbert GJ, Norton AR. ―Limbic encephalitis‖ and its association with carcinoma. Brain 1968; 91: 481. Cortelli P, Perani D, Montagna P, Gallassi R, Tinuper P. et al. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain 2006;129(Pt 3): 668-75. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127(Pt 8):1831-44. Dalmau J. Paraneoplastic disorders of the memory and cognition: clinical aspects and therapeutic approaches. Handb Clin Neurol. Dementias. Eds C Duyckart and I Litvan, 2008; 89:737-64. Dang-Vu TT, Schabus M, Deseilles M, Albouy G, Boly M, Darsaud A et al. Hemodynamic cerebral correlates of sleep spindles during human non-rapid eye movement sleep. Proc Natl Acad Sci USA 2007; 104(32):13164-13169. Darnell, RB Onconeural antigens and the paraneoplaastic neurologic disorders Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A.1996; 93(10): 4529-36 Daurandeu A, Wingertsmann L, Chrétien F, Delisle MB, Vital C, Parchi P et al. Neuronal apoptosis in Fatal Familial Insomnia. Brain Pathol 1998; 8: 531-537. Dauvilliers Y, Cervena K, carlander B et al. Dissociation in circadian rhythms in a pseudo hypersomnia form of fatal familial insomnia. Neurology 2004; 63(12): 2416-2418. De Girolami U, Seilhean D, Hauw JJ. Neuropathology of central nervous system arterial syndromes. Part I: the supratentorial circulation. J Neuropathol Exp Neurol 2009; 68(2):113-124. Dickson D W. Neuropathologic classification of dementias: introduction. Handb Clin Neurol. Dementias. Eds C Duyckart and I Litvan 2008; 487-92 Dom R, Malfroid M, Baro F. Neuropatyhology of Huntington‘s chorea. Studies of the ventrobasal complex of the thalamus. Neurology 1976; 26(1): 64-68. Dubas F, Gray F, Henin D, Foncin JF et al. Subacute polioencephalomyelitis without cancer. 4 anatomo-clinical cases and review of the literature. Rev Neurol (Paris) 1982 ; 138(10) :743-753. Dubas F, Gray F, Escourolle R, Castaigne P. Subacute polioencephalomyelitis with cancer. 6 anatomo-clinical cases and review of the literature. Rev Neurol (Paris) 1982;138(10):725-742.
60
Jean-Jacques Hauw and Chantal Hausser-Hauw
Duyckaerts C, Hauw J-J. Le corps de Lewy, marqueur abusif de la maladie de Parkinson. Bull Acad Natl Méd 2003;187:277-294. Duyckaerts C, Dickson DW. Neuropathology of Alzheimer's disease. Neurodegeneration. The molecular pathology of dementias and movement disorders. Ed Dickson D, Basel, ISN Neuropath press 2003:47-65. Duyckaerts C. Neuropathologic classification of dementias: Introduction. Handb Clin Neurol. Dementias. Eds C Duyckaert and I Litvan 2008;89:147-60. Etzioni A, Luboshitzky R, Tiosano D, Ben-Harus M et al. Melatonin replacement corrects sleep disturbances in a child with pineal tumor. Neurology 1996; 46(1):261-263. Emser W, Brenner M, Stober T, Schimrigk K. Changes in nocturnal sleep in Huntington‘s and Parkinson‘s disease. J Neurol 1988; 235(3):177-179. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson‘s disease. Mov Disord 1990; 5(4):280-285. Fichtenberg NL, Zafonte RD, Putnam S, Mann NR, Millard AE. Insomnia in a post-acute brain unjury sample. Brain Inj 2002; 16(3):197-206. Fisher-Perroudon C, Trillet M, Mouret J et al. Investigations polygraphiques et métaboliques d‘une insomnie durable avec hallucinations. Rev Neurol (Paris) 1974 ; 130 :111-125. Forcadas MI, Zarraz JJ. Insomnia and hallucinations caused by vascular lesions of the pontine. Neurologia 1994; 9(6): 211-223. Fuller P, Saper C, Lu J. The pontine REM switch: past and present. J Neurophysiol 2007;584(Pt 3):735-41. Gambetti P, Parchi P, Chen SG, Corteli P, Lugaresi E, Montagna P. Fatal insomnia: familial and sporadic.In: Dickson DW, Neurodegeneration : The Molecular Pathology of Dementia and Movement Disorders, ISN Neuropath Press, Basel 2003, pp326-332. Garrel S, Fau R, Perret J, Chatelain R. Troubles du sommeil dans deux syndromes vasculaires du tronc cérébral dont l‘un anatomo-clinique. Rev Neurol 1966 ; 2 :575-584. German DC, Manaye KF, White CL, et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 1992; 32: 667-676. Goldbert GJ, Norton AR. ―Limbic encephalitis‖ and its association with carcinoma. Brain 1968; 91: 481. Graus F, Saiz A, Lai M, Bruna J, Lopez F et al, Neuronal surface antigen antibodies in limbic encephalitis. Clinical-immunologic associations. Neurology 2008 ; 71 :930-936. Guentchev M, Hainfeliner JA, Trabattoni GR, Budka H. Distribution of parvalbuminimmunoreactive neurons in brain correlates with hippocampal and temporal cortical pathology in Creutzfeldt-Jakob disease. J Neuropathol Exp Neuro 1997; 56(10):11191124. Guilleminault C, Cathala HP, Castaigne P. Effects of 5 hydroxytryptophane on sleep of a patient with a brain stem lesion. Electroencephalogr Clin Neurophysiol 1973; 34:177184. Gutekunst CA, Li SH, Yi H, Mulroy JS et al. Nuclear and neuropil aggregates in Hunington‘s disease : relationship to neuropathology. J Neurosci 1999; 19(7): 2522-2534. Hausser-Hauw C. Manuel d'EEG de l'adulte. Veille et sommeil. Issy-les-Moulineaux, Elsevier Masson 2007, pp 161-162.
Neuropathology of Insomnia in the Adult: Still an Enigma!
61
Haïk S, Galanaud D, Linguraru MG, Peoch K, Privat N et al. In vivo detection of thalamic gliosis: a pathoradiologic demonstration in familial fatal insomnia. Arch Neurol 2008; 65(4):545-9. Hauw JJ, Agid Y. Progressive Supranuclear Palsy : Steele-Richarson-Olszewski disease. In: Dickson d Ed: Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: ISN Neuropath Press 2003, p 103-114. Hauw JJ, Hausser-Hauw C, Hasboun D, Seilhean D. Neuropathologie du sommeil des maladies neurodégénératives humaines Rev Neurol (Paris) 2008; 164 : 669-682 Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington‘s disease. Neurosci Lett 1991;133(2): 257-261. Henderson J, Carpenter K, Cartwright H, Halliday G. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 2000;123:1410-1421. Hirose K, Iwasaki Y, Izumi M, Yoshida M, Hashizume Y, Kitamoto T, Sahashi K MM2thalamic-type sporadic Creutzfeldt-Jakob disease with widespread neocortical pathology. Acta Neuropathol. 2006; 112(4):503-11. Hobson AJ. Sleep and dream suppression following a lateral medullary infact: a first-person account. Conscious Cogn 2002; 11(3):377-390. Huang Z, Urade Y, Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol 2007; 7:33-8. Ironside JW, Head MW. Biology and neuropathology of prion diseases. Handb Clin Neurol 2008; 89:779-797. Javoy-Agid F. Cholinergic and peptidergic systems in PSP. J Neural Transm 1994;42:205218. Johnson MD, Vnencak-Jones CL, McLean MJ. Fatal familial insomnia: clinical and pathologic heterogeneity in genetic half brothers. Neurology 1998;51(6):1715-7. Kase H. New aspects of physiological and patholphysiological functions of adenosine A2A receptor in basal ganglia. Biosci Biotechnol Biochem 2001; 65(7):1447-1457. Krasnianski A, Bartl M, Sanchez Juan PJ et al. Fatal Familial Insomnia : clinical features and early identification. Ann Neurol 2008; 63:658-661. Krout KE, Loewy AD. Periacueductal gray matter projections to midline and intralaminar thalamic nuclei of the rat. J Com Neurol 2000; 424: 111-141. Kumar R, Husain M, Gupta RK, Hasan KM, Haris M et al. Serial changes in the white matter diffusion tensor imaging metrics in moderate traumatic brain injury and correlation with neuro-cognitive function. J Neurotrauma 2009 Feb5 [Epub ahead of print] Landis CA, Collins BJ, Cribbs LL, Sukhatme VP et al. Expression of Egr-1 in the brain of sleep deprived rats. Brain Res Mol Brain Res 1993; 17(3-4):300-306. Landolt HP, Borbély AA. Age-dependent changes in sleep EEG topotgraphy. Clin Neurophysiol 2001; 112(2):369-377. Landolt HP, Glatzel M, Blattler T, Achermann P, Roth C, Mathis J, Weis J, Tobler I, Aguzzi A, Bassetti Cl. Sleep-wake disturbances in sporadic Creutzfeldt-Jakob disease. Neurology 2006 ; 66 :1418-1424. Landolt HP. Sleep homeostasis: a role for adenosine in humans? Biochem Pharmacol 2008; 75(11): 2070-2079.
62
Jean-Jacques Hauw and Chantal Hausser-Hauw
Liberski PP, Sikorska B, Hauw JJ, Kopp N, et al. Tubulovesicular structures are a consistent (and unexplained) finding in the brains of humans with prion diseases. Virus Res 2008 ;132 (1-2) : 226-228. Liguori R, Vincent A, Clover L et al. Morvan‘s syndrome : peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001;124: 2417-2426. Lim AS, Lozano AM, Moro E, Hamani C, Hutchison WD et al. Characterization of REMsleep associated ponto-geniculo-occipital waves in the human pons. Sleep 2007 ; 30(7): 823-827. Limousin N, Corcia P, Guennoc AM, Lucas B, Sazdovitch V, Haïk S, Toffol BD, Praline J. Sleep disturbances in variant of Creutzfeldt-Jakob disease. Sleep Med 2008 Dec 22. [Epub ahead of print] Lu J, Greco MA, Shiromani P, Saper CB. Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. J Neurosci 2000; 20:3830-3842. Lu J, Xu M, Saper CB.Identification of wake-active dopaminergic neurons in the ventral periacqueductal gray. Sleep 2002; 25 supplement, A290. Lu J, Sherman D, Devor M, Saper C. A putative flip-flop switch for control of REM sleep. Nature 2006; 441:589-94. Lugaresi E, Medori R, Montagna P, Baruzzi A, Cortelli P. et al. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med.1986; 315(16) : 997-1003. Lugaresi E, Provini F, Montagna P. The pathophysiology of fatal familial insomnia. Brain Pathol 1998; 8:521-526. Lugaresi E, Provini F, Montagna P. The neuroanatomy of sleep. Considerations on the role of the thalamus in sleep and a proposal for a caudorostral organization. Eur J Anat 2004; 8: 85-93. Luppi H, Gervasoni D, Verret L, et al. Paradoxical (REM) sleep genesis: The switch from an aminergic-cholinergic to a GABAergic-glutamatergic hypothesis. J Physiol (Paris) 2007;100 : 271-283. Macchi G, Rossi G, Abbamondi AL, Giaccone, G, Mancia D et al. Diffuse thalamic degeneration. A morphometric study. Brain Res 1997; 771(1):154-158. Manetto V, Medori R, Cortelli P, Montagna P, Tinuper P. et al. Fatal familial insomnia: clinical and pathologic study of five new cases.Neurology 1992; 42(2): 312-9. Mangin P, Krieger J, Kowalski J, Dupeyron JP, Pottecher T, Kurtz D. Comas posttraumatiques par lésions encéphaliques diffuses. Etude corrélative des niveaux de dysfonctionnement et des aspects EEG du nyctémère. Rev EEG Neurophysiol 1979; 9(2) : 161-170. McCarley R. Neurobiology of REM and NREM sleep. Sleep Med 2007;8:302-30. McCormick DA, Bal T. Sleep and arousal: thalamocortical mechanisms. Annual Rev Neuroscience 1997; 20: 185-215. McGinty D, Szymusiak R. Hypothalamic regulation of sleep and arousal. Frontiers in Biosci 2003; 8 : S1074-1083.
Neuropathology of Insomnia in the Adult: Still an Enigma!
63
McLean CA, Storey E, Gardner RJ, Tannenberg AE, Cervenáková L, Brown P. The D178N (cis-129M) "fatal familial insomnia" mutation associated with diverse clinicopathologic phenotypes in an Australian kindred. Neurology 1997; 49(2): 552-8. Mignot E, Taheri S, Nishino S. Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders. Nat Neurosci 2002; Suppl 5:1071-1075. Møller M, Baeres FM. The anatomy and innervation of the mammalian pineal gland. Cell Tissue Res 2002; 309:139-150. Montagna P, Cortelli P, Avoni P, Tinuper P, Plazzi G et al. Clinical features of fatal familial insomnia : phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene. Brain Pathol 1998; 8(3):515-520. Montagna P, Lugaresi E. Agrypnia Excitata: a generalized overactivity syndrome and a useful concept in the neurophysiopathology of sleep. Clin Neurophysiol 2002; 113(4):552-60. Montplaisir J, Petit D, Lorrain D, Gauthier S, Nielsen T. Sleep in Alzheimer‘s disease : further considerations on the role of brainstem and forebrain cholinergic populations in sleep-wake mechanisms. Sleep 1995; 18(3):145-148. Montplaisir J, Petit D, Décary A et al. Sleep and quantitative EEG in patients with progressive supranuclear palsy. Neurology 1997; 49(4):999-1003. Morres SA, Mai JK, Teckhaus L. Expression of the CD15epitope in the human magnocellular basal forebrain system. Histochem J 1992; 24(11):902-909. Mrowkra M, Jobges M, Berding G et al. Computerized movement analysis and beta-CITSPECTT in patients with resless legs syndrome. J Neural Transm 2005; 112:693-701. Müller C, Ackerman P, Bischof M, Nirkko A, Roth C, Bassetti CL. Visual and spectral analysis of sleep EEG in acute hemispheric stroke. Eur Neurol 2002; 48:164-171. Myers RH, Sax DS, Schoenfeld M etal. Late onset of Huntington‘s disease. J Neurol Neurosurg Psychiatry 1985; 48: 430-534. Nagashima T, Okawa M, Kitamoto T, Takahashi H, Ishihara Y, Ozaki Y, Nagashima K. Wernicke encephalopathy-like symptoms as an early manifestation of Creutzfeldt-Jakob disease in a chronic alcoholic. J Neurol Sci 1999; 163(2)192-198. Nofzinger EA, Mintun MA, Wiseman M, Kupfer DJ, Moore RY. Forebrain activation in REM sleep: an FDG PET study. Brain Res 1997; 770(1-2): 192-201. Notzinger EA, Buysse DJ, Germain A, Price JC, Miewald JM, Kupfer DJ. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 2004; 161(11): 2126-2128. Oyanagi K, Tsuchiya K, Yamazaki M, Ikeda K. Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features. J Neuropathol Exp Neurol 2001; 60:393-402. Papadopoulou M, Rentzos M, Vagiakis E, Zouvelou V et al. An unusual case of insomnia associated with Whipple encephalopathy: first case reported from Greece. Neurol Sci 2005; 26(3):174-177. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46(2):224-33.
64
Jean-Jacques Hauw and Chantal Hausser-Hauw
Parchi P, Capellari S, Chen SG, Gambetti P. Familial Creutzfeldt-Jakob. .In: Dickson DW, Neurodegeneration : The Molecular Pathology of Dementia and Movement Disorders, ISN Neuropath Press, Basel 2003, pp 298-306. Park M, Comella C, Leurgans S, et al. Association of daytime napping and Parkinsonian signs in Alzheimer's disease. Sleep Med 2006; 7: 614-618. Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol 2001; 49, 53-66. Paueksakon P, Blacklock JB, Powell SZ, Goodman JC. Septembre 2003: a 79-year-old female with right frontal lobe mass. Brain Pathol 2004; 14(1):113-115. Petersen A, Björkqvist M. Hypothalamic-endocrine aspects in Huntington‘s disease. Eur J Neurosci 2006; 244(4): 961-967. Petit D, Gagnon J-F, Fantini M, et al. Sleep and quantitative EEG in neurodegenerative disorders. J Psychosomatic Res 2004; 56: 487-496. Piao YS, Kakita A, Watanabe H, Kitamoto T, Takahashi H. Sporadic fatal insomnia with sponfigorm degeneration in the thalamus and widespread PrPSc deposits in the brain. Neuropathology 2005; 25(2):144-149. Powers J, Rawe SI. A neuropathologic study of Whipple‘s disease. Acta Neuropathol (Berlin), 1979; 48:223-226. Privat N, Laffont-Proust I, Faucheux BA, Sazdovitch V, Frobert Y, Laplanche JL, Grassi J, Hauw JJ, Haïk S. Human prion diseases: from antibody screening to a standardized fast immunodiagnosis using automation..Mod Pathol. 2008; 21(2):140-9. Provini F, Lombardi C, Lugaresi E. Insomnia in neurological diseases. Semin Neurol 2005; 25(1):81-89. Provini F, Cortelli P, Montagna p, Gambetti P, Lagaresi E. Fatal insomnia and agrypnia excitata: sleep and the limbic system. Rev Neurol 2008; 164: 692-700. Provini F, Vertrugno R, Pierangeli G, Cortelli P, Rizzo G, Filla A, Strisciuglio C, Gallassi R, Montagna P. Sleep and temperature rhythms in two sisters with P102L GerstmannSträussler-Scheinker (GSS) disease. Sleep Med 2008 (in press). Quinto C, Gellido C, Chokoverty S, Masdeu J. Posttraumatic delayed sleep phase syndrome. Neurology 2000; 54: 250-252. Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50(3):339-348. Rüb U, Del Tredici K, Schultz C, et al. Progressive supranuclear palsy: neuronal and glial cytoskeletal pathology in the higher order processing autonomic nuclei of the lower brainstem. Neuropathol Appl Neurobiol 2002a; 28:12-22. Rüb U, Del Tredici K, Schultz C, et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging 2002b; 23:245-54. Ruottinen HM, PartinenM, Hublin C, Bergman J, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54(2):502-504. Rye DB. The two faces of Eve: dopamine‘s modulation of wakefulness and sleep. Neurology 2004; 63 (8 suppl 3): S2-S7.
Neuropathology of Insomnia in the Adult: Still an Enigma!
65
Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007; 8:171-181. Salih F, Sharott A, Khatami R, Trottenberg T et al. Functional connectivity between motor cortex and globus pallidus in human non-REM sleep. J Physiol 2009 Jan 12 [Epub ahead of print] Saper C, Scammel T, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437:1257-1263. Sasaki K, Doh-ura K, Wakisaka Y et al. Fatal familial insomnia with an unusual prion protein deposition pattern: an autopsy report with an experimental transmission study. Neuropathol Appl Neurobiol 2005; 31(1):80-7. Sassin I, Schultz C, Thal D, et al. Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol (Berl) 2000;100:259-269. Scaravilli F, Cordery RJ, Kretzschmar H, Gambetti P, Brink B. et al. Sporadic fatal insomnia: a case study. Ann Neurol 2000; 48(4):665-8. Schmahmann JD. Vascular syndromes of the thalamus. Stroke 2003; 34:2264-2290. Seeger R C, Zeltzer PM, Sylvia A. Onco-Neural Antigen: A New Neural Differentiation Antigen Expressed by Neuroblastoma, Oat Cell Carcinoma, Wilms' Tumor, and Sarcoma Cells. J Immunology, 1979, 122: 1548-1555. Seki M, Suzuki S, Iizuka T, Shimizu T, Nihei Y, Suzuki N, Dalmau J. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J Neurol Neurosurg Psychiatry 2008;79(3):324-6. Semba K, Pastorius J, Wilkinson M, Rusak B. Sleep deprivation induced c-fos and junB expression in the rat brain: effects of duration and timing. Behav Brain Res 2001; 120:75-86. Serratrice G, Azulay JP. Mise au point. Que reste-t-il de la chorée fibrillaire de Morvan ? Rev Neurol (Paris) 1994; 150:257-265. Sewards TV, Sewards MA. Representation of motivational drives in mesial cortex, medial thalamus, hypothalamus and midbrain. Brain Res Bull 2003; 61(1): 25-49. Shiota J, Sugita K, Isono O, Araki S. A case of acute mountain sickness with bilateral lesion of pallidum. Rinsho Shinkeigaku 1990; 30(6): 630-634. Siegel J. Brain mechanisms that control sleep and waking. Naturwissenschaften 2004; 91:255-365. Sixel-Döring F, Schweitzer M, Mollenhauer B, Trenkwalder C. Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med 2008 Oct 20. [Epub ahead of print] Spargo E, Everall IP, Lantos PL. Neuronal loss in the hippocampus in Huntington‘s disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 1993; 56(5):487-491. Steriade M, Timofeev I. Neuronal plasticity in thalamocortical networks during sleep and waking oscillations. Neuron 2003; 37(4): 563-576. Swaab D. Neuropeptides in hypothalamic neuronal disorders. Int Rev Cytol 2004; 240:305375. Szücs A, Bodizs R, Barsi P, Halasz P. Insomnia and fronto-basal tumor: a case report. Eur Neurol 2001; 46(1):54-56.
66
Jean-Jacques Hauw and Chantal Hausser-Hauw
Tan KM, Lennon VA, Klein CJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008; 70:1883-1890. Taraszewska A, Matyja E, Koszewski W, Zaczynski A, Bardadin K, Czernicki Z. Asymptomatic and symptomatic glial cysts of the pineal gland. Folia Neuropathol 2008; 46(3):186-195. Taratuto AL, Piccardo P, Reich EG et al. Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease. Neurology 2002; 58(3):362-367. Thannickal T, Lai Y, Siegel J. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007;130: 586-95. Tobler I, Guas SE, Deboer T, Achermann P et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 1996; 380(6575): 639-642. Trenkwalder C, Walters AS, Hening WA et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999; 14:141-145. Trenkwalder C; Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005; 4:465-475. Tsuchiya K, Kosaka K. Neuropathological study of the amygdala in presenile Alzheimer's disease. J Neurol Sci 1990;100:165-173. Uchihara T, Kondo H, Kosaka K, Tsukagoshi H. Selective loss of nigral neurons in Alzheimer's disease: a morphometric study. Acta Neuropathol (Berl) 1992;83: 271-276. Verny M, Duyckaerts C, Agid Y, Hauw J-J. The significance of cortical pathology in progressive supranuclear palsy. Clinico-pathological data in 10 cases. Brain 1996;119: 1123-36. Vincent A, Buckley C, Schott JM et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127:701-712. Vijayaraghavan L, Vaidya JG, Humphreys CT, Beglinger LJ, Paradiso S. Emotional and motivational changes after bilateral lesions of the globus pallidus. Neuropsychology 2008; 22(3): 412-418. Vgontzas A. Chronic insomnia is associated with nyctemeral activation of the hypothalamicpituitary-adrenal axis. Clinical implications. J Clin endocrinol Metab 2001; 86: 37873784. Voderholzer U, Riemann D, Gann H et al. Transient total sleep loss in cerebral Whipple‘s disease: a longitudinal study. J Sleep Res 2002 ;11(4):321-329. Wainwright MS, Martin PL, Morse RP, Lacaze M et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Annals Neurol 2001; 50 (5): 612-619. Wang JY, Bakhadirov K, Devous MD Sr, Abdi H et al. Diffusion tensor tractography of traumatic diffuse axonla injury. Arch Neurol 2008; 65(5):619-626. Wanschitz J, Kloppel S, Jarius C, Birner P, Flicker H, Hainfellner JA, Gambetti P, guentchev M, Budka H. alteration of the serotonic nervous system in Fatal Familial Insomnia. Ann Neurol 2000; 48: 788-791. Warren NM, Piggott MA, Perry EK, Burn DJ. Cholinergic systems in progressive supranuclear palsy. Brain 2005 Feb;128(Pt 2):239-49.
Neuropathology of Insomnia in the Adult: Still an Enigma!
67
Wehrle R, Kaufman C, Wetter TC, Holsboer F, Auer D et al. Functional microstates within human REM sleep: first evidence from fMRI of a thalamocortical network specific for phasic REM periods. Eur J Neurosciences 2007; 25(3): 863-871. Wiegand M, Moller AA, Schreiber W, Lauer C, Krieg JC. Brain morphology and sleep EEG in patients with Huntington‘s disease. Eur Arch Psychiatry clin Neurosci 1991; 240(3): 148-152. Wiegand M, Møller AA, Lauer CJ, Stolz S, Schreiber W, Dose M, Krieg JC. Nocturnal sleep in Huntington‘s disease. J Neurol 1991; 238(4): 203-208. Winkelmann J, Lichtner P, Schormair B et al. Variants in the neuronal nitric oxide synthas (nNOS, NOS1) gene are associated with restless legs syndrome. Mov Disord 2008; 23:350-358. Wu YH, Feenstra MG, Zhou JN et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease : alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003; 88 (12): 5898-5906. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer‘s disease. J Pineal Res 2005; 38(3):145-152. Wu YH, Zhou JN, Balesar R et al. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotrophin-releasing hormone. J Com Neurol 2006; 499(6): 897-910. Yamashita M, Yamamoto T, Nishinaka K, et al. Severe brain atrophy in a case of thalamic variant of sporadic CJD with plaque-like deposition. Neuropathology 2001; 21(2): 138143. Yohrling GJ 4th, Jiang GC, De John MM et al. Analysis of cellular, transgenic and human models of Huntington‘s disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. Brain Res Mol Brain Res 2003; 119(1): 28-36. Zerr I. Clinical and therapeutic aspects of prion disease. Clinical and therapeutic aspects of prion disease. Handb Clin Neurol. Dementias. Eds C Duyckaerts and I Litvan 2008; 89:737-64.
In: Melatonin, Sleep and Insomnia Editor: Yolanda E. Soriento
ISBN: 978-1-60741-859-7 ©2010 Nova Science Publishers, Inc.
Chapter III
Non-Pharmacological Alternatives for the Treatment of Insomnia – Instrumental EEG Conditioning, a New Alternative?
1
Kerstin Hoedlmoser1, Thien Thanh Dang-Vu2,3,4, Martin Desseilles2,3,4 and Manuel Schabus1,2
University of Salzburg, Department of Psychology, Division of Physiological Psychology, Salzburg, Austria 2 Cyclotron Research Centre, University of Liège, Belgium 3 Psychiatry Department, Centre Hospitalier Universitaire (CHU), Liège, Belgium 4 Neurology Department, Centre Hospitalier Universitaire (CHU), Liège
1. Abstract There is already profound knowledge about the evidence that cognitive behavioral therapy (CBT) is effective for the treatment of insomnia (Benca, 2005; Morin et al., 1999; Morin, 2004; Morin et al., 2006). However, the characterization of nonpharmacological treatment effects like CBT on specific sleep parameters (e.g., sleep spindles, sleep architecture, electroencephalographic (EEG) power densities during sleep after CBT) are scarce (Cervena et al., 2004). In our approach we investigated if instrumental conditioning of 12-15Hz EEG oscillations would enhance sleep quality as well as declarative memory performance in healthy subjects. Additionally preliminary data indicating instrumental conditioning of 12-15Hz EEG oscillations as a promising treatment of insomnia will be presented. EEG recordings over the sensorimotor cortex show a very distinctive oscillatory pattern in a frequency range between 12-15Hz termed sensorimotor rhythm (SMR). SMR appears to be dominant during quiet but alert wakefulness, desynchronizes by the execution of movements and synchronizes by the inhibition of motor behavior. This frequency range is also known to be high during light
70
K. Hoedlmoser, T. T. Dang-Vu, M. Desseilles et al. non-rapid eye movement (NREM) sleep, and represents the sleep spindle peak frequency. In the early 70ies Sterman, Howe, and MacDonald (1970) could demonstrate in cats that instrumental conditioning of SMR during wakefulness can influence subsequent sleep. Hauri (1981) was then the first to apply effectively a combination of biofeedback and neurofeedback to humans suffering from psychophysiologic insomnia. Results revealed that the patients benefited from the instrumental conditioning protocols. As research surprisingly stopped at that point, we intended to clarify the effects of instrumental SMR conditioning (ISC) on sleep quality as well as on declarative memory performance with today‘s technologies and by using a well controlled design which included a control group receiving the same amount of attention and training. Our results confirmed that within 10 sessions of ISC it is possible to increase 12-15Hz activity significantly. Interestingly, the increased SMR activity (i) was also expressed during subsequent sleep by eliciting positive changes in various sleep parameters like sleep spindle number or sleep onset latency and (ii) was associated with the enhancement of declarative learning. In addition to these fascinating results, preliminary data from our laboratory point to the possibility that people suffering from primary insomnia could likewise benefit from this conditioning protocol as indicated by improved measures of subjective and objective sleep quality.
2. Introduction Insomnia is characterized by difficulty in initiating sleep, maintaining sleep, and/or nonrestorative sleep that causes clinically significant distress or impairment in social, occupational or other important areas of functioning (Littner et al., 2003). From a psychological perspective insomnia patients typically complain of being unable to stop their reverberating thoughts and ―rest their mind‖ which prevents them from sleeping. Insomnia is associated with decreased quality of life, absenteeism, increased work and car accidents, as well as increased general health care utilization. Insomnia may arise directly from sleep/wake regulatory dysfunction or indirectly from comorbid behavioral, psychiatric, neurological or medical conditions. Finding the underlying cause of insomnia is crucial for curing an individual‘s symptom. In summary, insomnia is a prevalent and clinically important problem. In fact it is the most commonly reported sleep problem in industrialized nations worldwide (Sateia, Doghramji, Hauri, & Morin, 2000). Epidemiological research shows that the prevalence of insomnia lies somewhere between 10 and 35% in the general adult population (Angst, Vollrath, Koch, & Doblermikola, 1989; Benca, 2005; Gallup-Organization, 1995; Johnson, Roth, Schultz, & Breslau, 2006; Morin, LeBlanc, Daley, Gregoire, & Merette, 2006; Ohayon, 2002). Unfortunately, the recognition of the problem of insomnia is widely underestimated and often remains unrecognized and untreated. According to a 1995 survey (Gallup-Organization, 1995) almost 70% of patients with chronic insomnia never discussed their sleep problem with their physicians. Psychiatric conditions (above all anxiety and depressive disorders) are highly prevalent among insomnia sufferers suggesting that such conditions may play an important role in the etiology and perpetuation of insomnia symptoms. In addition to the high rates of past or present psychopathology insomnia patients also have an increased risk of the development of further psychiatric illnesses (Weissman, Greenwald, Nino-Murcia, & Dement, 1997). However, it is still discussed whether insomnia
Non-Pharmacological Alternatives for the Treatment of Insomnia
71
is rather an early symptom than a cause of psychiatric conditions like depression or anxiety disorders (Buysse, 2004; Holbrook, Crowther, Lotter, Cheng, & King, 2000; Morawetz, 2003). Yet, it is well documented that insomnia gives rise to emotional distress and thus might itself be involved in the preservation, recurrence or even development of depression and anxiety disorders (Buysse, 2004; Morawetz, 2003). Empirical data demonstrates that insomnia is most often a chronic condition (defined as an inability to consistently sleep well for a period of at least one month). Retrospective studies of severely afflicted insomnia patients revealed that about 80% of the individuals had the problem for more than one year, with about 40% even reporting more than five years duration (Gallup-Organization, 1995). The consequences of chronic insomnia are severe. The most common adverse effects of sleep disturbances include fatigue/lethargy, mood disturbances, cognitive and motor impairments, social discomfort and non-specific physical complaints which often lead to seriously decreased quality of life, psychosocial discomfort, and economic repercussions including decreased work productivity (Gallup-Organization, 1995; Morin, 1993; Stepanski et al., 1989). Research indicates that already moderate levels of fatigue produce performance equivalents often greater than those observed at levels of alcohol intoxication deemed unacceptable when driving, working and/or operating dangerous equipment (Lamond & Dawson, 1999). It is thus not surprising that occupational and vehicular accidents secondary to poor sleep quality are consistently reported. Even more daunting is data suggesting that decreased sleep time (Kripke et al., 2002) and use of sleeping pills are associated with increased mortality (Kripke et al., 1998). According to a recent report by Kripke (2008) new hypnotics may increase cancer risk - especially the risk of skin cancer.
3. Diagnosis and Classification of Insomnia Depending on the chosen classification system insomnia patients are categorized somewhat differently. The ―International classification of sleep disorders‖ (ICSD-2; American Academy of Sleep Medicine, 2005) differentiates several subtypes of primary insomnia (e.g., psychophysiological, idiopathic, paradoxical, sleep state misperception). The more general classification systems ―International classification of diseases-10th revision‖ (ICD-10; World Health Organization, 2005) and ―Diagnostic and statistical manual of mental disorders-text revision, 4th edition‖ (DSM-IV-TR; American Psychiatric Association, 2000) classify ―nonorganic insomnia‖ (F51.0) and ―primary insomnia‖ (307.42), respectively. Since 2005 there are refined research diagnostic criteria for insomnia available which were developed by an American Academy of Sleep Medicine Work Group (Edinger et al., 2004) regarded as a starting point for improving insomnia research. As they provide the most homogeneous patient population, and satisfy traditional and cultural variations for the concept of a ―primary insomnia‖ it is recommended to identify study participants (as well as normal sleepers) by those criteria. Table 1 exemplarily lists research diagnostic criteria for insomnia disorder and primary insomnia, respectively. Additionally Edinger et al. (2004) provide research diagnostic criteria for the following Insomnia subtypes: insomnia due to a mental
K. Hoedlmoser, T. T. Dang-Vu, M. Desseilles et al.
72
disorder, psychophysiological insomnia, paradoxical insomnia, idiopathic insomnia, insomnia related to periodic limb movement disorder, insomnia related to sleep apnea, insomnia due to medical condition, insomnia due to drug or substance. Furthermore, they offer universal criteria to identify normal sleepers for insomnia research. Table 1. Research Diagnostic Criteria (modified from Edinger et al., 2004).
Research Diagnostic Criteria for Insomnia Disorder
A.
The individual reports one or more of the following sleep related complaints: 1. difficulty initiating sleep, 2. difficulty maintaining sleep, 3. waking up too early, or 4. sleep that is chronically nonrestorative or
Research Diagnostic Criteria for Primary Insomnia
A.
disorder. B.
psychiatric disorder.
The above sleep difficulty occurs despite adequate
2. There is a current or past mental or psychiatric disorder, but the temporal course
At least one of the following forms of daytime
of the insomnia shows some independence
impairment related to the nighttime sleep difficulty is
from the temporal course of the mental or
reported by the individual: 1. fatigue/malaise; 2. attention, concentration, or memory impairment;
psychiatric condition. D.
medical condition.
performance;
2. There is a current or past sleep-disruptive
4. mood disturbance/irritability;
medical condition, but the temporal course of
5. daytime sleepiness;
the insomnia shows some independence from
6. motivation/energy/initiative reduction; driving;
the temporal course of the medical condition. E.
The insomnia cannot be attributed exclusively to another primary sleep disorder (e.g., sleep apnoea,
8. tension headaches, and/or Gastrointestinal
narcolepsy, or parasomnia) or to an unusual
symptoms in response to sleep loss; and 9. concerns or worries about sleep.
One of the following two conditions applies: 1. There is no current or past sleep-disruptive
3. social/vocational dysfunction or poor school
7. proneness for errors/accidents at work or while
One of the following two conditions applies: 1. There is no current or past mental or
opportunity and circumstances for sleep. C.
The insomnia noted in A has been present for at least one month.
C.
poor in quality. B.
The individual meets the criteria for insomnia
sleep/wake schedule or circadian rhythm disorder. F.
The insomnia cannot be attributed to a pattern of substance abuse or to use or withdrawal of psychoactive medications.
Non-Pharmacological Alternatives for the Treatment of Insomnia
73
4. Pathophysiology of Primary Insomnia Polysomnographic (PSG) sleep recordings of patients with insomnia show abnormalities such as prolonged sleep latency or frequent awakenings, more stage 1 and less slow wave sleep (e.g., Merica, Blois, & Gaillard, 1998; Reite, Buysse, Reynolds, & Mendelson, 1995). Krystal et al. (2001) found diminished delta and greater alpha, sigma, and beta EEG spectral power in NREM sleep, which may be an objective physiologic correlate of subjective sleep complaints. Furthermore, Parrino et al. (2004) investigated the role of sleep microstructures for insomnia and reported a more unstable sleep represented by a higher rate of cyclic alternating patterns (CAP). These activation patterns appear in NREM sleep and tend to recur in repetitive clusters with a periodicity of 20–40 s. CAPs are markers of arousal instability, composed of a phase A (activation pattern) and a phase B (interval between two consecutive A phases). CAP is the EEG translation of unstable sleep and accompanies the dynamic events of the sleep process (e.g., falling asleep, stage shifts, intrasleep awakenings). Based on rich experimental evidence from Perlis and colleagues (Perlis, Giles, Mendelson, Bootzin, & Wyatt, 1997; Perlis, Mercia, Smith, & Giles, 2001; Perlis, Kehr, Smith, Andrews, Orff, & Giles, 2001; Perlis, Smith, Andrews, Orff, & Giles, 2001) fast brain oscillations including beta and gamma activity are elevated at sleep onset and during shallow NREM sleep stages in insomnia patients. The authors interpreted these results in terms of increased cognitive arousal at sleep onset and relate the uncommon high frequency activity to the common misperception of insomnia patients of not being subjectively asleep while objective EEG parameters indicate otherwise. The ―Neurocognitive Model of Insomnia‖ (Perlis et al., 1997) proposes that the increase in central nervous system (CNS) tone results in increased and persistent sensory and cognitive processing where under normal circumstances (like sleep) such processes would be vastly attenuated or inhibited. According to the model the increased sensory processing and perception thus accounts for difficulties in sleep initiation and sleep maintenance. Our proposed ISC intervention builds upon these findings. Specifically, we assume that high frequency beta and gamma activity – usually elevated in insomnia patients – will be strongly diminished at sleep onset and during (early) NREM sleep after successful ISC (Hoedlmoser et al., 2008). The introduction of the neurocognitive model with its focus on cortical or CNS arousal, has renewed the interest in the neurophysiological characteristics of insomnia and as such, the use of a method like ISC directly targeting the altered brain activity has also been put forward by others (cf. Cortoos, Verstraeten, & Cluydts, 2006 for a current review) as a promising treatment modality deserving attention.
5. Treatment According to the National Institutes of Health (NIH) ―state-of-the science statement on chronic insomnia in adults‖ (2005) there is still a paucity of large randomized trials for any of the widely used insomnia treatments that include pharmacotherapy, CBT, over the counter products (OTCs), and herbal remedies. The NIH states that the most common treatments for chronic insomnia are OTCs, alcohol, and prescription of medications although CBT has been proven to be as effective as sedative-hypnotic pharmacotherapy. Furthermore, there is no
74
K. Hoedlmoser, T. T. Dang-Vu, M. Desseilles et al.
evidence that OTCs, melatonin, or herbal remedies are more effective than a placebo. According to the NIH there is convincing evidence that the beneficial effects of CBT, in contrast to many of those produced by medications, last well beyond the termination of treatment. However, because few health professionals are experts in the use of psychotherapeutic interventions like CBT, it is still not a very widespread treatment. This is even more true for ISC which is methodologically complex and which has not been rigorously tested for efficacy in insomnia disorders.
5.1 Pharmacological Treatment A variety of drugs are available to treat insomnia. The following classes of drugs and individual agents are most commonly used: benzodiazepines and nonbenzodiazepines acting at benzodiazepine receptors, sedating antidepressants, antihistamines and antipsychotics (Walsh, Roehrs, & Roth, 2005). There are two pharmacological classes of hypnotics being approved by the United States Food and Drug Administration (FDA): benzodiazepinereceptor agonists (BRA; including the traditional benzodiazepines like flurazepam, temazepam as well as the non-benzodiazepine receptor agonists like zolpidem, eszopiclone, zaleplon) and melatonin-receptor agonists (e.g., ramelteon). BRA are occupying benzodiazepine receptors on the gamma-aminobutyric acid (GABA), type A, receptor complex, resulting in the opening of chloride ion channels and facilitation of GABA inhibition. All BRA hypnotics reduce sleep latency, most of them increase total sleep time, although decreasing the duration of SWS (Walsh, Roehrs, & Roth, 2005). However, even highly effective at reducing sleep latency, BRA are associated with varying degrees of residual daytime sedation, abuse liability, and toxicity (Griffiths & Johnson, 2005). Ramelteon is the first FDA-approved melatonin receptor (MT1, MT2) agonist. In patients with chronic insomnia, ramelteon reduces latency to persistent sleep and increases total sleep time. Although prescription of hypnotics is still the most widely used treatment for insomnia, it is sometimes inadvisable or contradicted. Some patients for example simply do not want to use hypnotics for various reasons (Morin, Gaulier, Barry, & Kowatch, 1992). For others hypnotic drugs do not alleviate their insomnia at all or gradually lose their efficacy after some initial relief. Furthermore, hypnotic medication may be contraindicated by the use of other medications, existing medical conditions, a patient‘s high risk to substance abuse or addiction and age (above all pediatric or geriatric patients). Adverse events that are associated with sedative use, such as ataxia, falls, or memory impairment are known to be particularly problematic for older people. However, there are additional variables (e.g., gender) that have to be considered when prescribing hypnotics (Toner et al., 1999). According to the NIH sedative-hypnotics have only been proven to be effective in the short-term management of insomnia (studies usually averaging 7 days) with adverse effects of these medications including daytime sleepiness, dizziness, cognitive impairment, motor incoordination, dependence, and rebound insomnia. However, it has to be mentioned that there are now three hypnotics approved by the FDA for indefinite use (eszopiclone, ramelteon, and zolpidem CR). Yet, empirical evidence suggests that daytime functioning of
Non-Pharmacological Alternatives for the Treatment of Insomnia
75
the suffering patients is often unchanged. That is, medication might sometimes only alter the perception of sleep (Perlis et al., 1997) but does not normalize sleep architecture. Therefore we believe that it is highly needed to assess new non-pharmacological alternatives directly aiming to produce more ―sleep-like‖ EEG patterns (e.g., by ISC treatment) and evaluate their effects on daytime variables such as subjective quality of life, attention and memory performance. For review and further discussion on the topic please refer to Perlis and colleagues (2003).
5.2 Non-Pharmacological Treatment of Insomnia Reports from patients with insomnia suggest that the disorder often starts as a stressrelated phenomenon (Hauri & Fisher, 1986) with the individual emotional and behavioral response to the condition playing an important role in the final outcome of the situation. We believe that these maladaptive cognitive, behavioral and emotional responses - precipitating and perpetuating insomnia - may be well dealt with non-pharmacological treatments (i.e., CBT and ISC). Indeed, there is already promising evidence that non-pharmacological methods besides hypnotics can be (i) efficient in treating insomnia symptoms (Morin et al., 2006; Morin, Colecchi, Stone, Sood, & Brink, 1999; Perlis et al., 2003) i.e., improving objective sleep measures such as sleep onset latency, wake after sleep onset, or total sleep time and can also (ii) lead to subjective improvement of patient complaints, with higher measurable quality of life after treatment.
5.3 Cognitive Behavioral Therapy (CBT) There is growing evidence that Cognitive Behavioral Therapy for Insomnia (CBT-I) is as effective as sedative hypnotics during acute treatment (4-8 weeks) and more effective even considering the long term efficacy. According to Morin (1999) between 70-80% of insomnia patients benefit from treatment, 50% achieve clinically meaningful outcomes and about one third become good sleepers. Until now there is little knowledge about effects of CBT-I on objective data like sleep architecture and sleep EEG power densities. Cervena et al. (2004) could show that after 8-weeks of CBT-I both subjective and objective sleep quality was improved: stages 2, REM sleep and SWS durations were significantly increased; slow wave activity (SWA) was increased and SWA decay shortened, beta and sigma activity during NREM sleep were reduced. Thereby they provided the first evidence that CBT-I may have a positive effect on CNS hyperarousal by decreasing high EEG frequencies and enhance sleep pressure and improve homeostatic sleep regulation by increasing SWA during NREM sleep. There are 3 main components of cognitive-behavioral management for insomnia complaints: behavioral, cognitive and educational modules (Morin, 2004). Interventions like ―Sleep Hygiene Education‖, ―Relaxation Training‖, ―Stimulus Control‖, ―Sleep Restriction‖ and ―Cognitive Therapy‖ can be administered effectively in a group or individual therapy setting. When applied correctly CBT-I has the potential to alleviate insomnia and to help
K. Hoedlmoser, T. T. Dang-Vu, M. Desseilles et al.
76
patients understanding and eliminating probable causes for their condition. Table 2 gives an overview about current cognitive-behavioral treatment practices for primary insomnia. Table 2. Cognitive-Behavioral Interventions for Insomnia (CBT-I). CBT-I INTERVENTION Sleep Hygiene Education Relaxation Training Stimulus Control Sleep Restriction Cognitive Therapy
DESCRIPTION Education about sleep practices, habits and environmental factors that may affect sleep Inhibition of autonomic activity and physiological arousal; facilitation of mental de-arousal Sleep stimuli (e.g., bedroom, bed) have to become reassociated with sleep; temporal adjustment to a consistent sleep pattern Reduction of time in bed to approximate time spent in bed to the length of actual sleep time A psychotherapeutic method to identify and change dysfunctional cognitions about sleep and insomnia
Sleep hygiene education and relaxation training are often used as starting point in CBT-I. Sleep hygiene education refers to general guidelines about health practices and environmental factors that may affect sleep. The main external factors known to have an effect on sleep are: caffeine (―Avoid caffeine and all stimulants after dinner‖), nicotine (―Avoid smoking near bedtime and upon night wakings‖), alcohol (―Do not drink alcohol in the late evening‖), exercise (―Do not exercise too close to bedtime; regular exercise in the late afternoon or early evening may deepen sleep‖) as well as noise, light and room temperature (―Minimize noise light, and excessive temperatures‖). Relaxation training is the most commonly used non-pharmacological therapy for insomnia. Thereby ―standard progressive muscle relaxation‖ has been the most widely investigated relaxation technique for insomnia. Relaxation techniques require disciplined, daily training and practice. Relaxation-based treatments may inhibit two types of arousal that interfere with sleep: autonomic and cognitive. According to Morin et al. (1999, 2006) progressive muscle relaxation meets the American Psychological Association (APA) criteria for empiricallysupported psychological treatments for insomnia, whereas there is no evidence that sleep hygiene education has a detrimental effect on outcome. However, sleep hygiene education is a necessary treatment component and should be incorporated into the overall intervention. Another step within CBT-I is ―Sleep Scheduling‖ which comprises the interventions stimulus control and sleep restriction. According to Bootzin (1991) insomnia is the product of maladaptive sleep habits. Typical sleep stimuli do not cause drowsiness and sleep, but instead are associated with wakefulness. Morin (2004) recommends 5 simple instructions that can help patients to re-associate sleep stimuli with the proper behavior: i) Go to bed only when sleepy, ii) Use the bed or bedroom only for sleeping (sexual activity is the only exception to this rule), iii) Get out of bed when unable to sleep after 15 minutes spent in bed, iv) Arise at the same time every morning, and v) avoid daytime naps. On the other hand sleep restriction can be used parallel, to compress sleep toward greater continuity, reduced wakefulness in bed
Non-Pharmacological Alternatives for the Treatment of Insomnia
77
and increased sleep efficiency. This intervention was induced by Spielmann (1987) who encouraged his patients to limit the amount of time spent in bed to the amount of time spent sleeping. Thereby a mild state of sleep deprivation is induced and leads to a faster sleep onset as well as greater sleep continuity and quality. Both treatments stimulus control and sleep restriction meet the APA criteria for empirically-supported psychological treatments for insomnia (Morin et al., 2006). Finally CBT-I seeks to identify and to change dysfunctional cognitions (faulty or distorted beliefs, expectations, appraisals or attributions) in insomnia. Cognitive therapy targets these cognitions and attempts to alter them. According to Morin (2004) these cognitions are the dangerous insomnia-bolstering concomitant of the maladaptive behaviors that perpetuate insomnia. Patients have to learn to re-evaluate the accuracy of their thinking and to re-interpret events and situations they experience in a more realistic and rational way (Morin & Espie, 2003). The main targets of cognitive therapy are: i) unrealistic expectations about sleep needs and daytime functioning, ii) misconceptions and false attributions about the causes of insomnia, iii) distorted perceptions of its consequences and iv) faulty beliefs about sleep-promoting practices. In general cognitive therapy should guide patients to view insomnia and its consequences from a more realistic and rational perspective. Corresponding to APA criteria (Morin et al., 2006) cognitive therapy meets criteria for empirically-supported psychological treatments. Additionally there is evidence that paradoxical intention – an individual cognitive restructuring technique to alleviate performance anxiety – meets the APA criteria for empirically-supported psychological treatments for insomnia (Morin et al., 1999; 2006).
5.4 Biofeedback Biofeedback is a technique in which people learn how to self-control certain internal bodily processes that normally occur involuntarily, such as heart rate, blood pressure, muscle tension, skin temperature and brain activity. To provide biofeedback special computer hardware is required. Biofeedback instruments are supposed to i) monitor a physiological process of interest, ii) measure what is monitored and finally iii) present what is measured as meaningful information by translating the raw signal e.g., into a tone that varies in pitch, a visual meter that varies in brightness, or a computer screen that varies the lines moving across a grid. The patients have to find mental strategies to self-control the parameter of interest. Through trial and error participants learn to identify and control their mental activities that will bring about the desired physical changes. The three most commonly used forms of biofeedback are i) electromyography (EMG; muscle tension) biofeedback, ii) thermal biofeedback (skin temperature) and iii) EEG biofeedback (neurofeedback; brain activity). Concerning biofeedback as treatment for sleep disorders there are two types of biofeedback that have been effectively used: EMG and EEG biofeedback. According to the ―Practice Parameters for the Psychological and Behavioral Treatment of Insomnia‖ by Chesson et al. (1999) and Morgenthaler et al. (2006) biofeedback is an effective and recommended therapy in the treatment of chronic insomnia. It has been rated as probably efficacious indicating that multiple observational studies, clinical studies, wait list controlled studies, and within subject
K. Hoedlmoser, T. T. Dang-Vu, M. Desseilles et al.
78
and intrasubject replication studies demonstrated efficacy. However, after receiving considerable attention in the 1970s and 1980s (cf. Table 3) there has been a big gap until today – only one study of biofeedback treatment for insomnia has been published in the last 20 years (Sanavio et al., 1990). This lack of research interest may be related to the fact that biofeedback requires more time than comparable forms of relaxations therapies with only little appreciable advantage. Additionally commercial hardware for detecting and managing psychophysiological parameters are needed and the biofeedback operator should understand the fundamental principles and methods for detecting and measuring physiological processes in depth. Despite this lack of research, biofeedback seems to be an efficacious treatment for insomnia. It is also to note that after the intense and promising research in the 1970s many people in the field applied the method rapidly to a variety of clinical disorders (e.g., migraine headache, anxiety disorders, epilepsy, tinnitus, attention deficit (hyperactivity) disorder, chronic pain) thereby skipping the much needed basic research documenting biofeedback efficacy convincingly. Therefore our starting point was to vigorously and objectively test the EEG biofeedback (or neurofeedback) methodology by conducting a highly controlled study using sensorimotor (12-15Hz, SMR) "instrumental conditioning" with the aim to influence brain patterns during waking as well as sleep (cf. chapter 5.5.1). Table 3. Overview of literature concerning Biofeedback and Insomnia. Reference
Subjects
Feedback protocol
Coursey et al. (1980)
22 subjects suffering sleep onset insomnia
EngelSittenfeld et al. (1980)
35 subjects suffering chronic insomnia
Freedman & Papsdorf (1976)
18 subjects suffering sleep onset insomnia
Hauri (1981)
48 subjects suffering primary Insomnia
EMG frontalis biofeedback; relaxation therapy (autogenic training); “Electrosleep Therapy”; PSG EMG frontalis biofeedback and EEG theta NFT; relaxation therapy (autogenic training); client-centred psychotherapy EMG frontalis biofeedback; relaxation therapy (progressive relaxation); control group: placebo (“relaxation” exercises); PSG 4 modalities: (i) EMG frontalis, (ii) EMGtheta, (iii) SMR (1214Hz) and (iv) no treatment; sleep logs, sleep recordings; PSG
Number and duration of sessions 12 (2 a week); 35-45min 1 month follow up 19 (2 a week); 1,5 hours 6 months follow up
Results
EMG biofeedback and relaxation therapy compared to “Electrosleep Therapy”: ↓ sleep onset latency; ↑ sleep efficiency ↓ hypnotic medication
6 (3 a week); 30 min 2 months follow up
EMG biofeedback and relaxation therapy: ↓ sleep onset latency
15 - 62 (2-4 a week); 1 hour 9 months follow up
amount of SMR-feedback-learning correlated significantly with sleep improvement
Non-Pharmacological Alternatives for the Treatment of Insomnia Hauri et al. (1982)
16 subjects suffering primary Insomnia
2 groups: (i) frontalis EMG and theta, (ii) frontalis EMG and SMR (12-14Hz); T7/T8, C3/C4; visual NFT; sleep logs, sleep recordings; PSG
32 (2-3 a week); 1 hour 6 x EMG 26 x theta/SMR 9 months follow up
Hughes & Hughes (1978)
36 subjects suffering chronic insomnia
1-5 1 hour 6 months follow up
Nicassio et al. (1982)
40 subjects suffering sleep onset insomnia
Sanavio (1988)
24 subjects suffering psychophysiological insomnia
EMG biofeedback; relaxation therapy; stimulus control; control group: pseudobiofeedback EMG frontalis biofeedback; relaxation therapy (progressive relaxation); control group: pseudobiofeedback; no treatment EMG frontalis biofeedback; cognitive behavioral therapy (CBT)
Sanavio et al. (1990)
40 subjects suffering sleep onset insomnia
VanderPlate & Eno (1983)
36 subjects suffering sleep onset insomnia
EMG biofeedback; CBT; stimulus control + relaxation therapy (progressive relaxation); control group: waitlist EMG biofeedback; pseudo-biofeedback; self-monitoring; control group: waitlist
79
objective sleep recordings revealed that tense and anxious insomniacs benefited only from thetaNFT, while those who were relaxed only benefited from SMR-NFT; according to sleep logs both NFT groups seems to be effective ↓ sleep onset latency for patients of all four groups (no sign. group differences)
5 1 hour; 6 months follow up
relaxation therapy and EMG biofeedback: ↓ sleep onset latency
6 (3 a week); 1 hour 3 and 12 months follow up
EMG biofeedback and CBT: ↓ sleep onset latency; CBT: ↓ reverberating thoughts; EMG-biofeedback: ↑ relaxation before falling asleep EMG biofeedback; CBT; stimulus control + relaxation therapy: ↓ sleep onset latency, ↓ WASO; effects remain stable after 1 and 3 years follow up EMG biofeedback and pseudo-biofeedback: ↓ sleep onset latency
6 (3 a week); 1 hour 36 months follow up 3 1 hour 2 months follow up
Abbreviations: ↑ = increase; ↓ = decrease; WASO = wake after sleep onset; CBT = cognitive behavioral therapy; PSG = polysomnography; EMG = electromyography; NFT = neurofeedback-training; SMR = sensorimotor rhythm; EEG = electroencephalography
5.5 Instrumental EEG Conditioning (IEC) Instrumental conditioning of EEG parameters – often